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ABSTRACT
The work presented in this thesis was undertaken to investigate the role of human
papillomavirus (HPV) testing for improved detection of cervical neoplasia in the
Scottish Cervical Screening Programme (CSP).
A longitudinal study of 975 archived cervical smears from women who had
histologically-confirmed cervical intraepithelial neoplasia (CIN) showed HPV
positivity using Hybrid Capture Assay II (HCAII) to increase with increased
cytological abnormality. 18% of smears overall contained high-risk HPV (HR-HPV)
DNA. Retrospective analysis of the associated cytology data showed that the positive
predictive value (PPV) of cytology alone for the detection of significant cervical
disease was 70.5% while that of HPV testing alone was 39%. Combined cytology
and HPV testing before biopsy would have increased the PPV to 78%. However, the
negative predictive value (NPV) of a negative HR-HPV result with normal cytology
was 100%. These results suggested that HPV testing may have a greater role in the
exclusion of severe cervical disease rather than as a predictor of its presence.
In a split-sample study, comparing conventional Pap and liquid-based cytology
(LBC), monolayer preparations from LBC samples reduced the inadequacy rate from
7.3% to 2%. LBC also reduced the number of borderline smear reports from 7.9% to
4.2% and increased the number of severe cytological abnormalities detected. The
clinical value of LBC was further endorsed in a direct-to-vial study, where LBC
replaced conventional smears within the CSP. Monolayer preparations from over
4700 LBC samples showed a reduction in the inadequacy rate from around 10% to
less than 1%. This reduced the level of anxiety in women and provided savings in
repeat clinic visits for patients, repeat samples for laboratories and administrative
time at both sites.
HPV testing would be a useful adjunct to cytology for improved management of
women with borderline smear results. In the split-sample study, 44.7% of women
with a previous borderline or low-grade cervical abnormality were HR-HPV DNA
positive. If all 110 HPV negative women had been managed by routine recall then
only two cases of CIN1 would have been missed, while 160 repeat visits and smears
would have been saved. This clearly has benefits for both patients and clinicians at
the primary care level and HPV-based triage has the potential to significantly reduce
referrals to colposcopy.
A robotic DNA extraction system (using a BioRobot®9604) and a real-time
polymerase chain reaction (PCR) assay using the LightCycler was developed as a
suitable rapid diagnostic test for high specimen throughput in primary screening.
Initial problems experienced with blockage of the silica columns during extraction
were overcome by reduction of the volume of LBC sample processed for DNA
extraction to 5mls. HPV DNA was detected in 15% of 1750 samples and in more
than 80% of samples showing moderate or severe dyskaryosis. Detailed melting
temperature (Tm) analysis of real-time PCR products suggested that HPV 16 and
HPV 18 accounted for 44.3% and 15.5% of the HPV positive samples respectively.
Further HPV genotyping using a Reverse Line Blot Assay (RLBA) under
l
development showed that multiple HPV infection was more common, with up to
seven different HPVs being detected in a single sample. Thus, detailed Tm analysis
of LightCycler PCR products is insufficiently specific for HPV genotyping in the
clinical setting. The RLBA is a more appropriate technique for high throughput PCR
product analysis. However, a single HPV test provides limited information, as HPV
genotypes infecting the cervix may change over time. The clinical importance of
persistent infection with different HPV genotypes is not yet clear.
There are currently no defined UK guidelines on cervical screening in HIV-
seropositive women. Although 44.8% of the Edinburgh HIV cohort were HR-HPV
positive by HCAII, this was not necessarily associated with the progression of
cervical neoplasia. 70% of HIV-seropositive women who had at least three cervical
specimens taken at approximately six monthly intervals harboured persistent HPV
infection. 22 different HPV genotypes were identified by direct DNA sequence
analysis, including some novel HPV genotypes whose oncogenicity has still to be
determined. Only HPV type CP8304 was associated with cervical dysplasia. The
work presented suggests that women with a CD4 count less than 200 cells/pl or HIV
RNA viral load greater than 5000 copies/ml are at greatest risk of developing high-
grade cervical disease. However, the results suggest that regular monitoring and
effective treatment and follow-up of these women has prevented cervical disease
progression to cancer and thus supports recommendations that HIV-infected women
should be monitored more regularly than immunocompetent women.
In conclusion, the data presented here support the further analysis, on a large scale,
of HPV testing in combination with cytomorphological assessment of cervical
specimens, preferably of LBC type, to enhance the sensitivity, specificity and
predictive values of the cervical screening programme, with particular relevance to
the triage of borderline neoplasms and the monitoring of immunodeficient patients. It
identifies the need to differentiate between high throughput HPV screening, using a
test such as HCAII, and HPV genotyping necessary for diagnosis and effective
clinical management in specific patient groups.
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Papillomaviruses are members of the Papillomaviridae family (Seventh Report of the ICTV,
2000). They are widespread in nature and infect birds and mammals. Since isolation of the
first papillomavirus in cottontail rabbits (Shope, 1933), the group has expanded considerably
and currently consists of more than 100 established and putative human papillomavirus
(HPV) genotypes, and is still escalating. HPV infections are tropic for squamous epithelial
cells and cause a variety of benign human proliferations including intraepithelial neoplasias,
anogenital, oro-laryngeal and oro-pharyngeal papillomas, and other types of keratoses (zur
Hausen, 1996).
1.1.1 Morphology
The papillomaviruses are small, non-enveloped, icosahedral particles that are 45-55nm in
diameter. The protein coat consists of 72 capsomeres arranged in a T=7 lattice. There are
two capsid proteins: one major (encoded by the LI gene) and one minor (encoded by the L2
gene). The papillomaviruses appear morphologically very similar to the polyomaviruses, but
there is no nucleic acid sequence relatedness between these two groups (Pfister, 1984).
1.1.2. Genome
The papillomavirus genome consists of circular dsDNA which has a molecular weight of
5xl06 Da and is approximately 8kb in size. The genome can be divided into early (E) and
late (L) regions containing at least six early and two late open reading frames (ORFs). The
function of these is outlined in Table 1.1. Messenger RNA (mRNA) is transcribed from the
ORFs that are located on only one DNA strand of the HPV genome. Due to the small HPV
genome size, the ORFs are distributed with considerable overlap.
1
Gene Function
El Initiation of viral DNA replication. ATPase-dependent helicase activity for
unwinding DNA and acts as an elongation factor for replication.
E2 Encodes two separate proteins: a full-length protein product (transcriptional
activator) and spliced mRNA short protein (transcriptional repressor)
required for DNA replication. Also involved in maintenance of episomal
state of the virus by inhibiting expression of E6 and E7 from their promoters.
E4 Late protein. Interacts with the cell intermediate filament network
(cytokeratins) causing them to collapse producing the cytoplasmic halo effect
known as koilocytosis.
E5 Membrane transforming protein. Interacts with cell membrane receptors such
as EGFR to activate mitogenic signalling pathways (important in E6-
associated p53 degradation).
E6 Cellular transformation. Can bind to p53 tumour suppressor gene and bring
about p53 degradation.
E7 Cellular transformation. Forms complexes with retinoblastoma tumour
suppressor gene (pRb) and Rb-related proteins pi07 and pi30.
LI Major capsid protein
L2 Minor capsid protein
Table 1.1 Functions assigned to the papillomavirus open reading frames (reviewed in
Scheffner et al., 1994 and Howley, 1996).
2
The other DNA strand appears to be non-coding due to the presence of widespread
termination codons in all three reading frames. During replication, complex transcriptional
and splicing events occur thus producing a far greater number of transcripts from the ORFs.
In addition, between the early and late genes there is a non-coding region known as the long
control region (LCR) or upstream regulatory region (URR). This contains promoter and
enhancer elements for the regulation of transcription from the early and late genes, thus
controlling the production of viral proteins, viral DNA replication and new viral particle
formation (Turek, 1994).
1.1.3 HPV classification
On a genetic level, mucosal and cutaneous papillomaviruses are subdivided into genotypes
and subtypes based on the extent of their DNA sequence relatedness, which can then be
summarised using a phylogenetic tree (Figure 1.1). In the past, an HPV isolate was classified
as a new type if it had less than 50% hybridisation in the liquid phase with any other known
HPV genome (Coggin and zur Hausen, 1979). Now, however, a new genotype is defined
when an isolate has less than 90% sequence homology in the E6, E7 and LI ORFs
compared to other known HPV types (de Villiers, 1994). A subtype has 90-98% homology
and a variant has greater than 98% homology.
Of the 83 classified HPV genotypes (18th International Papillomavirus Conference,
Barcelona, 2000), more than 40 are known to infect the genital epithelium. Such anogenital
HPV genotypes are broadly divided into two groups on the basis of their oncogenic
potential: low-risk or high-risk. Genital infection with 'low-risk' human papillomavirus
(LR-HPV) types such as HPV 6, 11, 42, 43 and 44 commonly result in the formation of a
benign outgrowth of cells known as a wart (condyloma acuminatum). These are self-
limiting hyperproliferations formed by alteration in the growth pattern of the host cell when
it is infected with a LR-HPV genotype. On the other hand, 'high-risk' human
papillomaviruses (HR-HPVs) are strongly associated with the development and progression
of preinvasive neoplastic lesions known as cervical intraepithelial neoplasia
3
Figure 1.1 Neighbour joining phylogenetic tree of 106 papillomaviruses based on the
consensus primer region of LI (Los Alamos National Laboratory - HPV Sequence
Database. Internet citation: http://hpv-web.lanl.gov).1
1 The outermost wide grey arcs show the five papillomavirus supergroups (A-E). The groups, which
comprise the supergroups, are indicated by inner arcs of grey.
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(CIN) and with cervical carcinoma. Such oncogenic types include HPV 16, 18, 31, 33 and
45. Indeed, women harbouring such types in the genital tract have been shown to be at
greater risk of neoplastic progression from CIN to carcinoma (Schiffman et al., 1993), with
HR-HPV DNA detected in 97.5% of high-grade CIN and cancers (Nobbenhuis et al.,
1999). The extreme rarity of HPV negative cancers has reinforced the rationale for
introducing HPV testing in cervical screening programmes (Walboomers et al., 1997).
1.2 The Cervix
The cervix is the lower part of the utems that projects into the vagina. It is normally covered
by a non-keratinising stratified squamous epithelium, which is well adapted to withstand the
normal vaginal environment. This epithelial layer is continuous with the vaginal squamous
epithelium and with the simple, columnar mucus-secreting epithelium of the endocervical
canal. The junction between stratified squamous and columnar epithelium normally lies at
the external os.
During adolescence, pregnancy or in some oral contraceptive users, the influence of ovarian
hormones causes an increase in the size and shape of the cervix so that the squamocolumnar
junction is exposed to the vaginal environment, forming a 'cervical ectropion'. Thus, the
endocervical columnar epithelium is exposed to the acidic vaginal environment which
causes the highly specialised, fragile columnar cells to become replaced by more resistant
stratified squamous epithelial cells, by a process called metaplasia. This area of metaplasic
squamous epithelium is indistinguishable from the vaginal epithelium and is referred to as
the transformation zone (TZ). The TZ appears to be unstable and susceptible to dysplastic
changes induced by external factors. This area is the most common site for the development
of cervical intraepithelial neoplasia and invasive carcinoma.
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1.3 Pathogenesis ofHPV Infection and the Role of HPV Proteins in the
Development of Cervical Neoplasia
HPV infects the basal cells of the squamous epithelium, possibly through small abrasions in
the tissue. The virus life cycle is then closely associated with keratinocyte differentiation. In
premalignant cervical lesions the HPV genome exists in a free, extrachromosomal, circular
form or 'episome' (Park et al., 1995). Viral genome amplification and gene expression
increase as the infected cell undergoes progressive differentiation until late gene expression
and viral production occurs in the terminally differentiated superficial cells. This form of
infection leads to benign morphological changes, such as koilocytosis, and possibly mild
dyskaryosis (Southern and Herrington, 1998). The virus is shed from epidermal cells when
they are sloughed off and can be transmitted by sexual or non-sexual routes.
However, in many (75-81%) cervical cancers the viral DNA integrates into the host cell
genome (Park et al., 1997; Pirami et al., 1997) and a consistent, though sometimes low,
copy number of the viral genome is maintained in transformed cells. Although no specific
chromosomal binding site has so far been identified, the integration event frequently causes
disruption or deletion of the E2 open reading frame (involved in transcriptional control).
This leaves viral transforming oncogenes E6 and E7 directly coupled to the viral promoter
and enhancer sequences of the LCR, which results in increased expression of HR-HPV E6
and E7 genes (zur Hausen, 2000). E6 encodes a protein that binds to and induces
degradation of the p53 tumour suppressor gene by proteolysis (Scheffner et al., 1990). The
lack of p53 function within the cell increases susceptibility to mutation and chromosomal
instability. E7 oncoproteins bind to the retinoblastoma tumour suppressor gene product
(pRb) and other retinoblastoma-related proteins (Dyson et al., 1989). Interference with the
normal function of pRB influences cell cycle control (from G1 to S phase) resulting in
increased transcription of genes necessary for DNA replication (Turek, 1994).
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1.4 Risk Factors for Cervical Neoplasia and Cervical Cancer
1.4.1 Introduction
Cervical cancer is the second most common cancer in women worldwide and the eighth
most common cancer in European women (Muir and Boyle, 1990). HPV infection is the
single most important risk factor for the development and progression of cervical
neoplasia. Clinical HPV infection results in lesions that can be detected by Papanicolaou
(Pap) smear, colposcopy and histology. However, other forms of HPV infection are
possible: subclinical infection requires identification by colposcopy (examination of the
cervix using relatively low, stereoscopic magnification and bright illumination) or by
cytological or histological assessment and latent HPV infection produces no clinical
symptoms and evidence of infection can only be detected using nucleic acid detection
methods. In the majority of women HPV infection is either latent or subclinical.
The prevalence of HPV infection has been estimated in many studies resulting in wide
variation in such estimates from a few percent up to over 30%. Furthermore, cervical HPV
infection is influenced by age with particularly high prevalence in women under 25 years of
age. In women aged 18-30 years HPV prevalence ranges from 21% to 40% (Bauer et al.,
1991; Evander et al., 1995; Ho et al., 1998), which probably reflects increased sexual
behaviour in this population. In most areas, HPV incidence then declines consistently with
age gradually dropping to 2-5% in women over 35 years (Cuzick et al., 1998). Interestingly,
however, in a Costa Rican study a clear increase in HPV incidence rate was shown in
women after the menopause (Herrero et al., 2000). Although this observation warrants
further study, it may indicate effects caused by changes in sexual behaviour or possible
reactivation of latent HPV infection in relation to ageing of the immune system after the
menopause.
To complicate matters even further, HPV infections have the potential to regress, persist or
progress. Most HPV infections are self-limiting and will spontaneously regress within a few
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months (median clearance time of 8 months in a study by Ho et al., 1998). On the other
hand, 30% of women with low-grade cervical intraepithelial neoplasia (CIN) will progress
to high-grade CIN (CIN 3) and at least 12% (but probably many more) of CIN 3 cases will
progress to invasive carcinoma (Arends et al., 1998). So, progression along the spectrum of
CIN 1-2-3 then to cervical carcinoma is not inevitable, with only a small fraction of CIN 1
cases progressing to malignancy- a process that can take many years. For example, 36% of
untreated CIN 3 lesions that contain HPV DNA progress to invasive cancer over 20 years
(Farthing et al., 1994). Thus, the development of cervical carcinoma is not a single-step
process that can be solely attributed to the presence of HPV and various other risk factors
have been implicated. These include sexual behaviour indicators (including the number of
sex partners and age at first intercourse), infection with other sexually transmitted agents,
number of pregnancies, oral contraceptive use, cigarette smoking and immune status (Kjaer
et al., 1996; Temmerman et al., 1999; Hildesheim et al., 2001). As such, the exact
mechanisms of HPV-associated cervical carcinogenesis are still only partially understood.
1.4.2 HPV genotype
There appears to be geographical variation in the distribution of HPV types found
worldwide. In Europe, HPV 16 is the most prevalent high-risk genotype (Bosch et al.,
1995). Follow-up studies have shown it is also the single most important HPV type for
predicting cervical disease progression, since HPV 16 infections start to progress earlier than
other HPV types, with an estimated 80% of persistent HPV 16-positive lesions eventually
progressing from a lower to a higher grade of CIN (Kataja et al., 1990). Since HPV 16
appears to be a better prognostic marker of progression to high-grade cervical neoplastic
lesions than other HPV genotypes (Cuzick et al., 1994), research to identify women at
highest risk of the development of cervical cancer has so far focused on detection of this
genotype. Specifically, HPV 16 has been detected in 30-77% of women with CIN 2-3 in
various studies (Schiffman et al., 1993; Gaarenstroom et al., 1994; Munoz and Bosch, 1996)
but is found less frequently in women with CIN 1 (Cuzick et al., 1994). In addition, women
harbouring HPV 16 in association with normal or mildly abnormal cytology are also more
likely to have a more severe underlying histological lesion (Cuzick et al., 1994).
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The second most common high-risk genotype, HPV 18, is associated with the development
of a more clinically aggressive or more advanced disease (Kurman et al., 1988; Burger et
al., 1996; Arends et al., 1993). The other prevalent HR-HPVs seen at an appreciable
frequency in invasive cervical cancer are HPV 45 and HPV 31 which were found in 8% and
5% of tumour specimens tested in a world-wide study by Bosch and colleagues in 1995.
1.4.3 HPV 16 variants
HPV 16 can be classified into more than 40 variants that differ by 2% homology or less in a
specified region of the genome. HPV 16 E6 has frequent sequence variations and it is
suggested that some variants are associated with a higher risk of developing CIN 2-3 and
invasive cancer than others due to their differential ability to induce p53 degradation (Xi et
al., 1997; Yamada et al., 1997). It has been estimated that women harbouring HPV 16
variants are at least 6.5 times more likely to develop CIN 2-3 than those with prototypic
strains (Xi et al., 1997). Indeed, HPV 16 E6 variants containing a substitution at residue 83
have been detected in 88% of invasive cervical carcinomas (Zehbe et al., 1998) suggesting
increased oncogenicity is associated with this polymorphism. In contrast, other studies have
shown no association of any HPV 16 E6 or E7 sequence variation with severity of cervical
neoplasia or HPV persistence (Londesborough et al., 1996; Bontkes et al., 1998).
1.4.4 HPV persistence
Persistent HPV infection, often defined as the detection of the same HPV type in
consecutive samples obtained at 3-6 monthly intervals, is a risk factor for the progression of
a preinvasive lesion to invasive cancer. In follow-up studies of women with cytologically
normal (Rozendaal et al., 1996; Liaw et al., 1999) and abnormal smears it has been shown
that persistent HR-HPV infection of cervical cells is necessary for the development,
maintenance and progression of CIN lesions (Wallin et al., 1999; Remmink et al., 1995; Ho
et al., 1995). In a study by ter Harmsel et al., (1999) more women with persistent HPV 16
infection (shown by at least three consecutive PCR positive tests at six monthly intervals)
were shown to develop CIN compared to women who were only transiently HPV
16-infected (shown by one positive test followed by two negative PCR results). Thus, it was
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concluded that persistent HPV 16 infection is associated with a higher risk of developing
cervical neoplasia, which is often high-grade. However, Mayrand et al., (2000)
demonstrated that HPV 16 DNA detected in consecutive samples may not indicate persistent
infection at all, but re-infection with a different HPV 16 variant.
1.4.5 HPV viral load
It has also been suggested that high HPV viral load, resulting from productive viral
replication, is a marker for persistent infection and thus an increased risk for the
development of cervical dysplasia. Hence, estimates of viral load may be useful in selecting
for treatment only women with high levels of viral DNA that are likely to persist or confer
an increased risk of cervical disease progression.
Recent studies have shown that HPV DNA quantitation can predict the risk of developing
cervical cancer much earlier than other screening methods. In particular, high HPV 16 viral
load has been shown to increase the relative risk of carcinoma in situ by at least 30 times
(Ylitalo et al., 2000). Women with persistently high HPV DNA load are most at risk of
cervical disease progression. Women under 25 years of age are particularly at risk since
25% with persistently high HPV DNA load will develop cervical malignancy within 15
years (Ylitalo et al., 2000). In a study of archival smear material, Josefsson and co-workers
(2000) produced similar findings and concluded that women with the 20% highest amount
of HPV 16 DNA were 60-fold more at risk of developing cervical carcinoma in situ than
HPV negative women.
Many studies have attempted to estimate HPV DNA load from the signal intensity produced
by commercially available hybridisation tests. However such assays were designed only to
show simply the presence or absence of HPV infection, thus any viral load estimation made
in this way is not reliable. Indeed, the grade of disease, the number of infected epithelial
cells present in the clinical specimen and the distribution of viral copies will all influence the
HPV viral load detected, which may even be different for individual HPV types.
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Additionally, the detection of just a few copies of HPV DNA may not be relevant for
subsequent cervical disease. With the advent of real-time PCR, quantitative assays have
been developed for accurate determination of HPV viral load in cervical specimens
(Johnston, 2000), but a specific viral load cut-off that defines women at high-risk of disease
progression has not yet been determined.
1.4.6 Immune status
1.4.6.1 General immunosuppression
Cellular immunodeficiency is considered to be an important risk factor for HPV
infection and persistence and for the progression of CIN (Petry et al., 1994). Skin
carcinomas, which are often preceded by viral warts and premalignant keratoses, are
particularly well-recognised in patients following renal transplantation (Berkhout et al.,
2000). Female renal transplant recipients are also at risk of genital HPV infection and
subclinical cervical HPV infection and cervical dysplasia, in particular with HPV types
16 or 18 (Brown et al., 2000). Approximately 15 years or more after receiving a renal
allograft nearly all recipients will have evidence of HPV infection and it is notable that
cervical or ano-perineal cancers represent some of the potentially fatal complications of
both immunosuppression following organ transplantation and HIV infection (Benton and
Arends 1996; Arends et al., 1997).
1.4.6.2 HIV-associated immunosuppression
Studies have consistently shown that HIV-infected women have an increased prevalence
of anogenital HPV infection with increased development of CIN and cervical cancer
compared to HIV-seronegative women (Schrager et al., 1989; Feingold et al., 1990;
Vermund et al., 1991; Marte et al., 1992; Branca et al., 1995; Sun et al., 1997; Williams
et al., 1994; Wright et al., 1994a). In addition, this immunocompromised population is
subject to a higher rate of CIN recurrence and treatment failure (Maiman et al., 1993).
The risk of HPV infection and the severity of cervical neoplasia has been linked to
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impaired cell mediated immunity, as measured by CD4 lymphocyte counts (Maiman et
al 1993; Johnstone et al., 1994; Vernon et al., 1994).
HIV-seropositive women have an eight-fold higher risk of HPV-related cervical
disease than HIV non-infected women (Capiello et al., 1997). Depending on the level of
immunosuppression, such HPV infections are approximately seven times more likely to
be persistent infections (defined as the detection of the same HPV at two or more
examinations during a period of 3-12 months) (Sun et al., 1997). In addition, HIV-
infected women have a higher percentage of infections with multiple HPV types
compared to HIV non-infected women with two or more high-risk HPV types being
commonly found (Shah et al., 1997).
Invasive cervical cancer was added to the list of CDC AIDS-defining illnesses in 1993
(Centres for Disease Control, 1992; Klevens et al., 1996), but preservation of immune
function by the introduction of highly active antiretroviral therapy (HAART) may
reduce the risk of cervical disease in HIV-seropositive women. Alternatively, if
HAART has little or no impact on the regression of cervical disease then cervical
neoplasia may become increasingly common as patient survival is prolonged. However,
it is too early to assess fully the impact of HAART on the natural history of CIN in
HIV-infected women. Early data suggests that successful suppression of plasma HIV
viral load using antiretroviral drugs may reverse immunosuppression resulting in
regression of CIN lesions despite the presence of persistent HPV infection (Heard et al.,
1998). Further studies are required to confirm these findings.
1.5 Host Cell Genetic Alterations in HPV Infection and Cervical
Neoplasia
1.5.1 p53 tumour suppressor gene
p53 function plays a key role in DNA repair. In the normal situation, it is present in a very
low concentration in cells but when DNA is damaged, its concentration increases. It then
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acts as a transcription factor inducing the expression of an inhibitor that leads to cell cycle
arrest in both G1 and G2. This allows DNA repair if possible or apoptosis and cell death if
the damage is severe. Degradation of p53 by HR-HPV E6 binding is of central importance
in tumourigenesis as loss of p53 function increases susceptibility to mutations in the host
cell DNA. Storey et al., (1998) showed that host p53 protein was polymorphic at codon 72
(c72) in that the p53 protein contained either an arginine (CGC) or a proline (CCC) residue
at this position (within exon 4). This was the first evidence that there was a possible genetic
susceptibility to the development of squamous carcinoma of the cervix among white women
since polymorphic variants differed in their susceptibility to degradation mediated by the
HPV E6 oncoprotein. The E6 proteins from HR-HPV types were more effective at
degrading the arginine form (p53Arg) than the proline form (p53Pro). Storey and colleagues
found that patients with HPV-associated cervical cancer were much more likely to have the
p53Arg form and estimated that patients with two copies of the arginine form had a 7-fold
increased risk of developing cervical cancer than individuals with two copies of the proline
form.
Although several groups worked speedily to support these findings using larger case-control
studies, they were unable to confirm the association between the p53 Arg polymorphism and
cervical neoplasia (Hildesheim et al., 1998; Helland et al., 1998; Josefsson et al., 1998).
Rosenthal and colleagues (1998) examined the distribution of the p53 polymorphism in a
similar group of white women (50 cases and 246 controls) but did not find a significant
excess of c72 arginine alleles. In another UK-based study (Giannoudis et al., 1999), no
significant differences were identified in the frequencies of p53Arg genotype in women with
varying degrees of dysplasia (equivalent to 118 LSIL, 118 HSIL and 43 invasive cancers)
and without cervical disease (n=30). Additionally, there was no significant association
between p53 genotype and infection with HR- or LR-HPV types. In a larger case-control
study of 205 women (Sonada et al., 1999), the frequency of individuals homozygous for
arginine at c72 was lower in the squamous cell carcinoma cases but higher in the control
group than the findings by Storey and colleagues. The role of p53 c72 polymorphism was
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also examined in women with premalignant disease (353 cases and 496 controls) by
Lanham et al., (1998) but no evidence was found to show that the arginine genotype at c72
of p53 was involved in the progression of HPV-associated cervical malignancy. Szarka et
al., (1999) performed a study in Hungarian women that showed that the p53Arg
homozygous genotype does not increase the risk of cervical carcinoma specifically in
HPV16-infected women.
Possible reasons have been advanced to explain why the results of Storey et al., (1998)
cannot be reproduced in other investigations. The aforementioned study involved only a
small number of women with cervical cancer (n=30) and slightly more controls (n=41). The
results generated therefore may have been influenced by the small sample size. In addition,
it has been reported that the frequency of the p53 Arg/Pro polymorphism varies with ethnic
group (Beckman et al., 1994). Elderly oriental women (60-96 years) with cervical
carcinoma showed a higher proportion of p53 point mutations (11%) caused by
endogeneous mutagenesis (Nakagawa et al., 1999), although this result fell short of
statistical significance. In contrast however Yamashita et al., (1999) reported no relationship
between p53Arg and predisposition to HPV-associated cervical neoplasia in their study of
HPV-infected SIL and invasive cancer cases from Japanese women compared to a control
group.
1.5.2 Telomerase
The analysis of telomerase expression may provide another valuable tool for the detection of
neoplastic cells. Telomerase is an enzyme that allows the maintenance of telomere
sequences following DNA replication. Telomeres act as protective caps at the ends of
chromosomes. Every time a cell divides it loses 50-100bp at the ends of its telomeres.
When a critical number of base pairs are lost, it triggers a signal for the cell to stop dividing
and senesce. Activation of a specialised reverse transcriptase (telomerase) allows cells to
avoid this progressive shortening of telomeres by adding back the telomere sequences that
are lost, therefore allowing cells to multiply indefinitely. HR-HPV E6 induces telomerase
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activity by increasing the expression of the telomerase catalytic subunit, human telomerase
reverse transcriptase (hTERT) (Weinberg, 1998). This action is independent of E6-p53
degradation (Klingelhutz et al., 1996). Degradation of p53 by E6 may however be important
at a later stage in neoplastic progression as loss of p53 function increases susceptibility to
mutations in the host cell DNA. Nevertheless, telomerase activity alone is not enough to
immortalise keratinocytes and inactivation of the retinoblastoma tumour suppressor pathway
(that regulates transition from G1 to S phase of the cell cycle) by E7 is also required
(Kiyono et al., 1998).
Snijders et al., (1998) investigated telomerase activity and hTERT mRNA expression in
relation to HR-HPV DNA presence in women with precancerous cervical lesions. hTERT
mRNA levels were strongly associated with detectable telomerase activity and these were
only detected in cases that harboured high-risk HPV DNA. It was concluded that
telomerase activity with an accompanying increase in the level of hTERT mRNA, reflected
a rather late stage in the progression of CIN to carcinoma which follows HR-HPV infection.
1.6 The Cervical Screening Programme (CSP)
Cervical screening was first introduced in Britain in 1967, although it was not initially
introduced as a population-based programme. Now cervical screening is well established
throughout the National Health Service (NHS) and aims to reduce the mortality rates
associated with cervical cancer by early detection and treatment of pre-malignant disease.
Every year 360,000 women between 20-64 years are invited, free of charge, for cervical
screening. Computerised call and recall was introduced in 1988 and women receive an
invitation every 3-5 years (Patnick, 2000). The current cervical screening procedure
involves standard cytological assessment of epithelial cells from the cervical transformation
zone by a conventional Pap smear and if appropriate colposcopic assessment with cervical
biopsy or large loop excision of the transformation zone (LLETZ).
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Since the introduction of the Pap smear, widespread cervical screening in industrialised
countries has reduced cervical cancer incidence rates by 70% or more to approximately 10
per 100,000 per year. In developing countries however, possibly due to the lack of
successful Pap smear screening programmes, the cervical cancer incidence rate is more than
40 per 100,000 per year and mortality is high (Lorincz, 1996). Despite an 87% screening
coverage in Scotland, cervical cancer still remains the 10th most frequently diagnosed cancer
with 122 deaths reported in 1999 (internet citation: http://www.nhsis.co.uk).
1.7. Cytological Assessment of Cervical Neoplasia
Specimens for conventional Pap smear preparation are collected from the cervix using
either an Ayre or Aylesbury® spatula (CellPath, Powys, Wales) and as much of the
cellular material as possible is transferred onto the surface of a glass slide. The cells are
fixed and the slide is transported to the laboratory where it is stained with Papanicolaou
stain. Microscopic assessment of the epithelial cells can then be performed. Cytological
techniques can provide suggestive evidence of HPV infection by identification of
koilocytes; non-neoplastic epithelial changes caused by the viral cytopathic effect.
Koilocytes are abnormal squamous cells with characteristic perinuclear vacuolation,
which show irregular but clear edges bounded by dense cytoplasm (Figure 1.2). They are
the hallmark of productive HPV infection. However, such morphological changes are
not specific or sensitive for oncogenic HPVs and are more likely to detect LR-HPV
types that produce benign lesions.
1.7.1 Cytology classification schemes
The diagnostic terminology applied to cervical cytological abnormalities has undergone
several changes over time, which can sometimes lead to confusion in the literature.
In the UK, neoplastic changes in the squamous epithelium detected by cytological
assessment of Pap smears are described using terminology introduced by the British Society
for Clinical Cytology (BSCC) in the 1980s. This system describes preinvasive neoplastic
16
lesions of the cervix that can advance through various stages of dysplasia, followed by
carcinoma in situ and then invasive carcinoma and attempts to correlate the histological
findings with appropriate cytological abnormalities. The classification scheme uses the term
'dyskaryosis', which can be divided into mild, moderate or severe categories according to
the degree of severity of nuclear atypia and other changes. These correlate with the
histological grades of CIN 1, 2 and 3 respectively. The main observation of dyskaryosis is
the enlarged nuclear: cytoplasmic ratio that increases as the lesion progresses. The BSCC
terminology uses five grades in total: 1. Unsatisfactory for assessment (with a reason stated),
2. Negative or within normal limits (WNL), 3. Nuclear changes bordering on mild
dyskaryosis, also called 'borderline' (B/L), 4. Dyskaryotic cells: mild, moderate or severe, 5.
Malignant cells suggestive of invasive cancer (squamous or adenocarcinoma).
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Figure 1.2 Conventional Pap-stained cervical smear showing koilocyte development
(provided courtesy ofDr E. McGoogan).
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In the USA, the Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses
(National Cancer Institute Workshop, 1989) is widely adopted to describe cytological
abnormalities. This system classifies precancerous lesions under the term squamous
intraepithelial lesion (SIL), which is subdivided into two categories: low-grade squamous
intraepithelial lesions (LSIL) and high-grade squamous intraepithelial lesions (HSIL). There
is also a further category of atypical squamous cells of undetermined significance (ASCUS).
1.7.2. New technologies for cytological assessment
An alternative approach for improved cytomorphological detection of cervical neoplasia is
liquid-based cytology (LBC). This requires the sample that is removed from the cervix
being rinsed into a vial of preservative fluid, which is then used to prepare a thin layer smear
preparation using automated technology operated by skilled laboratory staff. These slide
preparations show optimal cell preservation, reduced debris from mucous, inflammatory
cells or blood and minimal cell overlap. Two such devices are AutoCyte PREP (AutoCyte,
North Carolina, USA) and ThinPrep® 2000 (Cytyc Corporation, Maryland, USA). The
added advantage of LBC is that only a proportion of the cells in the cervical scrape sample
are used to produce the thin layer preparation and so the residual cells can be used for HPV
testing without requesting another patient visit.
Several studies have positively reported on the utility of LBC for improved cervical
screening (Dupree et al., 1998; Austin, 1998; and others discussed in Section 6.4.1) and the
feasibility of ThinPrep®-HPV combination testing as a replacement or adjunct to the
conventional Pap smear has been investigated (Sherman et al., 1997). Improved LBC
preparations result in reduced smear screening and interpretation time while showing
comparable or increased detection of cervical abnormalities in comparison with
conventional Pap smears (Aponte-Cipriani et al., 1995; Bolick and Hellman, 1998; Lee et
al., 1997). While the cost of reagents and hardware is more expensive for liquid-based
cytology it is argued that long term cost savings are likely due to the reduction in both the
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number of inadequate and equivocal smear reports. In addition, LBC has been shown to be
useful for identifying women with B/L smears who have an underlying CIN lesion (Ferris et
al., 1998; Cram et al., 1999; Manos et al., 1999). By reducing the frequency of repeat Pap
smear testing and colposcopy referrals, costs will be reduced even further and, in turn, the
prospect of increasing the screening interval from every three years for some women will
bring additional cost savings.
Computerised automated cytology screening devices that use advanced neural network
technology to assess the degree of cellular abnormality present in a cervical smear
preparation are now avaliable. One such system, called PapNet (Netherlands B.V.,
Zekeringstraat, Amsterdam) has two components: a scanning machine and a review
platform. Initially, Pap-stained smears are loaded onto a motorised microscopic stage where
an electronic camera digitises 128 images from the most abnormal cells in each smear,
which can be stored on disk. The cytoscreener can then focus on these areas on a personal
computer to obtain a rapid and reliable impression. Slides requiring further microscopic
review can then be fully microscopically assessed by a cytotechnologist. Initial evaluations
of the system compared to conventional methods of screening have been positive
(Bosanquet et al., 1999).
1.8. Histological Assessment of Cervical Neoplasia
When significant dyskaryotic changes have been identified cytologically, patients are
referred for colposcopic assessment and histological examination of biopsy specimens
taken at colposcopy is used to define accurately the degree of dysplasia and to plan
appropriate treatment. Colposcopy involves examination of the cervix using relatively
low power, stereoscopic magnification and bright illumination. This method has a high
sensitivity (>90%) for the detection of high-grade disease but also has low specificity
(<50%) that results in a high rate of over treatment. Cervical neoplasia assessed
histopathologically is described as CIN which, in Europe, is classified into three grades
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according to the degree of severity. CIN 1 and 2 correspond to mild and moderate
dysplasia respectively and CIN 3 includes both severe dysplasia and carcinoma in situ.
Preinvasive lesions are confined to the surface cervical epithelium and underlying crypts
but do not invade through the basement membrane into the underlying connective
tissues. With any evidence of invasion through the basement membrane into the
underlying tissues, the lesion is defined as invasive or microinvasive squamous
carcinoma of the cervix.
1.9. Adenocarcinoma
Squamous carcinomas account for a high proportion of cervical malignancies with the
remainder being made up mostly of adenocarcinomas arising in the endocervix.
Adenocarcinoma is preceded by dysplastic changes in the endocervical glandular
epithelium termed cervical glandular intraepithelial neoplasia (CGEN) which often co¬
exists with squamous CIN. Either or both the surface epithelium and the underlying
crypts may be affected. The current grading system for CGIN divides lesions into high
grade (including adenocarcinoma in situ and severe glandular dysplasia) or low grade
(moderate and mild glandular dysplasia). The association between CGIN and HPV is not
as strong as for squamous CIN, but frequently adenocarcinomas are associated with
HPV DNA, particularly HPV 18 (Arends et al., 1998). It has been suggested that
glandular tumours of the cervix are more aggressive than squamous cervical tumours
(Hildesheim et al., 1999).
1.10 Limitations of the NHSCSP
Despite great efforts to improve the coverage of the NHSCSP, still only 85% of eligible
women attend their screening appointments. In some countries, recent studies have
focused on methods of self-sampling as a way of improving the population coverage
and also as a cost-effective approach for screening in under-developed countries which
lack organised screening programmes. So far, a good correlation (85-93%) has been
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reported between HPV results from self-obtained vaginal samples and cervical smears
taken by trained staff (Hillemans et al., 1999).
More importantly, the Pap smear method itself has several limitations resulting in a high
false negative rate of approximately 20% (Gay et al., 1985; van der Graaf and Vooijs,
1987). A significant problem with the Pap smear method is the large number of sub-
optimal and B/L smear results that are reported. Poor cell transfer or fixation of the Pap
smear often occurs at the time of making the slide. Up to 90% of the cells harvested
from the cervix are discarded with the sampling device and this contributes to the
proportion of smears designated 'unsatisfactory' due to the lack of cells derived from the
transformation zone. Such limitations were highlighted in a recent audit of the UK
screening programme that found that 47% of women under 70 years of age with invasive
cervical cancer had an apparently adequate screening history (Sasieni et al., 1996).
Similarly, invasive cervical cancer has been identified in women who had a minor
cytological abnormality many years previously followed by a number of (presumably
false) negative smears (Morell et al., 1982; Stanbridge et al., 1992). Media coverage of
such unfortunate cases has resulted in some loss of public confidence in the present
cervical screening process based solely on Pap smears.
It is therefore widely accepted that a screening programme based on conventional cytology
alone has important limitations and new methods are required to improve both sensitivity
and specificity. The main issues for consideration are the age to start and stop screening; the
appropriate screening interval; the role of self-sampling and choice of primary test. Since
1993, when a survey of experts concluded that HPV DNA testing had a limited role in
clinical practice (Cole, 1993), the reproducibility and sensitivity of HPV DNA tests has
improved greatly. There is now substantial evidence to suggest that HPV testing would be
useful in cervical screening programmes of the future although some controversy surrounds
how this should be targeted for greatest effect.
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1.11 Role of HPV Testing in the NHSCSP
1.11.1 Primary screening
HPV testing may be a useful adjunct to cytological assessment that could result in the earlier
detection of women at risk of developing high-grade CIN or cervical carcinoma (Cuzick et
al., 1995; Cuzick et al., 1999b). It is predicted that adding HPV testing to primary screening
could increase the yield of high grade CIN by 50-100% with a positive predictive value
similar to that for moderate dyskaryosis (Cuzick, 1998).
There is no doubt that universal HPV testing in all women attending cervical screening
clinics would identify underlying cervical disease that was not detected by cytology. 5-10%
of women with normal cytology (possibly more according to Liaw et al., 1999) will harbour
HPV in their cervices which may indicate the presence of high-grade CIN (Melkert et al.,
1993; Kjaer et al., 1996). Such women with a HR-HPV positive test at base line, are 116
times more likely to develop CIN 3 after a follow-up time of 4-6 years, than women with
normal cytology and an HR-HPV negative result (Rozendaal et al., 1996). However, since
the population prevalence ofHPV infection is high, HPV testing in primary screening would
also identify women with HR-HPV infection who had no cervical disease. In particular,
HPV infection in younger women, aged 18-25 years, tends to be at a high viral load but the
viral infection often spontaneously regresses in this age group thus making the predictive
value of a positive HPV test very low (Ho et al., 1995).
In older women however, the viral load is often lower but the vims is more likely to persist
(Hildesheim et al., 1994). Although it is estimated that low-grade disease will regress in
over 50% of cases in 3 to 4 years, persistence of low-grade cervical neoplasia (CIN 1) has
also been shown to increase with age (McCance, 1998). Thus restricting HPV testing to
women over 30 years of age, who have a more stable pattern of HPV infection, would
substantially improve the specificity in primary screening by significantly increasing the
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predictive value of a positive HPV test. Additionally, HPV testing could rationalise the
current screening guidelines by extending the screening interval for women considered to be
at low risk (both cytologically and HPV negative) (Rozendaal et al., 2000), particularly in
women over 50 years of age who have never had an abnormal smear. This would reduce the
need for prolonged surveillance of women, which also has important cost implications for
health care services. In the UK, the Health Technology Assessment (HTA) Committee of
the Department of Health has performed a systematic review of the available evidence on
the role of HPV testing in cervical screening (Cuzick et al., 1999a). The findings are
discussed further in Chapter 6.
1.11.2 Triage of women with borderline smears
5-10% of all smears are designated B/L as there is some doubt that they are clearly normal.
The vast majority of these smear results will have no clinical relevance since the positive
predictive value of a B/L result has been shown to be only 3% (Cuzick et al., 1999b). Ten
percent of this group however will have an underlying high-grade lesion. In women with
mild dyskaryosis the underlying prevalence of high-grade CIN is much higher at up to 40%
(Flannelly et al., 1994). Yet a randomised study by Cruickshank et al., (1999) found HPV
testing using PCR to be of no significant benefit over immediate referral of women with
mild dyskaryosis to colposcopy, concluding it was unlikely to be of benefit in managing
women with mild dyskaryosis.
The current guidelines for women with low-grade abnormalities are unclear and B/L
cytology results present a management problem since all women with this diagnosis will
require follow-up to avoid missing the small percentage of clinically significant disease.
Follow-up usually involves repeat cytology and/or referral for colposcopy. Present
guidelines recommend referral for colposcopy after three B/L smear results or two mild
abnormalities at six monthly intervals. In the Edinburgh area, approximately 60% of such
women attending colposcopy are found to be within normal limits (WNL). Extrapolated to
the whole of Scotland, this means that approximately 1000 women with no significant
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cervical neoplasia undergo unnecessary colposcopy each year (Dr. McGoogan, personal
communication). In a study of 566 women with low-grade atypia who were not treated at
their first colposcopy visit, 54.1% of abnormalities resolved; 24.4% developed persistent
disease and 21.5% were subsequently treated (Teale et al., 2000). With an increase in the
number of annual referrals for colposcopy of women with persistent borderline changes,
unnecessary pressures are being imposed on colposcopy clinics and many women are being
subjected to an unnecessary, psychologically stressful procedure. Their return to routine
screening is also delayed.
This current procedure could be improved if an additional test could increase the detection
of high-grade CUM without reducing the specificity of cytology alone. Thus, only those
women with cervical disease would require referral to colposcopy and those without
neoplastic changes could be followed using standard cytological surveillance. HR-HPV
DNA positivity, compared to cytology alone, has been shown to improve the detection rate
of high-grade cervical neoplasia in women with B/L smears (Hatch et al., 1995, Cox et al.,
1995; Herrington et al., 1995). However, this was not been confirmed in other studies where
HPV testing was shown to have a low sensitivity (Kauffman et al., 1997). Triage of women
with low-grade cytological abnormalities using a repeat Pap smear and an HPV test was
shown to have low specificity in a study by Wright et al., (1995). Although the approach
correctly identified 92% of women with biopsy- proven CIN, 71% of the women would
have been referred for colposcopy. A large randomised multicentre clinical trial
(ASCUS/LSIL Triage Study (ALTS)) has been performed in the USA to investigate the
sensitivity and specificity of immediate colposcopy, repeat cytology every three months and
HPV testing for the detection of CIN 3. Enrolment into the ALTS study finished in
December 1998 and analysis of early data has been published (The ALTS Group, 2000). If
continued studies in large populations confirm that HR-HPV detection can predict the
women least likely to have high grade CIN and therefore not requiring aggressive follow up,
this could alter current practice.
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1.11.3 Follow-up of women following treatment for CIN
HPV testing may improve the accuracy of follow up of women who have been treated for
precancerous or early invasive lesions. Currently, these women have annual smears for five
years and sometimes for the rest of their lives. HPV positivity after treatment could help
select those women who had failed to respond to the treatment regime or had persistent HR-
HPV infection. Alternatively, the lack of HPV would identify those women whose lesions
had been successfully treated and they could be returned to routine recall.
1.11.4 Management of HIV-seropositive women
As previously mentioned, women with HIV infection have an increased frequency of
anogenital HPV infection with increased development of both CIN and cervical cancer.
Furthermore, cervical disease recurs with greater frequency and progresses more rapidly
in severely immunocompromised women harbouring HR-HPV types. On this basis,
there is a definite need for adequate cervical surveillance of HIV-seropositive women
(Vonau and Boag, 2000). This was highlighted in a recent study showing that HIV-
infected women with no evidence of cervical disease developed histology-confirmed
neoplasia within three years (Ellerbrock et al., 2000). Although annual cytological
screening is performed in many centres there are, at present, no defined UK guidelines
on cervical screening in HIV infected women (Jungmann et al., 1998). There is,
however, a general consensus that HIV-infected women with relatively intact immunity
(CD4 counts >500 cells/pi) should be treated in the same way as HIV non-infected
women (Six et al., 1998).
The sensitivity of the conventional Pap smear in identifying cervical abnormalities in
HIV-seropositive women has been questioned. In some studies, cytology has been
shown to predict accurately the presence of colposcopic or histologically confirmed
disease (Wright et al., 1994a; Adachi et al., 1993). In other studies, the false negative
rate for cytology has been shown to be as high as 23% (Tweddel et al., 1994) with
cytological evaluation alone failing to identify severe histological abnormalities in
42.6% of HIV-infected women (Uberti-Foppa et al., 1998). HPV testing may identify
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more accurately those HIV-infected women at greatest risk of neoplastic progression.
Indeed, combined HPV and Pap smear testing has been shown to improve detection of
histologically confirmed cervical disease (Uberti-Foppa et al., 1998). HPV DNA
detection has been shown to be beneficial for primary cervical cancer screening in HIV
seropositive women by more accurate identification of high-grade cervical disease than
the Pap smear (Petry et al., 1999).
As patient survival times are increased due to the use of antiretroviral drugs, specific
guidelines are needed to develop an effective programme for the early identification and
management of precancerous lesions in HIV-seropositive women, particularly those
who may be severely immunocompromised.




POTENTIAL APPLICATIONS OF HPV DNA TESTING WITHIN THE
CERVICAL SCREENING PROGRAMME
1. ROUTINE SCREENING FOR CERVICAL NEOPLASIA
Advantages: Good sensitivity; may allow screening interval to be increased for women
at low risk of cervical disease progression.
Disadvantages: Poor specificity since predictive value of an HPV positive test is very
low in younger women. May only be cost effective if HPV testing was restricted to
women over 30 years old.
2. TRIAGE OF WOMEN WITH BORDERLINE CYTOLOGICAL
ABNORMALITIES
Advantages: May identify women at risk of neoplastic progression. Potential to reduce
unnecessary repeat smears and visits.
Disadvantages: Cost effectiveness unknown.
3. POST-TREATMENT SURVEILLANCE
Advantages: Could more rapidly detect lesions that have been incompletely excised.
Could reduce the length of surveillance for HPV negative women.
Disadvantages: Few studies in this area- more research needed.
4. MANAGEMENT OF WOMEN WITH CHRONIC IMMUNOSUPPRESSION
Advantages: May reduce false negative cytology rates and identify more accurately
women at risk of neoplastic progression.
Disadvantages: Effect of HAART on natural history of HPV and CIN is unknown.
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1.12 Laboratory Identification of HPV Infection
Since HPVs cannot be readily propagated in cell cultures (due to the inability of
keratinocytes to terminally differentiate in vitro) and only small amounts of viral antigens
are present in infected exfoliated cells, the laboratory diagnosis of HPV infection requires
molecular techniques such as DNA hybridisation or nucleic acid amplification. Several
approaches have been used for HPV detection in cervical specimens with widely differing
results. Older methods such as Southern blots, dot blots and in-situ hybridisation analyses
are not as sensitive as current nucleic acid hybridisation or amplification methods or are too
time consuming and labour intensive for widespread application.
HPV testing within cervical screening programmes requires the use of a rapid, sensitive and
practical detection system, capable of automation and high-throughput of clinical
specimens. The ability to distinguish between different HPV genotypes and to quantify the
amount of HPV DNA present in a clinical sample would be added advantages. The two
principal methods currently available for HPV DNA detection in screening applications are
Hybrid Capture Assay II (HCAII) and polymerase chain reaction (PCR).
1.12.1 Hybrid capture assay
The first generation tube-based Hybrid Capture Assay has been used in epidemiological
studies (Schiffman et al., 1995, Cox et al., 1995) and now a second-generation microplate-
based test (HCAII) is commercially available for HPV DNA detection in cervical samples
(Lorincz, 1996). This is a molecular solution hybridisation assay in a microplate format for
the detection of eighteen HPV genotypes including both high-risk and low-risk genotypes.
It is more sensitive than the previous tube-based test (Poljak et al., 1999). Some workers
have adapted the signal strength to give a quantitative result reflecting viral load (Clavel et
al., 1998), but a correlation between signal strength and grade of cervical lesions has not
always been found (Sun et al., 1995; Recio et al., 1998). Some studies have shown the
Hybrid Capture technology to be as accurate and sensitive as some PCR assays using PCR
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product detection by gel electrophoresis (Farthing et al., 1994; Sun et al., 1995). Others have
found it to be less sensitive than consensus, nested or type-specific PCR methods (Cavuslu
et al., 1996; Cope et al., 1997).
1.12.2 Conventional PCR
Several PCR methods have been developed to detect a broad spectrum of mucosotropic
HPV types, in exfoliated cervical cells and biopsy material, using general or consensus
primers to amplify target sequences from either the conserved El or LI open reading frames
of the HPV genome. The two most commonly used LI primer systems are the MY09/11
degenerate primers (Manos et al., 1989) and the GP5+/6+ consensus primers (de Roda
Husman et al., 1995a) that amplify a broad spectrum of HPV genotypes, but with variability
of detection sensitivity among specific HPV types. Primers derived from conserved regions
of the El gene include consensus primers GP1 and GP2 that amplify a 444bp target
sequence (van den Brule et al., 1990), consensus primers CPI and CPII that amplify a
188bp target sequence (Smits et al., 1992) and IU and IWDO primers that contain inosine
residues at certain base positions to increase primer thermal stability (Gregoire et al., 1989).
It is impossible to differentiate between different HPV types by agarose gel electrophoresis
of consensus PCR amplicons since the amplified HPV products are all very similar in size.
1.12.2.1 PCR primer sets based on LI
1. GP5+/6+
GP5/6 primers were originally designed to detect a broad spectrum of HPV genotypes by
allowing mismatch acceptance between two primers and the target DNA during PCR by
using conditions of reduced stringency (Snijders et al., 1990). PCR sensitivity of GP5 and
GP6 primers (van den Brule et al., 1990; Snijders et al., 1990; van den Brule et al., 1992;
Remmink et al., 1995; Kjaer et al., 1996) could be increased 10 to 100 fold by elongation at
the 3' end, thus producing GP5+ and GP6+ primers (de Roda Husman et al., 1995a; Jacobs
et al., 1995) which amplify a 150bp sequence of the LI ORE. GP5+/6+ primers were
designed to have highest sensitivity for the most common HR-HPV genotype, HPV 16, as
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fewest mismatches occur between these primers and the HPV16 LI ORF target sequence.
More mismatches occur between the GP5+/6+ primers and other HPV genotypes so these
may be amplified with reduced efficiency.
2. MY09/11
Degenerate MY09/11 primers have been synthesised with nucleotide differences at several
positions to make them complementary to the target DNA. Thus MY09/11 primers are a
mixture of 25 individual primer sequences that will amplify a 450bp region of the LI open
reading frame.
3. PGMY09/11
The MY09/11 primers have been redesigned to improve the sensitivity of amplification
across the range of genotypes. To avoid using degenerate bases, multiple primer sequences
were created for the same primer binding region of the LI gene. These were then combined
into an upstream pool of 5 oligonucleotides (PGMY09) and a downstream pool of 13
oligonucleotides (PGMY11). The PGMY09/11 primers are significantly more sensitive
than the MY09/11 primers and increased detection of multiple HPV infections from 33.8%
to 40% (Gravitt et al., 2000).
The PGMY09/11 oligonucleotide pools have also been adapted for a reverse line blot assay
for the simultaneous detection and identification of HPV genotypes (Gravitt et al., 1998).
The added advantage of this assay is that it allows discrimination between multiple HPV
types in a single hybridisation test. Twenty-seven HPV probe mixes are immobilised onto a
nylon strip along with two probe controls and two (3-globin cellular controls.
4. "Shorty" primers
For the sensitive detection of high-risk HPV infection only, new primers have been
designed from the PGMY system specifically for the detection of high-risk HPVs. These
'shorty' primers amplify a 170bp region of the LI gene and have at least an equivalent, if
not higher, level of detection than PGMY primers for thirteen different high-risk types
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(Kornegay et al., 2000). Short PCR products also decrease the potential for missing a
positive infection due to target DNA degradation in clinical specimens, including DNA
recovered from archived material such as paraffin blocks.
5. SPF1/F2
In 1998, a novel broad-spectrum primer set was developed to amplify a 65bp region of the
LI gene. These primers have been shown to be more sensitive than both GP5+/6+ and
degenerate MY09/11 primers (Kleter et al., 1998). This short product fragment PCR
(SPF-PCR) assay will detect at least 43 different HPV genotypes. Furthermore, a SPF-PCR
hybridisation line probe assay (LiPA) was developed using these primers for the
simultaneous detection and identification of 16 different HPV types (Melchers et al., 1999).
This assay was further developed for genotyping of 25 different HPV types (Kleter et al.,
1999).
1.12.2.2 Primer Sets Based on E6/E7
There is some debate about the optimal location of primer binding sites within the genome
for HPV DNA amplification. E6 and E7 are always retained following integration but have
a lower level of sequence homology throughout the range of genital HPVs, thus E6/E7
primers have detected a limited number of HPV types in some studies (van den Brule et al.,
1993). A higher rate of HR-HPV detection was found when E6 primers were compared to
LI in some studies (Lungu et al., 1995, Adams et al., 1996) but a comparison of five HPV
primer pairs showed that a combination of two primer sets was essential for identification of
all HR-HPV types (Harnish et al., 1999).
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1.12.3 Real-time PCR
The commercial LightCycler™ (Idaho Technology Inc., supplied by Biogene Ltd.,
Kimbolton, Cambridgeshire) combines rapid PCR technology and sophisticated
computer software required for programming and product analysis. This allows DNA
amplification and analysis of results simultaneously, thus producing a 'real-time PCR'
system. Rather than using a metal block thermocycler as used in conventional PCR
methods, LightCycler technology utilises circulating air as a medium. In addition,
amplification reactions are performed in sealed capillaries made of borosilicate glass,
which have a high surface-to-volume ratio. These improvements allow rapid
temperature control (maximum ramp rate of 20°C/sec) and hence a significant reduction
in testing time (typically 40 cycles in 25 minutes). Commercially prepared master mixes
containing reaction buffer, Mg2+, dNTPs and Taq are available to allow fast pre-PCR
processing. A fluorescent dye called SybrGreen I™ is added to PCR reactions which
binds to the minor groove of double-stranded DNA and emits light on excitation
(Wittwer et al., 1997a). This is detected by a microlens at the end of each capillary
which bounces the light from a blue light-emitting diode into the volume of liquid, and a
photodiode which detects the fluorescence signal generated. Thus, as PCR product
accumulates, high precision optics are used to monitor the increase in fluorescence
which can be followed on the computer screen.
Because the melting temperature of DNA is dependent on sequence, length and GC
content, PCR products can be distinguished by their melting curves. As the temperature
increases, dsDNA becomes denatured and SybrGreen molecules become unbound
resulting in a decrease in fluorescence. Sudden drops in fluorescence represent the
melting of a PCR product and therefore individual products are identified by differences
in melting temperature (Tm). The determination of melting curves can be performed on
each sample after amplification without opening the reaction vessels, thus reducing the
risk of contamination.
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A single-tube, real time, nested PCR system has recently been developed to detect HPV
DNA using both MY09/11 and GP5+/6+ primers in the same reaction. The sensitivity
and specificity is comparable to both PCRs performed separately on a conventional
block thermocycler (Strauss et al., 2000).
1.12.4 PCR-ELISA
To make PCR more suitable for routine use, the GP5+/6+ primer system was developed into
a rapid, non-radioactive, PCR-enzyme linked immunosorbent assay (PCR-ELISA) for the
detection of HPV 16 and 18 DNA. This method is based on GP5+/6+ PCR using one
biotinylated primer followed by detection of PCR products in a microwell plate format using
DIG-labelled oligoprobes. Due to the additional hybridisation stage this method is more
sensitive and specific detecting down to 10-100 HPV copies (Jacobs et al., 1996). This
technique was further expanded for group-specific detection of 14 high- and 6 low-risk
HPV genotypes (Jacobs et al., 1997) with a sensitivity of 10-200 copies depending on the
genotype. A clinical sensitivity of 90% for the detection of CIN II/III lesions has been
demonstrated using this system (Nindl et al., 1999). Furthermore, a quantitative
PCR-ELISA has been developed to measure the amount of HPV 16 DNA per genome
equivalent in cervical scrapings. This approach is based on a combined competitive PCR for
both HPV16 using GP5+/6+ and P-globin DNA (Jacobs et al., 1999).
Similar PCR-ELISA methods have been developed for the detection of high-risk types
using amplification of the E6 ORF followed by detection using fluorescein labelled probes
(Lungu et al., 1995). Commercially available systems, such as the SHARP Signal System
(Solution Hybridisation Assay for PCR products) and the Boehringer Mannheim PCR-
ELISA kit have also been investigated (Terry et al., 1994; Poljak and Seme, 1996).
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1.13 Which HPV Test to Use?
In any clinical virology laboratory, there is differentiation between screening and diagnostic
assays. Therefore, it is possible that PCR and HCAII may have different uses in particular
clinical situations. PCR based tests for HPV DNA detection are highly sensitive and can
detect low levels of virus which may be transient and not of clinical significance. Therefore
in primary screening, a non-amplification test such as HCAII may be more suitable since
highly sensitive HPV detection tests raise the problem of clinical interpretation of low level
infections. For clinical management it may not also be necessary to detect the broad range of
HPV types, but only detect the HR-HPV infections. Due to the high sensitivity and type
specificity achievable with PCR-based tests, they may be useful in ascertaining that no HPV
is present when considering extending the screening interval for women with normal
cytology. Additionally, PCR assays using consensus primers may be useful in
epidemiological studies when it is necessary to detect very low levels of virus so the natural
history ofHPV can be studied.
Nevertheless, both general PCR and HCA II have important limitations. Both are fairly
labour intensive, expensive and neither can differentiate (without follow-up tests) between
individual HPV types or detect infection with multiple HPV types. After PCR, follow-up
investigations that will identify individual HPV types include sequencing (van den Brule et
al., 1992), type-specific probes (de Roda Husman et al., 1994; Jacobs et al., 1995) or
restriction fragment analysis (RFLP) of PCR products (Adams et al., 1996).
The major hurdle facing the introduction of HPV testing into existing cervical screening
programmes, regardless of the HPV testing method of choice, is the issue of cost. So far,
little information is available. Most studies assessing the economic implications of the
introduction of HPV testing have used mathematical models to assess the potential resource
savings by a reduction in the number of repeat Pap smears and referrals for colposcopy or
histological follow-up (van Ballegooijen et al., 1997; Brown and Garber, 1999; Goldie et
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al., 2001). They do not however address the actual cost savings in terms of the number of
cancers prevented or the numbers of life years gained by reduced mortality. Cuzick and
Sasieni (1997) estimated that if the introduction of HPV testing would allow safe extension
of the cervical screening interval from 3 to 5 years, then a saving of approximately £30
million per year would be possible. To confirm this, large longitudinal screening studies are
required which must also include assessment of the financial costs of combined liquid-based
cytology and HPV testing. In France, one such study has been performed to compare the
cost effectiveness of LBC and HPV testing with that of conventional Pap smears for cervical
cancer screening (Cochand-Priollet et al., 2001). In the UK, similar trials are underway
which have health economics cost analysis incorporated in the study design.
1.14 Summary
Despite the close association between HR-HPV infection and the development of cervical
cancer, there is some reluctance to use HPV testing as a primary tool for cervical cancer
screening due to the occurrence of a few cases of HPV negative cervical cancer. There is
some evidence that HPV negative cancers are found in older women and are associated with
a poorer prognosis (Walboomers and Meijer, 1997). In contrast, there is also much
controversy about whether such cases represent a true HPV-negative cervical carcinoma
subset or whether false HPV negative results have been generated reflecting either
disruption ofHPV during integration, failure to detect a new HPV type or very low levels of
viral DNA. In addition, HPV testing has lower specificity than cytology for high-grade
CIN, especially in younger women.
On the other hand, a strong clinical case can be made for the application of HPV DNA
testing for triage of women with B/L smears by providing a more objective test result that
will improve identification of premalignant cervical lesions. This has the potential to
increase the sensitivity and specificity of the NHSCSP whilst reducing the costs by
rationalising the management for individual women via reduced repeat smears and
colposcopy clinic visits.
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1.15 Aim and Topic of This Thesis
This work in this thesis was performed to investigate the role of HPV testing in the
NHSCSP for improved detection of cervical neoplasia, with particular emphasis on the
suitability ofHPV testing methods for use in a diagnostic laboratory setting.
With the advent of liquid-based cytology, the suitability of preservative fluids for DNA
extraction was assessed, in both split-sample and direct-to-vial studies, since this allows both
cytomorphological assessment and HPV tests to be performed from the same cervical
sample. To allow high throughput HPV testing of clinical LBC specimens, an automated
DNA extraction protocol was developed using a QLAGEN BioRobot 9604®.
The introduction of HPV testing must improve the sensitivity, specificity and predictive
value of the current methods. Two of the most well established techniques, Hybrid Capture
II and GP5+/6+ PCR, were used extensively for HPV DNA detection. Since, however,
neither of these methods can distinguish between individual HPV genotypes, novel
approaches for HPV detection and identification were also evaluated. To improve sample
turn-around within the laboratory, a real-time PCR assay was developed for rapid HPV
DNA detection and further identification of specific HPV types. Genotyping was also
performed by DNA sequence analysis and a reverse line blot assay (under development) to
determine the exact HPV types infecting the cervix and to distinguish between persistent
HPV infection or re-infection with different HPVs. In an attempt to determine whether HPV
testing would be most effectively targeted within the CSP for HPV screening or diagnosis,
the above tests were selectively performed on cervical specimens collected from specific
patient populations including women with previous borderline cytological abnormalities,
women attending for routine cervical screening and immunocompromised women.
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CHAPTER 2
GENERAL MATERIALS AND METHODS
2.1. Preparation of cytology slides using ThinPrep® 2000
Technical staff at the University of Edinburgh Pathology Department (UEPD) made
ThinPrep® smears using ThinPrep® 2000 technology. Sample vials were placed one
at a time into the ThinPrep® machine. Mucous, blood or non-diagnostic debris was
first broken up by gentle dispersion and then the sample was thoroughly mixed. A
series of negative pressure pulses were generated that allowed the fluid to be drawn
through a filter. The appropriate amount of diagnostic cellular material was then
transferred to a defined screening area on a glass slide using mechanical positioning
and positive air pressure. The slide, which contains a thin even layer of cells that is
virtually free of obscuring artefacts, was fixed using CellFyx™ solution (Cytyc
Corporation) before Pap staining was performed using the standard method.
Occasionally it was necessary to prepare a second slide in order to obtain a
satisfactory thin layer preparation.
2.2. Automated Screening of Cytology Slides
For ethical purposes, a permanent record was made of some cytology slides before
destruction. PAPNET uses neural network computer technology to analyse each of
the cells in a Pap smear and make a permanent record of the 128 most suspicious
cells. Slides were sent to PAPNET NSI, (NSI Europe B.V., Zekeringstraat,
Amsterdam) for this purpose.
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2.3. Cervical Cytology Reporting
Trained Cytotechnologists at the UEPD screened all the conventional Pap cervical
smears. UEPD serves the South-East Scotland population of 250,000 women in the
screening age group (18-60 years) which generates an annual workload of 85,000
smears. Cytological appearances were classified as borderline, mild, moderate or
severe dyskaryosis according to the BSCC's terminology and guidelines for
adequacy of cervical smears (Evans et al., 1986). LBC smears were screened by
particular staff members trained in this method.
2.4. Management of Cervical Disease
Follow-up of cytological abnormalities was performed at the Royal Infirmary of
Edinburgh Colposcopy Clinic. Patients with histological evidence of CIN of any
grade were treated using either cold coagulation or, more recently, loop diathermy in
the conventional manner performing a LLETZ which allows histological
confirmation of the lesion.
2.5. DNA Extraction from Clinical Specimens
2.5.1. Guanidinium isothiocyanate/ silica method
After soaking the archival smears in xylene for 2-7 days to remove the coverslips,
cells were scraped from each slide using a sterile scalpel blade and transferred to an
eppendorf tube containing 1ml of xylene. DNA extraction was performed using a
modification of the guanidinium isothiocyanate (GTC)/silica method of Boom et al.,
(1990). After centrifugation, the cell pellets were resuspended in 900(il GTC-
containing lysis buffer (Appendix 1), mixed thoroughly and incubated at room
temperature for 2.5 hours. 40|il of sterile silica beads in 0.1M HC1 were added and
incubated for one hour at room temperature with occasional mixing. The silica beads
and bound DNA were centrifuged at 5000 rpm for 1 minute, washed twice with
500(tl GTC-containing wash buffer and once with 70% ethanol. After the pellets
were air-dried at room temperature for 30 minutes, the DNA was eluted by addition
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of 250|il TE buffer, pH8.0 at 58°C. DNA was then precipitated using 1ml 96%
ethanol/50[il 3M sodium acetate, pH5.2. Finally, the cell pellets were washed in 70%
ethanol, air dried and then resuspended in 1 20j_l1 sterile water.
2.5.2. QIAamp® DNA mini kit
QIAamp® extraction procedures from QIAGEN Ltd. (West Sussex, UK) use a
modification of the method of Boom et al., (1990) to purify DNA. After specimen
processing, cell pellets were resuspended in 200pl TE buffer, pH7.2 for DNA
extraction using the QIAamp® DNA Mini Kit which is designed for purification of
DNA from human tissue samples such as muscle, heart, liver and brain. Due to the
relatively high mucous content of LBC samples and the large volume of sample
remaining after the thin layer smear preparation had been made, it was found that the
QIAGEN protocol for body fluids was unsuitable for efficient extraction. Thus, the
tissue protocol, which has an improved lysis stage, was necessary.
180jil of primary lysis buffer (ATL) and 20(ll of proteinase K were added to each
sample which was incubated at 55°C for at least one hour in a water bath (particular
mucous-rich specimens required longer incubation times of up to 2 hours). 200|il of
secondary lysis buffer (AL) was then added and incubated at 70°C for 10 minutes.
After the addition of 210|j.l ethanol, the sample was transferred to a QIAamp® spin
column in a 2ml collection tube and centrifuged at 8000 rpm for one minute. The
filtrate was discarded before addition of wash buffer (AW1) then centrifugation at
8000 rpm for 1 minute. The filtrate was again discarded before addition of 500(ll
wash buffer (AW2). Following centrifugation at 13000 rpm for 3 minutes, the DNA
was eluted twice using 200|j.l Buffer AE. Both eluates were pooled to give a final
elution volume of 400|il.
After showing the suitability of this extraction method for cervical specimens, cell
pellets were then stored directly in ATL buffer and frozen at either -20°C or -70°C.
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2.5.3. QIAVac® 24
The QIAGEN QIAVac® 24 system was designed for convenient vacuum processing
of up to 24 spin columns in parallel. Samples and wash buffers were drawn through
the column membranes under vacuum rather than by centrifugal force. This reduced
the hands-on-time involved during the QIAamp® extraction protocol thus
increasing the speed of the extraction process. Some QIAamp® spin columns were
processed using VacConnectors with VacValves. The VacValves were inserted
directly into the luer extensions of the QIAVac® 24 manifold. VacConnectors
(disposable connectors that fit between the QIAamp® spin columns and the
VacValves) were used to prevent direct contact of the spin columns and VacValves
thus avoiding any cross-contamination. They were discarded after a single use.
Vacuum pressure was generated using a water-pump thus drawing liquid through the
silica membranes. If the sample flow rates differed significantly between samples
then the VacValves could be opened or closed to ensure a consistent vacuum.
2.6 Hybrid Capture Assay II (HCAII)
HCAII (Digene Diagnostics Ltd.) is a molecular solution hybridisation assay for the
qualitative detection of thirteen high-risk HPVs and 5 low-risk genotypes using two
separate ssRNA probe cocktails to distinguish the oncogenic and non-oncogenic
types. In the majority of studies, this assay was performed using the HR-HPV probe
cocktail only for the detection of HR-HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59 and 68 that are associated with cervical neoplasia and cancer. The low-
risk probe will detect HPV 6, 11, 42, 43 and 44.
After specimen processing, DNA was denatured using a denaturation reagent (DNR)
containing sodium hydroxide and purple indicator dye which was added in half
volumes as compared to the specimen starting volume (e.g. 500|il per 1ml sample).
After mixing, DNA was denatured in a waterbath at 65°C for one hour. 25pl of RNA
probe cocktail was then added to the samples, resulting in a colour change from
purple to yellow. The samples were shaken on a rotary shaker at 1100 rpm for 5
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minutes and then re-incubated at 65°C for another hour to allow hybridisation to
occur. After a 5 minute cooling period, the lOOpl sample volume was transferred to
microtitre capture plate wells that were coated with anti- RNA:DNA hybrid
antibodies. During a one hour hybridisation period (with shaking), hybrids were
immobilised onto the solid surface. After blotting, detection reagent containing
alkaline phosphatase conjugated antibodies was then added and the plate incubated at
room temperature for 30 minutes. The plate was then washed manually six times
using Digene wash buffer and blotted well. A chemiluminescent substrate was then
added that was cleaved by the bound alkaline phosphatase producing a light signal
that can be measured accurately. Since multiple conjugated antibodies can bind to
each hybrid, substantial signal amplification occurred. After a 15 minute incubation
in the dark, the emission of light was measured as relative light units (RLUs) using a
DML 2000 luminometer connected to a computer. The RLU value obtained was
proportional to the amount of target DNA present. Samples with a RLU/cut-off
value >1 indicated a positive result for any of the HPV types contained in the probe
pool.
Positive and negative control material was included in every run. Each control was
run in triplicate and the assay cut-off value was calculated from the positive control
results obtained. The negative control contains carrier DNA in Digene Specimen
Transport Medium (STM). The positive control contained lpg/ml HPV 16 DNA in
STM.
It should be noted that the first-generation, tube based HCA (HCA I), was used at
the beginning of one study (Chapter 5) and was replaced by the second-generation
test (HCA II) as soon as it became available. The HCA I methodology is not
discussed here as samples were retested with HCAII, and HCAI only detected nine
HR-HPV types which were also detectable by HCAII. In addition, the study using
DNA extracted from archival smears was performed using a protocol adapted for
lOOp.1 amounts following manufacturers' instructions (Chapter 4).
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2.7 Sample Conversion for HCAII
Before HCA II testing, PreservCyt® specimens required initial processing using a
Digene Sample Conversion Kit. After vortex mixing, a 4ml volume of PreservCyt®
fluid was removed from the specimen vial into a 20ml sterile universal. 0.4 ml of
Digene Sample Conversion Buffer was added to each sample, mixed then
centrifuged at 3660rpm for 15 minutes. A stock solution of STM/DNR mix was
made by adding 120|il STM and 60pl DNR per sample to be tested. After
centrifugation, the supernatant was removed from each sample and the cell pellet
resuspended in 150|il STM/DNR mix. This volume was then transferred to a sterile,
labelled sarstedt vial and denatured at 60°C for 45 minutes. Samples were then stored
at -20°C until batch HCAII testing was performed, starting at the hybridisation stage.
2.8 Conventional PCR
The PCR is a molecular amplification technique that utilises a heat-resistant DNA
polymerase from Thermus aquaticus to extend primers chosen to flank a target
region of DNA. Multiple heating and cooling steps result in alternating cycles of
DNA synthesis and denaturation leading to an exponential accumulation of the
specific PCR product defined at its ends by the positions of the primers.
2.8.1 GP5+/6+ PCR
The general primers GP5+ and GP6+ (Table 2.1) were used to amplify a 150bp
region of the LI gene. These consensus primers detect at least 27 different
mucosotropic HPV genotypes, including both high- and low-risk genotypes,
simultaneously by allowing for base mismatching during primer binding at a low
annealing temperature of 40°C. A 150bp region of the major capsid protein gene can
be amplified using this pair of primers from each of HPV 6, 11, 13, 16, 18, 30, 31,
32, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61 and 66 (de
Roda Husman et al., 1995a).
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PCR amplification was performed in 50|ll PCR solution containing 25pmols of each
primer, 200pM of each deoxynucleoside triphosphate, lx reaction buffer, 3.5mM
MgCl2, 1U Taq polymerase (Life Technologies Ltd, Paisley, Scotland) and 10|il
extracted DNA. The mixture was overlaid with oil and then subjected to 40 cycles of
amplification (1 minute denaturation at 94°C, 2 minutes primer annealing at 40°C,
1.5 minutes DNA synthesis at 72°C). The first cycle was preceded by 4 minutes of
denaturation at 94°C and the last cycle was extended by 4 minutes at 72°C. At least
one positive and negative control was included in each PCR run.











Table 2.1 Sequences of PCR primers
2.8.2 P-globin PCR
(5-globin primers (Table 2.1) were used for amplification of a 209bp region of this
cellular gene (Saiki et al., 1985) as a positive control to confirm that cellular DNA
was present and could be amplified by PCR.
PCR amplification was performed in 50|il PCR solution containing 50pmol of each
primer, 200|lM each deoxynucleoside triphosphate, lx reaction buffer, 1.5mM
MgCl2, 1U Taq polymerase (Life Technologies) and 10p,l extracted DNA. The
mixture was overlaid with oil and then subjected to 40 cycles of amplification (1
minute denaturation at 95°C, 2 minutes primer annealing at 55°C, 1.5 minutes DNA
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synthesis at 72°C). The first cycle was preceded by 4 minutes of denaturation at 95°C
and the last cycle was extended by 4 minutes at 72°C. At least one positive and
negative control was included in each PCR run.
2.8.3. HotStart PCR
To minimise the amount of non-specific PCR amplification and reduce
primer-dimer artefacts, TaqStart™ Antibody (Sigma-Aldrich Co. Ltd., Dorset,
England) was added to most PCR reactions. This is a neutralising monoclonal
antibody that binds to Taq polymerase thus preventing its activity in the PCR
reaction mix. When the temperature is raised above 90°C during the first high
temperature step in the PCR process, the enzyme-antibody complex dissociates. This
results in the restored activity of the Taq polymerase enzyme while the TaqStart™
Antibody is rendered non-functional by heat denaturation.
For each PCR reaction mix, a working solution of TaqStart™ antibody was made.
For 10 PCR amplifications, 4.4|il TaqStart™ Antibody was added to 17.6|ul of
dilution buffer (provided by the manufacturer). 4.4pl of Taq polymerase (5units/p.l)
was then added to this diluted TaqStart™ Antibody and incubated at room
temperature for 10 minutes to allow binding of the antibody to the enzyme. 2.4p.l of
this mix was then added per PCR reaction.
2.8.4 PCR contamination precautions
All PCR reactions were performed under conditions designed to minimise sample
contamination. DNA isolation, preparation of PCR reactions, sample addition and
analysis of PCR products was conducted in four separate areas. Dedicated pipettes
with sterile filter disposable tips were used at each stage. All reagents and
amplification tubes used in each run were prepared in the PCR 'clean room'. DNA
samples were added to the PCR mix in a separate sample loading room. PCR was
performed using either Hybaid Omni-e or Hybaid Omnigene thermocyclers followed
by PCR product analysis in an additional area used only for gel electrophoresis.
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2.9 PCR Controls
2.9.1. Cultured cell lines
Cells from the human cervical cancer cell lines SiHa and HeLa were obtained from
laboratory stocks frozen in liquid nitrogen. SiHa and HeLa cells contain respectively
1-2 copies of HPV16 DNA (El Awady et al., 1987) and 30-40 copies of HPV 18
per cell (Arends et al., 1991).
These cell lines were cultured in Eagles Balance Salt Solution with 10% foetal
bovine serum (Appendix 1) until monolayers became confluent (in approximately
4-5 days). The monolayers were then washed twice with 4-5ml of Dulbeccos
solution to remove serum and then 0.8ml 2.5% trypsin in 10ml Dulbeccos solution
was added. After approximately 2 minutes, the trypsin was removed and each flask
was incubated at 36°C until the cells could be shaken from the glass (< 2 minutes).
Following resuspension in 5ml growth medium, the cells were counted using an
'improved Neubauer' counting chamber. lOOjil of cells was added to 900|il trypan
blue stain and a drop of this mix was allowed to fill an area on the counting chamber
under a coverslip. The number of viable cells/ml was calculated. Cells were either
stored in 1ml volumes at -20°C (with the cell count noted) or used to reseed another
flask at 0.6m cells/flask. DNA was extracted from 200|il of cells with a known cell
count/ml using the QIAamp® DNA Mini Kit protocol in accordance with the
manufacturer's tissue protocol. Extracted DNA from SiHa and HeLa cells was used
as positive PCR control material.
2.9.2. Cloning of HPV 16 and HPV 18 LI DNA
DNA was extracted from four separate aliquots of both SiHa and HeLa cells using
the QIAGEN Tissue extraction protocol. GP5+/6+ consensus primers were used to
amplify the LI region. The integrity of the PCR product was analysed by agarose gel
electrophoresis and an estimate of the PCR product concentration was made. The LI
region was cloned into the pGEM®-T Easy Vector using the pGEM-®T Easy
Vector System (Promega UK, Southampton, England).
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The high copy number pGEM@-T Easy Vector (3018bp) contains T7 and SP6 RNA
Polymerase promoters flanking a multiple cloning site (MCS) within the a-peptide
coding region of the enzyme (3-galactosidase (Lac Z gene). Successful cloning into
overhanging T ends interrupts the coding sequence of (3-galactosidase allowing
recombinant clones to be directly identified by colour screening on indicator plates.
The pGEM®-T Easy Vector contains multiple restriction sites within the MCS
including recognition sites for the restriction enzymes EcoR I, BstZ I and Not I, to
allow for the release of the insert by digestion with a single restriction enzyme.
Depending on the concentration of PCR product formed, either 2(0.1 (for strong PCR
product) or 4pl (for weak PCR product) of PCR product was added to each IOjj.1
ligation reaction. Each ligation reaction also contained lOx buffer, lpl pGEM®-T
Easy Vector (commercially prepared by cutting Promegas pGEM®-5zf(+) Vector
with EcoR V and adding a 3'-terminal thymidine to both ends), l(il T4 DNA ligase
(3 Weiss units/pl) and deionised water. The mixtures were incubated at 4°C
overnight. One positive control, containing a control insert DNA (to allow
assessment of ligation efficiency), and one negative control (comprising vector with
no insert), were included following the manufacturer's instructions. The negative
control allowed determination of the number of background blue colonies resulting
from non-tailed or undigested pGEM®-T Easy vector alone.
Transformation experiments were performed at the Department of Veterinary
Medicine, Summerhall, University of Edinburgh using JM109 High Efficiency
Competent Cells (kindly provided by Dr Bob Daziel). These bacterial cells were
compatible with blue/white screening and standard ampicillin selection. Following
brief centrifugation, 2(tl of each ligation reaction was added to a 1.5ml eppendorf
tube on ice. Another tube with 0.1 ng uncut plasmid for determination of the
transformation efficiency of competent cells was also prepared. JM109 cells were
then removed from -70°C storage and thawed on ice for approximately 5 minutes.
After gentle mixing, 50(tl of cells was added to each ligation reaction tube and lOOpl
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of cells was added to the transformation efficiency control tube. After mixing by
inversion, the tubes were cooled on ice for 20 minutes. Cells were then heat-shocked
by placing the tubes in a water bath set at exactly 42°C for 45-50 seconds. The tubes
were then immediately placed back on the ice for 2 minutes. 950|il SOC medium
(Appendix 1) at room temperature was added to the ligation reaction tubes and 900(0,1
SOC medium was added to the transformation efficiency control tube. All tubes were
then incubated at 37°C (with shaking) for one hour. The transformation efficiency of
the competent cells was checked by transforming them with an uncut plasmid
according to manufacturers' instructions. lOOpl of each transformation culture was
plated onto duplicate LB/ ampicillin/ IPTG/ X-gal plates. A 1:10 dilution with SOC
medium was made for the transformation control as recommended. All plates were
incubated overnight at 37°C. Clones that contained PCR product inserts produced
white colonies. Colonies were picked and grown overnight at 37°C in LB medium
(Appendix 1). Plasmid DNA was then isolated using QIAGEN QIAPrep® Plasmid
Miniprep procedure according to manufacturers' instructions. In summary, the
pelleted bacterial cells were resuspended in 250jil of Buffer PI (provided by the
manufacturer) to which 250|ll of Buffer P2 (provided by the manufacturer) was
added. After mixing, 350jil of Buffer N3 (provided by the manufacturer) was then
added and samples were centrifuged for 10 minutes. The supernatant from each
sample was transferred to a 2ml collection tube. After brief centrifugation (30-60
seconds), the flow-through was discarded and endonucleases were removed by a
wash with 0.5ml of Buffer PB (provided by the manufacturer). This was followed by
another brief centrifugation step and the flow-through was discarded. 0.75ml of
Buffer PE (provided by the manufacturer) was then added to wash the membrane and
remove any salts present. After centrifugation, the flow-through was again discarded
and centrifugation performed for an additional 1 minute to remove residual wash
buffer. DNA was eluted into a fresh 1.5ml tube by addition of 50pl of sterile water
and centrifugation for 1 minute. The plasmid DNA was then treated with restriction
enzyme EcoRl (provided by Dr. Daziel).
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2.9.3 Plasmid preparation
The DNAs of HPVs 16, 18, 45, 6 and 11 isolated from clinical material, were kindly
provided by Prof. Dr. E-M de Villiers (Referenzzentrum fuer humanpathogene
Papillomviren, Heidelberg, Germany). HPV 6 was provided cloned in vector pUC19;
HPVs 11, 16, 18 in pBR322 and HPV 45 in pGEM4. HPV 33 was cloned in plink322
obtained from Dr G. Orth (Institut Pasteur, Paris, France) and HPV 31 was cloned in
pT713 and was obtained from Dr A. Lorincz (Digene Diagnostics, Gaithersburg,
MD, USA).
Transformation was performed using Library Efficiency DH5°c™ Competent Cells
(Life Technologies, Paisley, Scotland). Plasmid-containing colonies were selected
using L-Amp plates then cultured in L-broth containing ampicillin. Plasmid DNA
was isolated from this bacterial cell culture using Hybaid Recovery Quick Mini Spin
Kit (Hybaid Ltd., Middlesex, England) following the manufacturers' instructions.
This procedure utilises a modified alkaline/SDS method and spin column technology
to prepare a pure lysate. After centrifugation of the bacterial cells, the culture
medium was carefully removed and 210pl cell lysis solution was added and mixed
by inversion. The samples were then incubated at room temperature for 5 minutes.
280pl of neutralising solution was added, the samples mixed by inversion and then
centrifuged at 13000 rpm for 10 minutes. The lysate was then added to a spin column
and centrifuged at 13000 rpm for 1 minute to bind the plasmid DNA to the silica
membrane. After washing, using 700|J.l wash solution, the plasmid DNA was eluted
into a 1.5ml eppendorf tube using 75|il sterile water added directly to the centre of
the silica matrix. A final centrifugation step was performed at 13000 rpm for 2
minutes.
Extracted DNA was digested with restriction enzymes and electrophoresed in 1%
agarose to check the identity of DNA. Finally, GeneQuant II spectrophotometric
analysis (Amersham Pharmacia Biotech, St. Albans, Herts, England) was performed
to measure the DNA concentration. This work was carried out in the Department of
Pathology, University of Edinburgh under the supervision of Mr. Robert Morris.
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2.10 Reverse Line Blot Assay (RLBA)
Biotinylated PGMY09/PGMY11 primers (provided by Roche Molecular Systems)
were used to amplify a 450bp fragment of the Li ORF from a broad range of genital
HPV types and biotinylated BGH20/BPC04 primers were used to simultaneously
amplify a 268bp fragment of the human [3-globin gene (Roche Molecular Systems,
Alameda, CA). Each lOOpl PCR solution contained 1.05pM of PGMY09/11 primers,
0.05pM of BGH20/BPC04 primers, 2()0pM of dATP, dCTP and dGTP, 600pM of
dUTP, lx reaction buffer II, 4mM MgCL, 7.5U AmpliTaq Gold and 5pl extracted
DNA. dUTP was substituted for dTTP so that potential laboratory carryover
contamination with HPV or (3-globin PCR products was eliminated with the
incorporation of uracil-N-glycosylase (UNG). The mixture was then subjected to 40
cycles of amplification (30 seconds at 95°C, 1 minute at 55°C, 1 minute at 72°C). The
first cycle was preceded by 9 minutes of denaturation at 95°C. After the last cycle
samples were held at 4°C until required for the next step.
After amplification, the PCR product was denatured by addition of lOOpl of
Amplicor Denaturation Solution (provided by manufacturer) to each PCR reaction
tube and incubated at room temperature for 15 minutes. 75pi of denatured PCR
product was then added to a well in a tray containing a single HPV genotyping strip
in 3ml of pre-warmed hybridisation solution (at 53°C). Strips were placed on a
platform shaker (set at 70 rpm) inside an incubator set at 53°C for 30 minutes.
After removing the hybridisation solution from the wells by aspiration, 3ml of room
temperature wash solution was added to each tray well, mixed, and then immediately
aspirated to remove any residual hybridisation solution. 3ml of pre-warmed wash
solution (at 53°C) was added and shaken for 15 minutes at 53°C. The wash buffer
was then removed by aspiration and 3ml of conjugate (streptavidin-horseradish
peroxidase) solution was added to each well. The tray was shaken at 50rpm for 30
minutes at room temperature. After removing the conjugate solution from the wells
by aspiration, 3ml of room temperature wash solution was added to each well,
mixed, and immediately aspirated to remove any residual conjugate solution.
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Another 3ml of room temperature wash solution was then added to all wells and the
tray shaken for 10 minutes on the platform shaker.
Following aspiration, this was repeated with another 10 minute wash step. After
aspiration of the wash solution, 3ml of citrate buffer, made from a 20x stock solution
provided by the manufacturer, was added to each strip and incubated for at least 5
minutes. The buffer was removed by aspiration then 3ml of colour development
solution added to each well and the tray was shaken at 50rpm for 5 minutes. After
aspiration of the colour development solution, the strips were heat sealed in plastic
pockets containing a small volume of citrate buffer. The strips were interpreted
manually using the HPV Overlay guide provided (Figure 2.1) then stored in the dark
at 4°C. Both control lines had to be positive for the test to be considered valid. For
interpretation purposes, the intensity of the bands present were graded as +, ++ and
+++ representing a weakly positive, positive and strongly positive hybridisation
result respectively.
2.11. Agarose Gel Electrophoresis
After amplification, PCR products were analysed by gel electrophoresis using 2%
agarose gels stained with ethidium bromide using lx TAE electrophoresis buffer
(Appendix 1). A lkb DNA molecular weight ladder (Life Technologies) was used to
confirm the size of the PCR products generated. Gels were electrophoresed at
70-100 volts for 40 minutes. A photographic record of the gels under UV light was































Figure 2.1 Overlay guide for the RLBA showing the HPV genotypes detected on
each test strip. 27 HPV typing probes are immobilised on a single nylon strip and
two control probes (high positive and low positive) that hybridise to the amplified (3-
globin control product.
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2.12. Purification of PCR Products
Before sequencing was performed, samples showing non-specific amplification were
purified using QIAquick® Gel extraction kit (QIAGEN Ltd.) following
manufacturer's instructions. Firstly, DNA fragments of the correct size were excised
from the 2% agarose gel under UV illumination, using a sterile scalpel blade. The
fragments were then treated with 300pl Buffer QG (provided by manufacturer) at
50°C for 10 minutes. This solubilised the agarose gel slice and provided the
appropriate conditions for binding of DNA to the silica membrane. After addition of
lOOpl isopropanol, the sample was transferred to a QIAquick® spin column in a 2ml
collection tube and centrifuged for 1 minute at 13,000 rpm. The flow through was
discarded and then 0.5ml Buffer QG added to each column before a further
centrifugation step. Washing of the membrane was performed using 0.75ml Buffer
PE (provided by manufacturer), which was left for 5 minutes before centrifugation.
A dry spin of the column was then performed. The DNA was eluted by addition of
30pl of Buffer EB (provided by manufacturer) to the centre of the QIAQuick®
membrane followed by a final centrifugation step. 10|LLl of the eluted DNA was used
in the PCR amplification reaction. After gel electrophoresis a clean, specific product
was observed and a volume of this PCR product was used for sequencing.
2.13. Restriction Enzyme Digests
Restriction enzymes are used to cut DNA at particular recognition sites to generate
fragments of a defined length that can be distinguished by agarose gel
electrophoresis. The restriction enzymes used were Bam HI (recognition site 5'
G/GATCC 3'), Eco R1 (recognition site 5' G/AATTC 3'), Bgl II (recognition site 5'
A/G°AT*CT 3') and Hind III (recognition site 5' A/AGCTT 3'). All enzymes were
provided by Sigma-Aldrich Co. Ltd. (Poole, Dorset, England). Each reaction
contained 11pi of sterile water, 2pl lOx buffer, 2pl enzyme and 5pi DNA and digests
were performed in a 37°C water bath for 1-2 hours.
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2.14. DNA Sequencing
DNA sequencing was performed by staff at DNASHEF Technologies (Department
of Haematology, Royal Infirmary of Edinburgh). Both strands of the PCR product
were sequenced using ABI Prism® BigDye™ Terminator Cycle sequencing with
Ready Reaction Kits (Applied Biosystems, Perkin Elmer United Kingdom,
Warrington, UK). Reaction mixes were prepared by adding 4pl Terminator Ready
Reaction Mix (which contains fluorescently labelled A—,C—,G-, and T-Dye
Terminators, dNTPs, AmpliTaq DNA polymerase, MgCE and Tris-HCl pH9), 2|al
SB Buffer (5x), l-5pl of PCR product, l|il primer (GP5+ or GP6+) and 8-12|il
deionised water.
The tubes were placed in a thermocycler and subjected to 25 cycles of the following:
96°C for 10 seconds; 50°C for 5 seconds then 60°C for 4 minutes. Samples were held
at 4°C until ready to purify. After centrifugation, ethanol/sodium acetate precipitation
was performed. For each sequencing reaction, 2|il 3M sodium acetate, pH4.6 and
50pl 95% ethanol were added to a 1.5ml eppendorf tube. The entire volume of
extension reaction product was added to this mix. After mixing by inversion, the
extension products were left to precipitate at room temperature for 15 minutes.
Samples were centrifuged at 14000rpm for 20 minutes and the supernatant was
carefully aspirated. The pellets were rinsed in 250pl 70% ethanol, vortexed and then
centrifuged at 14000rpm for 5 minutes. The supernatant was again carefully removed
by aspiration and the pellets were placed in a heat block at 96°C for 2 minutes until
dry. The pellets were resuspended in 4pl of a 5:1 mixture of formamide/blue
dextran-EDTA, denatured at 96°C for 2 minutes and placed on ice until ready to use.
Electrophoresis of samples was performed on a 4% polyacrylamide gel using the
ABI PRISM 377. Data was saved as chromatogram files that could be transported
electronically. DNA sequence files were visualised using chromas software package
1.42 (Griffith University, Brisbane, Australia) via internet citation
www.technelysium.com.au/chromas.html.
The DNA sequences from both strands were aligned and compared to published
HPV sequences in the GenBank database (Los Alamos National Laboratories) using
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Basic Local Alignment Search Tool (BLAST) software (Altschul et al., 1990) via the
National Centre for Biotechnology Information web site at
http://www.ncbi.nlm.nih.gov/. If the sequence could not be interpreted, due to more
than one peak present at the same position at multiple sites, this was considered to
signify a mixed infection with more than one HPV genotype represented by two or
more DNA fragments in the PCR solution.
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CHAPTER 3
NEW OR MODIFIED METHODS DEVELOPED FOR
HIGH-THROUGHPUT HPV ANALYSIS
3.1. Liquid-Based Cytology Specimen Processing for Automated DNA
Extraction
After a ThinPrep® smear had been prepared, the total volume of residual PreservCyt®
fluid in the sample vial was processed for DNA extraction in an attempt to increase the
potential for detecting low-level HPV infections. The fluid was measured in a sterile
universal tube with the volume noted and the cells present were pelleted by
centrifugation at 3600 rpm for 15 minutes. An additional note was made if the sample
was particularly mucoid or bloody in nature. After centrifugation, the supernatant was
discarded and the pellet resuspended in 180pl ATL lysis buffer (provided by QIAGEN
Ltd.) and transferred to a labelled, sterile sarstedt vial. In addition, some samples were
processed using either 10ml, 5ml or 1ml of the residual PreservCyt® fluid. This was
done to assess the sensitivity of the automated DNA extraction and PCR systems.
Furthermore, some of the samples that had 10ml only processed were also subjected to
treatment with CytoLyt™ (CL) fluid (Cytyc Corporation), a methanol-based, buffered
preservative solution designed to lyse red blood cells, prevent protein precipitation,
dissolve mucous and preserve morphology of cytology samples. It was designed as
transportation medium for non-gynaecological cytology samples such as respiratory and
gastrointestinal specimens, prior to processing. After initial centrifugation of the 10ml
specimen volume in a sterile universal, the supernatant PreservCyt® fluid was removed
and replaced with 10ml of CL solution. After thorough mixing, samples were
centrifuged at 3660 rpm for another 10 minutes and the supernatant decanted. The cell
pellet was then resuspended in 180pl ATL buffer, ready for DNA extraction.
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3.2 Automated DNA Extraction using BioRobot® 9604
The BioRobot® 9604 (QIAGEN Ltd.) is a molecular biology workstation for nucleic
acid extraction and purification from clinical samples attached to a PC with dedicated
software (Figure 3.1 and Figure 3.2). The BioRobot platform contained a specimen rack
area to hold the processed specimen pellets in ATL buffer (12 racks containing eight
samples in a 96-well plate format). Four individual probes attached to a robotic arm
allowed movement across the platform. Six racks of plugged tips were loaded onto the
workstation. These tips were attached to the probes for the delivery of certain reagents,
which were loaded into defined slot areas on the BioRobot platform. Plugged tips were
used to transfer an 180|il aliquot of the sample from the specimen rack to a plastic
96-well square block containing diluted proteinase K. This block was loaded on an
electronically controlled thermostat system which was used to incubate the samples at
56°C for one hour for sample lysis. 200|ll of a secondary lysis buffer (AL; provided by
the manufacturer) was added to the samples before another incubation step at 70°C for
10 minutes. At this stage, ethanol was added to a separate 96-well square block to which
the lysates were added before transfer of the entire volume to the QIAamp® 96 vacuum
plate which was located on the vacuum manifold. To prevent contamination, an overlay
of wash buffer (AW1; provided by the manufacturer) was added before samples were
drawn through the QIAamp® membranes under vacuum pressure driven by a peristaltic
pump. During this process DNA was bound to the membrane while residual material
was washed away. The membranes were washed with wash buffers AW1 and AW2
(provided by the manufacturer), pumped from individual buffer bottles, and the plate
was centrifuged at 6000 xg for 10 minutes with a micropore sheet attached to dry the
membranes before the elution step was performed. DNA was eluted into plastic
collection microtubes using 200pl AE buffer. Two separate elution steps were
performed to give a final elution volume of 400|il. The tubes were then sealed with strip
caps, labelled and stored at -70°C until PCR testing.
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Figure 3.1 The BioRobot® 9604
Figure 3.2 Diagrammatic representation of the BioRobot® 9604 platform
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The advantages of this system include the potential for high throughput of clinical
samples for DNA extraction with reliable results and consistent yields. Since a licensed
protocol was not available for DNA extraction from LBC samples, computer software
was modified to perform the tissue extraction protocol on the BioRobot® 9604. This
work involved close collaboration with BioRobot Application Specialists and several
members of the QIAGEN technical support and customer service teams. The system was
extensively tested using cell pellets from approximately 4000 LBC samples. Initial
processing of the LBC specimens was still done manually, as described above, and
several different processing strategies were investigated.
3.3 HPV DNA detection using real-time LightCycler PCR
The commercial LightCycler™ (Idaho Technology Inc., supplied by Biogene Ltd.)
combines rapid PCR technology and sophisticated computer software required for
programming and product analysis (Figures 3.3). This allows DNA amplification and
analysis of results simultaneously, thus producing a 'real-time' PCR system.
3.3.1 Primer design
Standard GP5+/6+ primers were synthesised by Cruachem and were HPLC-purified.
Type specific primers were designed in-house by modification of the GP5+/6+ primer
pair to change the primer sequences to make them specific for HPV 16 and 18. These
were produced following thorough searching of the HPV Sequence Database (Los
Alamos National Laboratory) in the GP5+/6+ region of the LI gene of all sequenced
HPV types and detailed analysis of product length, optimal annealing temperatures, base
variations between types and the possibility of non-specific amplification. Table 3.2
shows the DNA sequences of the HPV 16 and HPV 18 type- specific primers.
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Figure 3.3 The LightCycler PCR machine linked to a personal computer and schematic
































Table 3.2 DNA sequence of type-specific primers used for real-time LightCycler PCR
3.3.2 LightCycler PCR amplification
Since ready made LightCycler PCR master mixes containing reaction buffer, Mg2+,
dNTPs and Taq polymerase were available, only the fluorogenic reporter dye
(SybrGreenI™), primers and template DNA needed to be added. Reaction mixes
contained 0.5pl of 5|lM forward and reverse primers, 0.25|il of 1:1000 SybrGreen I ™
and 2.5pl of master mix containing 4mM MgCL (Biogene Ltd.) and TaqStart antibody
(Sigma-Aldrich Co. Ltd., Poole, Dorset). PCR reactions were made up in 0.5ml
eppendorf tubes in the PCR 'clean room' and 1.25jil template DNA added in a separate
'sample addition' area. The reaction mix was then loaded into a polypropylene cup
moulded to a glass capillary and sealed with a plastic stopper. After brief 10 second
centrifugation step to bring the sample down to the bottom of each capillary, they were
loaded into the LightCycler carousel which can hold up to 32 samples per run. The
cycling profiles were optimised for each set of primers and these are detailed in Table
3.3. Positive and negative controls were included in each run. Positive control material





GP5+/6+ 5 95°C for 0 seconds, 50°C for 3 seconds, 72°C for 3 seconds
35 85°C for 0 seconds, 55°C for 3 seconds, 72°C for 3 seconds
TS16 PCR 5 95°C for 0 seconds, 59°C for 3 seconds, 72°C for 3 seconds
35 82°C for 0 seconds, 59°C for 3 seconds, 72°C for 3 seconds
TS18 PCR 5 95°C for 0 seconds, 62°C for 3 seconds, 72°C for 3 seconds
35 85°C for 0 seconds, 62°C for 3 seconds, 72°C for 3 seconds
Table 3.3 Optimal cycling parameters used for real-time LightCycler PCR.
3.3.3 Melting temperature analysis of PCR products
Melting temperature (Tm) analysis is performed after PCR amplification is complete. The
melting temperature of DNA, defined as the temperature at which 50% of the duplices
become single-stranded, is dependant on the sequence, length and GC content. For detailed
melt analysis, one capillary containing specific PCR-amplified product was loaded at a time
into the LightCycler carousel. A single cycle of amplification was performed to anneal both
DNA strands at 50°C for 0 seconds followed by progressively increasing the cycling
temperature by thermal ramping at a transition of 0.2°C per second, to reach 85°C for 0
seconds. During this period, the fluorescent signal due to SybrGreen 1™ dissociating from
the minor groove of double-standed DNA was measured more frequently and therefore a
more accurate melting temperature was assigned. For analysis of the melting curves, the
computer software plots the first negative derivative of fluorescence (F) with respect to
temperature (T) (dF/dT) on the y-axis against the temperature (Temp) on the x-axis. The
peaks produced indicate when the maximum melting of the DNA strands occurred and thus
gives the specific Tm for each DNA duplex.
The entire assay including manual DNA extraction, PCR amplification and melting
temperature analysis took 3 hours.
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CHAPTER 4
DETECTION OF HPV IN ARCHIVAL SMEARS USING HYBRID CAPTURE
ASSAY II
4.1 Introduction
Cervical cancer is preventable providing neoplastic changes are identified prior to
malignant progression and treated. It is therefore difficult to relate HPV detection to
the progression of cervical disease by prospective studies since it is ethically
unacceptable not to treat precancerous disease that has a high potential for
progression. Retrospective follow-up studies, however, using archival Pap smears
can allow the natural history of HPV infection to be studied over a considerable
length of time and the relationship of HPV detection to normal and abnormal
cytology to be evaluated. In most cases, HR-HPV infection has a long duration
before the development of a high-grade lesion. Using archival material, Josefsson
and colleagues (2000) showed that the average time between HPV detection and the
development of cervical carcinoma in situ was 7.8 years. PCR testing of smear
material has shown that most cases of newly confirmed CIN 2 or worse had previous
HPV positive smears 5-6 years beforehand. More importantly, HPV DNA testing by
PCR identified the development of high-grade CIN three years before the
conventional diagnosis in 80% of cases and six years beforehand in two thirds of
cases (Carozzi et al., 2000).
Retrospective archival smear analysis relies on efficient recovery of DNA from
material that has been stored for a number of years. Several workers have achieved
amplification of HPV DNA from archival smears following a variety of different
DNA extraction methods. As an alternative to standard phenol-chloroform extraction
with ethanol precipitation of DNA, techniques such as simple freeze-thawing;
proteinase K digestion with subsequent boiling (Puranen et al., 1996; Jackson et al.,
1989); proteinase K and Tween 20 digestion followed by salting-out proteins using
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NaCl (Poljak et al., 1995) and guanidinium isothiocyanate (GTC)/silica have all been
investigated.
The integrity of the DNA recovered from archival smears appears to be dependent on
the method used and several comparative studies have attempted to test the efficacy
of these methods to recover DNA from archival material. In a study by de Roda
Husman et al., (1995b) GTC/silica extraction was found to be most efficient at
recovering DNA from archival smear material. This extraction method produced
strongly positive (3-globin PCR results and HPV DNA could be detected at 50-500
copies of HPV 16 per 50,000 cells. Furthermore, the GTC/silica extraction method
was used by Walboomers et al., (1995) to show that HPV DNA was present in 25
false negative cervical smears, from 16 women, taken up to six years before the
diagnosis of cervical cancer. Such findings support the hypothesis that HPV negative
cervical carcinomas do not exist (Walboomers and Meijer, 1997).
4.2 Aims of this Study
Previously, in a pilot study of 156 archival smears that had been stored for 12-13
years, it was shown that hybridisation by HCAII and amplification by GP5+/6+ PCR
could be used to detect genital HPV DNA (McGoogan et al., 1998). The aim of this
study was to investigate the role of HR-HPV in cervical disease progression by
retrospective examination of archival cervical smears over a ten-year period. The
relationship between HR-HPV detection and the development of cytological and
histological abnormalities was evaluated for 223 women who were regular
participants in the NHS Cervical Screening Programme.
64
4.3 Methods
4.3.1 Selection of archived cervical smears
The University of Edinburgh Pathology Department (UEPD) laboratory computer
database was searched to identify 223 women who had a cervical biopsy between
1991 and 1993, and who had at least two cervical smears in the five year periods
before and after the biopsy. Most biopsies had been taken from women referred for
colposcopy with a cytological abnormality (16 with low grade CIN and 87 with
high-grade CIN). However, some women had been referred for colposcopy for other
reasons with various findings on histology (negative xlO, koilocytosis xl7, polyp
xl3, condyloma acuminatum x9, chronic cervicitis xl, ulcer xl and glandular
dysplasia x3). In addition, histology did not always confirm the cytological findings,
thus providing a group covering the whole spectrum of CIN.
Cervical smears selected from 5 years before and up to 5 years after each biopsy
were removed from the UEPD archive. In total 975 Pap-stained cervical smears
taken from the 223 women between 1987 and 1997 were extracted from the files.
Since cervical smears are normally kept for at least 10 years, Lothian Research
Ethics Committee requested that a record be made of each smear before destruction.
Representative smear fields were recorded using computer-assisted PAPNET®
smear screening (Section 2.2). The smears obtained were presumed to have been
fixed in methylated spirits in the standard way but this was impossible to confirm.
4.3.2. Removal of cellular material from slides
After soaking the slides in xylene for 2-7days until the coverslips became detached,
cells were scraped from each slide using a sterile scalpel blade and transferred to an
eppendorf tube containing 1ml of xylene. After 45 minute incubation at room
temperature, the cells were pelleted by centrifugation at 7000rpm for 2minutes and
washed twice with 96% ethanol. Pellets were air dried at room temperature and
stored overnight at -20°C. DNA extraction was performed using a modification of
the GTC/silica method of Boom et al., (1990) (Section 2.5.1).
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4.3.3. HPV DNA detection by HCAII
Samples were tested using the HCAII high-risk probe pool containing HPV 16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 (Section 2.6). The assay was performed
according to manufacturers' instructions using a protocol adapted for lOOpl volumes.
The results obtained were compared to the cytology result in the same smear and
with histological findings from 167 biopsy specimens.
4.3.4 HPV DNA detection by PCR
PCR amplification could not be performed from denatured HCAII specimens directly
since no approved protocol was available. Attempts to amplify HPV DNA from
cervical cells resuspended in Digene STM were unsuccessful since STM appeared to
be inhibitory to PCR (data not shown).
Thus, to confirm the integrity of the DNA after CTC/silica extraction, PCR
amplification was performed on 10pl extracted DNA using (3-globin primers
(Section 2.8.2). Agarose gel electrophoresis was performed to visualise the amplified
PCR products (Section 2.11).
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4.4 RESULTS
4.4.1. Assessment of smear cellularity
Twenty-one of 975 Pap smears were found to have unsatisfactory cytology and were
not included in this analysis. To assess the amount of cellular material on each
smear, the visual size of pellets scraped from the remaining 954 slides was recorded:
343 slides produced small pellets (scored +), 490 gave medium pellets (scored ++)
and the remaining 121 gave large pellets (scored +++).
4.4.2. HR-HPV DNA detection using HCAII
Using HCAII, 172 HR-HPV positive results were obtained in 954 extracts from
archival smears obtained from 117 patients. HR-HPV positivity increased from 10%
to 30% as the size of pellet produced increased (Table 4.1).
4.4.3. HPV DNA detection by PCR
All attempts to confirm the integrity of the DNA in the archival smear extracts were
unsuccessful. Following (3-globin PCR amplification, no specific product was
visible upon agarose gel electrophoresis.
4.4.4 HPV positivity in relation to cervical pathology
HR-HPV detection by HCAII was found to increase as the grade of cervical
dysplasia increased (Table 4.2). 8.3% of smears obtained from women with no
cytological abnormality were HR-HPV DNA positive. The HR-HPV detection rate
increased to 41% in material extracted from smears taken from women with high-
grade cytological abnormalities.
Most biopsies had been taken between 1990 and 1992, and 21% of HR-HPV
positive smears were in this group (Table 4.3). From 1993 onwards, fewer HR-HPV
positive results were obtained from follow-up smears due to the removal of
neoplastic lesions at colposcopy with biopsy in the 1990-1992 period.
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Small (+) 343 312 31 (9.9%)
Medium (++) 490 386 104 (21%)
Large (+++) 121 84 37 (30.6%)
Total 954 782 172 (18%)





Within normal limits (WNL) 560 515 45 (8.3%)
Borderline (B/L) 91 76 15 (16.5%)
Mild dyskaryosis 117 81 36 (30.8%)
Moderate or severe
dyskaryosis
186 110 76 (40.9%)
Total 954 782 172 (18%)
Table 4.2 Detection of HR-HPV in DNA extracts from 954 fixed and stained Pap
smears showing different grades of dyskaryosis
Year smear made Total HR-HPV Detected
Before 1990 250 47 (18.8%)
1990 to 1992 563 118(21%)
1993 to 1997 162 10 (6.2%)
Total 975 175
Table 4.3 Detection of HR-HPV in DNA extracts from 975 fixed and stained
archival smears made in different years
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The positive and negative predictive values (PPV and NPV) of cytology and HR-
HPV testing for detection of severe histological abnormalities can be calculated from
the data shown in Table 4.4. The PPV of cytology alone was 70.5% (86/122) while
that of HPV detection alone was only 39% (48/122). Combined cytology and HPV
testing before biopsy would have increased the PPV to 78%. The NPV of a negative
HR-HPV result and normal cytology was 100%.
Cytology Result
HR-HPV Histology
Status Number CIN 2/3 CIN1/K+ WNL
Moderate or severe
dyskaryosis
Pos 40 + 39* 1 0
Neg 47 47* 0 0
Mild dyskaryosis
Pos 3t 3 0 0
Neg 17 12 2 3
B/L
Pos 3t 3 0 0
Neg 16 10 2 4
WNL
Pos 2t 1 0 1
Neg 34 7 2 25
Total 162 122 7 33
Table 4.4 Comparison of cervical cytology results and HR-HPV detection in
relation to histological findings.
WNL = within normal limits; B/L = borderline; CIN = cervical intraepithelial
neoplasia; K+ = koilocytosis
'
values used to calculate the PPV of HPV testing alone for the detection of severe disease.
*
values used to calculate the PPV of cytology alone for the detection of severe disease.
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To analyse these results further it is necessary to look at individual patient profiles
(Figure 4.1). It can be seen that PI and P2 developed high-grade cytological
abnormalities (equivalent to HSIL) with CIN3 detected on biopsy, in the absence of
HR-HPV detection. Indeed in PI, three episodes of severe abnormality were
recorded during the period of study. In P3, it is also interesting to note that two HR-
HPV negative smears were obtained in the two years immediately preceding HSIL or
CIN3 despite earlier HR-HPV positive smears. P4 in contrast did not show any CIN
on biopsy despite four previous HR-HPV positive smears. These patient profiles are
representative of the 157 fully analysed cases. They span an age range of 24-31
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Figure 4.1 Profiles for six women showing HR-HPV DNA detection by HCAII
from cellular material scraped from archival smears in relation to the cytological and
histological findings
ASCUS = atypical squamous epithelial cells of undetermined significance; LSIL =




The effectiveness of cytological screening is highly dependent on the quality of
taking, preparing and reading smears. Conventional cervical smears prepared on site
by the smear taker are subject to great variation in technical quality and allow little
control of the parameters required for optimal microscopic analysis (McGoogan and
Reith, 1996). In addition, differences in sampling efficiency can produce varying
amounts of cellular material on the original smear. Since the above factors could
affect the quantity of DNA extracted, the visual size of the cellular pellets scraped
from each slide was recorded. Interpretation of the smear itself using the naked eye
was not taken into consideration since the presence of blood or mucus can influence
the macroscopic appearance. Variation in the amount of material recovered from the
smears did have an effect on the HPV positivity, with the highest number of HPV
positive results being obtained from those smears that had greatest cellularity, as
estimated by the size of the cell pellet scraped from each slide (%2 trend = 34.7614 on 1
degree of freedom, P< 0.001 and %2 = 0.2807 on 1 degree of freedom, P = 0.60).
Overall, 18% of smears were HR-HPV DNA positive. HPV positivity was found to
significantly increase with increasing grade of cytological abnormality. (x2trend =
115.9360 on 1 degree of freedom, P< 0.001 and jj - 0.5067 on 2 degrees of freedom,
P = 0.78). Rather than using HR-HPV testing as a predictor of cervical disease
progression, results suggested that HPV testing would have a greater role in
excluding severe disease, since the negative predictive value of a negative HR-HPV
test and normal cytology was 100%. Bollen and colleagues (1997) obtained similar
results, with negative HPV results selecting for absence of high-grade intraepithelial
lesions. However, another study suggested that 100% of cone biopsies showing CIN
2-3 would be identified if they were HPV positive but showing low-grade
abnormalities (Fait et al., 1998). In the Edinburgh archival smear study this would
not have been the case.
Colposcopic intervention was largely successful in removing much HPV infection,
shown by the significant decrease in the HPV positivity rate in smears after 1993,
when treatment at colposcopy would have been given = 14.2722 on 1 degree of
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freedom, P< 0.001). This has similarly been shown in a study by Bollen et al.,
(1997). None of the 10 women who had subsequent HPV positive test results during
1993 to 1997 had further cytological abnormalities. However, it appears that half of
these women had very low-level HPV infection as shown by RLU indices of
between 1.41 and 1.7. Indeed, these may signify false positive HCAII results.
In this study, HPV positivity was considerably higher than that obtained in our pilot
study using 13 year old smears and HCAI, in which only 2.3% with normal cytology,
4.5% with low-grade abnormalities and 21.7% of smears with high-grade cervical
disease were HR-HPV positive (McGoogan et al., 1998). The higher percentage of
positives obtained in this group reflects the greater sensitivity of HCAII and the
length of storage time for the smears (maximum storage 10 years). However, the
HPV positivity rate for smears showing high-grade lesions was lower than obtained
in later studies with liquid-based cytology samples (see Chapters 6 and 7). Possible
reasons for this reduction in the sensitivity of HPV testing include low copy number
of HPVs rendering the extracted DNA undetectable by HCAII. The possibility that
some samples that were HR-HPV DNA negative may contain low-risk HPV
genotypes also cannot be excluded but HCAII testing using the low-risk probe
cocktail was not performed as part of this study.
PCR amplification of DNA from archival smears was problematic. Preliminary
attempts to achieve a reproducible PCR assay were unsuccessful, which was
attributed to the presence of inhibiting substances in the extracts that prevented
nucleic acid amplification occurring. It has been documented that the haematoxylin
solution and aluminium sulphate components of the Papanicolaou stain can interfere
with PCR (Chen et al., 1996). Even positive control material spiked with DNA
extracted from archival smear material resulted in no subsequent amplification of the
target DNA, although this could be partly overcome by dilution of the DNA before
addition to the PCR reaction. In other studies, dilution of the digested cellular DNA
(1:100) did not appear to remove the inhibitors but PCR analysis was possible if the
Pap smears were firstly destained with 1% HC1 or if phenol-chloroform extraction
was performed (Chen et al., 1996). Phenol-chloroform extraction appeared to be
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effective at removing inhibitors even if all the stain was not removed (Gall et al.,
1993). In HCAII testing, inhibition was not apparent but it is conceivable that the
lower HPV positivity obtained may also be due to the inhibitory effects of residual
stain. Although, in a study by McDonald et al., (1999) electrophoresis of DNA from
stained smears was degraded to a much greater extent than DNA extracted from
unstained smears.
Further PCR protocol development was not pursued as part of the study reported here
and a protocol was not developed to allow PCR testing on denatured HCAII samples
directly. If this had been possible, more HPV positive cases might have been
detected using PCR amplification, which is more sensitive than HCAII (Cavuslu et
al., 1996). In a previous pilot study involving 156 archival smears that had been
stored for 12-13 years, we found that both HCAII and GP5+/6+ PCR could be used
for the detection of HPV DNA (McGoogan et al., 1998). Nevertheless, in a small
study of 11 archival smears by Puranen et al., (1996) four out of five smears showing
high-grade abnormalities remained HPV DNA negative by PCR. Similarly Carozzi
et al., (2000) found that 21 of 92 (22.8%) smears showing high-grade disease did not
appear to be preceded by HPV infection. This was confirmed in the study reported
here, but this is unlikely to be attributed to the age of the smears since other patients
did have HR-HPV positive smears from similar dates. The lack of detectable HPV
could be attributed to either the small amount of DNA present (<1 copy/cell) in these
smears or deletion of the LI region due to viral integration. DNA in archival material
stored for long periods may also be subject to degradation, which could cause
generation of false negative HPV results. Additionally, the quality of fixation of the
original smear could affect cell preservation over extended time periods. In a study
by de Roda Husman et al., (1995b), storage time was found to have an effect on the
size of PCR target that could be amplified, since PCR targets of more than 200bp
could not be amplified from smears that had been stored for a long time. Similarly,
Carozzi et al., (2000) found the proportion of HPV DNA positive smears among
cases only decreased slightly with increased storage time (less than or more than 4
years).
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Another critical factor for the detection of HPV DNA in archival smears appears to
be the method used for DNA extraction. The GTC/silica extraction method is very
laborious and involves many manipulation steps during which the DNA could be
lost. A recent comparative study involving two proteinase K-based treatments and
two GTC-based assays found a GTC/silica-based column method, named the High
Pure PCR Template Preparation (HPPTP) assay, to be the most effective at DNA
extraction from archival cervical smears resulting in a larger amplifiable DNA yield.
These commercially available extraction columns, gave 15-44% extraction
efficiency whereas the GTC/silica method of Boom et al., (1990) gave an efficiency
range of only 1-3% in comparison (Jacobs et al., 2000).
Due to some of the problems outlined above, the use of archival smear material is
likely to underestimate HPV positivity compared with that obtained by using fresh
material. However increased HPV DNA positivity in archival smears has been
achieved by other workers using two sets of consensus PCR primers for HPV
detection. Following DNA extraction using a QIAGEN tissue kit protocol, Carozzi
and colleagues (2000) used consensus primers pU-lM and pU-2R (Fujinaga et al.,
1991) to amplify a 233-268bp fragment within the E6-E7 region of HPV 16, 18, 31,
33, 52 and 58. McDonald and colleagues (1999) obtained strong PCR positive results
using the consensus El primers CPI-IIG (Tieben et al., 1993) in some sample
dilutions that produced PCR negative results with the HPV LI primers GP5/6. CPI-
IIG, that amplify a 188bp fragment of the El ORF of a broad spectrum of HPV
types, have also been used successfully in another study resulting in HPV DNA
detection in all 13 abnormal smears that had been stored for 4 years (Svare et al.,
1998). A possible explanation for the above findings may be improved DNA
detection due to more efficient amplification of a smaller HPV DNA target. Jacobs et
al., (2000) found that (3-globin PCR positivity decreased with the increasing length
of amplified PCR product. Now, primer systems are available for PCR amplification
of smaller DNA fragments. For example, the SPF10 primer set will amplify a 65bp
fragment of the HPV LI open reading frame (Kleter et al., 1998). These primers may
be more efficient at amplification from archival DNA, which has been degraded over
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time. However, due to lack of time and resources, this could not be investigated in
this study.
HPV positivity might also have been increased if re-extraction of samples could
have been attempted, since de Roda Husman et al., (1995b) found that performing an
additional lysis and elution step on (3-globin PCR negative samples increased the
HPV positivity rate from 65% to 96%. A further round of extraction was found to
increase the efficiency of HPV DNA extraction even further, from 96% to 98%. In
addition, detection of HPV directly in paraffin-embedded biopsy tissue from the
women in the study reported here may have provided information regarding the
natural history of cervical HPV infection.
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4.6. Conclusion
HPV testing by HCAII is a suitable screening tool for archival smears. Extraction of
DNA from archival smears was shown to be problematic for PCR amplification,
confirming several other studies in recent years. With the advent of new extraction
methods which remove inhibitors and PCR primers that amplify shorter target
sequences, there remains a role for longitudinal studies of archival material to
provide useful information on the natural history of HPV infection and the relevance
of its detection.
Although the PPV of a positive HR-HPV result for a CIN 2-3 biopsy was lower than
cytology (39% vs 70.5%), the combined results would have been of value in ensuring
the appropriate women were referred for colposcopy. More importantly, the NPV of
a normal biopsy following a negative HR-HPV test in the presence of cervical
cytology within normal limits was 100%. Thus, the lack of HPV detection may be a
better predictor than cytology for the absence of subclinical HPV-associated cervical
neoplasia although both HPV negativity and normal cytology remain necessary to
give a 100% negative predictive value. Such HPV negative women with normal
cytology are at low-risk of developing a high-grade cervical lesion over the next 3 to
4 years (Rozendaal et ai, 1996).
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CHAPTER 5
HPV DETECTION AND IDENTIFICATION OF HPV GENOTYPES USING
DNA SEQUENCE ANALYSIS IN CERVICAL SCRAPE SAMPLES FROM
HIV-SEROPOSITIVE WOMEN
5.1 Introduction
Before the onset of the HIV epidemic in the 1980s, it had already been established
that immunosuppressed individuals were particularly susceptible to HPV infection.
For example, cell mediated immunosuppression due to organ transplantation,
chemotherapy and/or radiation therapy increased the risk of developing HPV
infections, particularly genital warts (Benton and Arends, 1996). In addition,
transplant patients receiving immunosuppressive drugs had an increased risk of CIN
(Ozsaran et al., 1999). HIV is now a major cause of cell-mediated
immunodeficiency worldwide due to the cytopathic effects of HIV on T-lymphocyte
'helper' (CD4+) cells of the immune system. This makes the host susceptible to a
variety of opportunistic infections since effective immune responses are suppressed.
In comparison to the general female population, HIV-seropositive women have been
shown to have an increased risk of developing invasive cervical carcinoma,
especially HIV-infected intravenous drug users (Serraino et al., 1999) thus
supporting the inclusion of invasive cervical carcinoma as an AIDS-defining
condition (Centres for Disease Control, 1992). Several studies have consistently
shown that HIV-seropositive women, compared to HIV-seronegative women, show
increased HPV prevalence and persistence with increased development of CIN
(Table 5.1), which is more aggressive and progresses more rapidly to invasive
cancer. However, the exact prevalence of CIN in HIV-seropositive women is
difficult to determine due to the different populations studied and variations in the
methodology used. Comparisons between different studies can be very difficult since






















































































Table5.1Summaryofstudi sinvestigatingcervic lytologandHPVpreval ncenIV-s rop sitiveer eg tiw en
Some studies also lack comparison between HIV-infected women and a parallel
control population of HIV non-infected women with similar behavioural
characteristics. Moreover, there is an ethical requirement for treatment if significant
cervical disease is identified. However, even after treatment by loop electrosurgical
excision or ablation, cervical lesions in HIV-positive women are more likely to
recur or persist (Wright et al., 1994b). Within two years of treatment, 34% may have
recurrent cervical lesions (Beattie et al., 1994) but as many as 82% HIV-positive
immunosuppressed women have been shown to have recurrent lesions after treatment
for CIN by conization (Six et al., 1998). Recurrence of CIN in HIV seropositive
women after standard ablative treatment has been shown to be related to increasing
immunosuppression (Maiman et al., 1993), with recurrence rates at 3 years reported
to be above 85% for women with CD4 counts less than 200 cells/pl (Fruchter et al.,
1996).
Despite this, an increased cervical HPV detection rate has not always been found
when HIV immunosuppression increases and some studies have found no apparent
increase in cervical neoplasia in HIV-infected women if adequate screening and
treatment programmes have been in place (Fruchter et al., 1996). Such findings have
prompted some authors to suggest that the role of HIV as an independent risk factor
for CIN is not yet proven (Norman and McCarthy, 1994). Although both HIV and
HPV are sexually transmitted, it appears that the association between them is
complex and cannot be fully explained by the level of immunosuppression alone.
Various studies have attempted to clarify the demographic or behavioural risk factors
associated with increased prevalence of HPV in HIV-infected women, with mixed
outcomes. A large national multicentre study of 1713 HIV-infected women (the
Womens Interagency HIV Study (WIHS)) found that factors linked to sexual and
reproductive history (e.g. number of sexual partners within six months of
enrollment), HPV infection (e.g. abnormal cytology history) and HIV infection (e.g.
CD4 count and HIV RNA level) all influenced the risk for abnormal cytology
(Massad et al., 1999). Smaller studies have also suggested that sexual behavioural
characteristics are associated with increased HPV detection in HIV-seropositive
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women, including the number of sex partners and number of pregnancies (Piper et
al., 1999; Temmerman et al., 1999). Smoking (more than 20 cigarettes per day) has
also been shown to be a significant risk factor for the development of cervical
disease in HIV-infected women also (Heard et al., 1997). In contrast, Klein et al.,
(1994) failed to show any association between several demographic or behavioural
variables and the risk of cervical abnormalities in HIV-seropositive women.
Nonetheless, it should be remembered that in addition to such classical risk factors
for the progression of cervical disease in HIV positive individuals, other variables
such as the particular HPV genotype(s) involved and the duration of HPV infection
may also be important.
The mechanism through which HIV-associated immunosuppression increases the
risk for CIN is not well understood. Some workers have suggested that HPV and
HIV interact at a molecular level where the tat—1 gene (a regulatory protein of HIV-
1) enhances HPV gene expression (Chopra and Tyring, 1997). It has also been
suggested that the development of many HIV-associated neoplasias is influenced by
microsatellite alterations in chromosome 3p, which reflects widespread genomic
instability. Microsatellite alterations have been found at much greater frequency in
CIN in HIV-infected women although the underlying mechanism is unknown
(Wistuba et al., 1999). Possible effects of immunosuppression on the natural history
of HPV include the reactivation of latent HPV infections and the establishment of
chronic or persistent infections. A very strong link between HPV detection and CD4+
lymphocyte count has been shown since HPV appears to be detected more frequently
and more persistently in HIV-infected women with reduced CD4 counts (Vernon et
al., 1995; Sun et al., 1997; Palefsky et al., 1999) with 90% of cases with CD4 counts
below 200 cells/pl harbouring HPV DNA (Johnson et al., 1992). The efficiency of
HIV suppression may even influence the infecting HPV type since in a study by
Johnson and colleagues (1992), half of the HIV infected women with CD4 counts
<200 cells/pl were found to harbour HPV 18, compared to only one of 22 women
with CD4 counts above 200 cells/jil. However, this finding has not been confirmed
by others (Branca et al., 2000). In addition, HIV-infected women with CD4 counts
of 200-500 cells/pl have a 3-fold increased risk of developing cytological
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abnormalities. When immunosupression increases further and CD4 counts fall to
below 200 cells/pi these women have 4-fold increased risk of abnormal cytology
(Six et al., 1998). There is also a 4-fold increase in the number of women with
untreated low-grade cervical disease that will not regress to normal (Delmas et al.,
2000).
To improve the immune status and prognosis of HIV-infected individuals, potent
antiretroviral drugs have been developed. Nowadays, these are generally
administered in combinations of three or more agents and usually consist of one
protease inhibitor combined with at least two reverse transcriptase inhibitors. Such
combinations are known as highly active antiretroviral therapy (HAART). There are
currently eighteen approved drugs for HIV infection (Internet citation:
www.aidsmeds.com/lessons/Drug_Chart.htm). Some studies have suggested that
there is a protective effect provided by antiretroviral therapy against the occurrence
of cervical disease in HIV seropositive women. Effective HAART regimes have the
potential to reduce the plasma HIV RNA viral load, which would allow some
restoration of immune function. This could conceivably also reduce HPV persistence
and the degree of CIN found in HIV-infected women. Alternatively if HAART has
little or no impact on the regression of cervical disease then the prevalence of
cervical neoplasia is likely to increase as patient survival time increases.
5.2 Aim of this study
The main objective of this work was to monitor the presence of HPV infection in
relation to cervical pathology in HIV-seropositive women in Edinburgh. Over a
four-year period, HPV testing was performed on collected cervical scrape samples
using HCAII and GP5+/6+ PCR. Direct DNA sequencing of the GP5+/6+ PCR
product was investigated as an HPV genotyping tool. Data on cervical cytology,
histology, HIV viral load results, antiretroviral drugs and CD4 cell counts was also




Women were enrolled from the cohort of 164 HIV infected women who attend the
colposcopy clinic at the Edinburgh Regional Infectious Diseases Unit. This cohort of
HIV-infected women was one of the first well-documented groups where infection
arose largely as a result of intravenous drug use (IVDU) and needle sharing. The
majority seroconverted over a fairly short period of time in the mid-1980s. The
women are all of Caucasian origin and are representative of the homogeneous
population resident in Lothian.
The stable well-defined nature of this group and the regular attendance of most at
clinics make it an ideal cohort for a longitudinal study of natural history of HIV-
associated HPV infection. Thus, a prospective study to monitor the presence and
persistence of HR-HPV types in these HIV-infected women has been ongoing since
1996. A clear association between abnormal cervical cytology and HIV infection has
previously been reported with some degree of CIN found in 35% of these HIV-
seropositive women (Johnstone et al., 1994; Beattie et al., 1994).
5.3.2 Specimen collection
At the same time as cervical sampling for conventional cytological analysis, cervical
brush specimens were collected in either lOmls PBS solution (n=198) or CytoRich
preservative fluid (AutoCyte Inc, Burlington, NC) (n=185). All specimens were
collected by Dr. Gerry Beattie, Consultant Gynaecologist.
383 cervical brush specimens were collected from 114 women (age range 20-55
years; mean age 33.6yrs) who attended regularly at approximately six-monthly
intervals. Specimen collection occurred between 1996 and 2000. A single cervical
sample was obtained from 34 women. 62 women had between two and six specimens
collected and seven or more samples were obtained from 18 women.
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5.3.3 Specimen processing
Specimen processing was performed by dividing each sample into two equal
volumes. After centrifugation at 3660 rpm for 15 minutes, one aliquot was
resuspended in 150|il of Digene STM/DNR mix for HPV testing by HCAII, and the
other was resuspended in 180pl of ATL Buffer (QIAGEN Ltd., West Sussex. UK)
for DNA extraction. All samples were then stored at -20°C until HPV testing was
performed.
5.3.4 Detection of HPV DNA and identification of HPV genotypes
HCAII testing was performed according to manufacturers' instructions using the
high-risk probe pool for detection of HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59 and 68 (Section 2.6). Only if the DNA sequencing result identified the presence of
HPV 6, 11, 42, 43 or 44 was the low-risk HCAII probe pool used to confirm the
result.
DNA extraction was performed using the QIAamp® DNA Mini Kit Tissue protocol
(Section 2.5.2). Consensus GP5+/6+ PCR amplification was performed as described
in Section 2.8.1 and PCR products were analysed in 2% agarose stained with
ethidium bromide. If non-specific product amplification was observed, the specific
product band was excised from the gel and purified using QIAquick® gel extraction
procedure (Section 2.12). After repeat GP5+/6+ PCR amplification and gel
electrophoresis, a single specific product was then observed which was used for
direct sequencing.
Both strands of selected PCR products were sequenced by DNASHEF Technologies
(Department of Haematology, Royal Infirmary of Edinburgh) using ABI Prism®
BigDye™ Terminator Cycle sequencing with Ready Reaction Kits (Section 2.14).
GP5+/6+ primers were used as the sequencing primers and the sequences from both
strands were aligned and compared to those of known HPV types as described in
Section 2.14. If the sequence could not be interpreted due to multiple peaks present
at the same positions, then this was considered to signify a mixed infection with
more than one HPV genotype represented by two or more DNA fragments in the
84
PCR product solution. The RLBA was used to show the exact HPV genotypes
present when multiple HPV infection was suspected (Section 2.10).
5.3.5 HIV-1 viral load testing and CD4 cell counts
Plasma HIV RNA level is used as a predictor of clinical outcome for HIV-infected
individuals and CD4 lymphocyte counts are used as a marker of immunosuppression.
In general, HIV-infected persons with CD4 counts of <200 cells/pl are considered
functionally immunosuppressed whereas individuals with CD4 counts above 200
cells/pl are relatively immunocompetent (Johnson et al., 1992).
HIV-1 RNA was measured diagnostically at the RCVL by the HIV-1 Amplicor
assay (Roche Diagnostics Ltd., Lewes, East Sussex) and the results made available.
HIV viral load testing began at RCVL in June 1996 using an assay with a lower limit
of detection of 400 copies/ml of plasma. From June 1999, an ultra-sensitive assay
was used when clinically requested which had a lower limit of detection of 50
copies/ml plasma. CD4 counts were made available from patient results held at
RCVL.
5.3.6 Cytology and histology results
Cervical smears were assessed under standard diagnostic conditions (Section 2.3).
Details of cytological assessment and histological evaluation were made available
from records held at the UEPD. Patients with histological evidence of CIN of any
grade were treated using either cold coagulation or, more recently, loop diathermy in
the conventional manner.
Ethical permission for this study was granted by Lothian Health (LREC/1999/4/78).
The DNA sequencing work was supported by Royal Infirmary of Edinburgh Small




5.4.1 Correlation between cytology and HPV DNA detection
A total of 383 specimens were collected during the duration of this study. Thirty two
specimens were omitted from further analysis as there was either no corresponding
Pap smear available (n=30) or no cytology result available (n=2). A further five
samples were lost and could not be tested using HR-HCAII so these were also
excluded.
225 of the 335 samples (65%) collected from HIV-infected women with satisfactory
Pap smears had no evidence of cervical abnormalities and 110 (32.8%) had abnormal
smear results. 46 of these (13.7%) were associated with a B/L smear result; 37
(10.9%) with mild dyskaryosis; 20 (5.8%) with moderate dyskaryosis and 7 (2.1%)
with severe dyskaryosis.
HR-HPV DNA was detected by HCAII in 155 of 346 specimens (44.8%). HR-HPV
positivity rose from 25.7% of samples associated with normal cytology to 95% of
samples associated with moderate dyskaryotic smears and 100% of samples
associated with severe dyskaryotic smears. The degree of abnormality observed
cytologically together with the percentage of HR-HPV positive samples is shown in
Table 5.2.
More than one cervical sample was obtained from 80 women. The HPV positivity
overall was similar whether first, last or all samples were considered. No high-grade
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5.4.2 Comparison of GP5+/6+ PCR and HCAII for detection of HPV DNA
One hundred and thirty-two specimens (from 66 women) were tested by both HR-
HCAII and GP5+/6+ PCR methods. A single specimen had been collected from 22
women, two specimens from 24 women and three or more from 20 women. Sixty of
132 (47%) specimens were found to be HPV positive by HR-HCAII and 78
specimens (59%) were found to be HPV positive by consensus GP5+/6+ PCR (Table
5.3). On direct comparison of HR-HCAII and GP5+/6+ PCR data, concordant results





POS 51 9 60
X
OZ
X NEG 27 45 72
TOTAL 78 54 132
Table 5.3 Comparison of HCA II (high-risk probe pool only) and GP5+/6+ PCR for
HPV detection
5.4.3 Direct DNA Sequencing of GP5+/6+ PCR products
Of the 78 GP5+/6+ PCR positive specimens from 44 women, 73 were subject to
DNA sequence analysis (using the GP5+/6+ primers as the sequencing primers) to
identify the exact HPV type present (Table 5.4). Four PCR positive samples were not
sequenced and one sample failed to generate interpretable sequence data (sequence
failure) but was later tested by RLBA. Abnormal cytology was associated with about
one third (21/62) of the specimens in this group (B/L 6.5%; mild dyskaryosis 14.5%;
moderate dyskaryosis 9.7%; severe dyskaryosis 3.2%).
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Many HPV genotypes previously isolated from the genital mucosa were found. The
majority of HPV DNA positive samples contained a single genotype (79%) (Figure
5.1). Twenty-nine HR-HPVs, 14 LR-HPVs and 15 novel HPV genotypes were
identifed. However, in 15/73 samples, multiple HPV infection was indicated. HPV
16 and HPV 18 were the most common HR-HPV genotypes but the HPV 16
positivity rate was only 9.5%. The most prevalent LR-HPV genotypes were HPV 42
and JC9710. In total, 22 different HPV genotypes were identified in single infections
and analysis of these genotypes identified in normal and dysplastic smears is shown
in Table 5.4. Both cases of severe dyskaryosis were found to harbour HPV 18 DNA.
Sequence analysis of 25 of 27 HR-HCAII negative, GP5+/6+ PCR positive samples
showed that 18 samples contained low-risk or novel HPV genotypes that would not
be detected by the HCAII high-risk probe cocktail (HPV 42 four times, JC9710 four
times, HPV 11 twice, HPV 32 twice, HPV 6b, HPV 54, , HPV 73, CP8304 (Figure
5.2), CP1608 and HPV 67). Nine of these 18 samples were then tested using the
HCAII low-risk probe cocktail. All four HPV 42 isolates and the HPV 6b isolate
gave LR-HCAII positive results. Samples containing HPV 32, HPV 73 and JC9710
gave LR-HCAII negative results since these types are not included in the probe
cocktail.
Sequence analysis of 15 samples suggested that one or more HPV genotype was
indicated, as sequence data showed multiple nucleotide peaks at the same positions
(Figure 5.3). However, the exact HPV genotypes present could not be confirmed by
this method. This group contained six samples that were HR-HCAII negative but
GP5+/6+ PCR positive. Three of these were tested using the HCAII low-risk probe
cocktail: two were LR-HCAII negative and one sample gave a LR-HCAII positive
result. RLBA testing was performed on all six samples containing more than one
HPV genotype for clarification.
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CYTOLOGY
Unknown U/S WNL B/L Mild Mod & Sev TOTAL
PCR
HPV neg 7 1 41 0 0 0 49
HPV pos 11 2 44 4 9 8 78
TOTAL 18 3 85 4 9 8 127
DNA SEQUENCING
Not sequenced 0 0 5 0 0 0 5
Single infection 11 1 30 4 6 6 58
Multiple infection 0 1 9 0 3 2 15
TOTAL 11 2 44 4 9 8 78
HIGH-RISK HPV
HPV 16 3 1 2 1 7
HPV 18 4 1 2 7
HPV 39 1 1 2
HPV 45 1 1 2
HPV 52 1 1
HPV 56 1 1 2
HPV 58 2 1 3
HPV 31 1 1
HPV 35 1 1
HPV 51 1 1 2
HPV 54 1 1
TOTAL 10 0 8 2 4 5 29
RARE/NOVEL HPVs
HPV 701 1 1
HPV 732 1 1
CP6108 2 2
CP8304 1 4 1 1 7
MM73 1 2 3
HPV 67 1 1
TOTAL 1 1 9 1 2 1 15
LOW RISK HPVs
HPV 6b 1 1
HPV 11 2 2
HPV 32 3 3
HPV 42 3 1 4
JC9710 4 4
TOTAL 0 0 13 1 0 0 14
Table 5.4 DNA sequencing results in relation to cytology.
U/S = unsatisfactory; WNL = within normal limits; B/L = borderline; Mild
= mild dyskaryosis; Mod = moderate dyskaryosis; Sev = severe dyskaryosis
1 HPV 70 = HPV 18 sub-group; related to HPV 39 (Longuet et al., 1996)
2 MM9 = HPV 73; high-risk genotype (Stewart et al., 1996; Wallin et al., 2000)
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5.4.4 HPV genotyping using the RLBA
To identify the exact HPV genotypes present in 15 specimens (from 14 women)
considered to contain more than one HPV genotype, RLBA testing was performed.
Two samples had single HPV genotypes present; three samples had dual HPV
infection; two samples had three different HPV genotypes present; three samples had
four HPV types present and six different HPV genotypes were detected in one
sample (Figure 5.4 and Table 5.5). Four specimens did not appear to contain any of
































Line HR-HCAII GP5+/6+ Direct
No. Patient result PCR DNA HPV genotypes
Identifier (RLU index) result Sequencing detected by RLBA
1 PS7 Pos (169.24) Pos Mixed HPV 16,18,MM7
2 TJ1 Pos (9.13) Pos Mixed HPV 16,31,39,45
3 BD1 Pos (902.07) Pos Mixed HPV
16,51,52,58,6,MM8
4 JD2 Neg (0.15) Pos Mixed HPV 16,59,MM7
5 CA8 Neg (0.26) Pos Mixed HPV 52, 11, 66, MM8
6 SiHa DNA NT NT NT HPV 16
7 Neg Control NT NT NT None
Figure 5.4 HPV genotyping using the Reverse Line Blot Assay showing five
samples containing more than one HPV type
NT = not tested
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No. of RLBA
Lab No. Cytology Result Bands HPV Genotype(s)






GJB/98/0052 mod 2 HPV 16
HPV 52 (<+)
GJB/98/0058 mild 3 HPV 16
HPV 18
MM7
GJB/98/0062 U/S 2 HPV 18
HPV 54




GJB/99/0128 neg 3 HPV 16 (+)
MM7 (+++)
HPV 59 (+++)








GJB/99/0139 mild 2 HPV 18 (++)
HPV 59 (+++)
GJB/98/0050 neg 0 ND
GJB/99/0084 neg 1 HPV 59 (+++)
GJB/99/0090 neg 0 ND
GJB/99/0103 neg 1 HPV 16
GJB/99/0109 neg 0 ND
GJB/99/0115 mild 0 ND
Table 5.5 HPV genotyping using the Reverse Line Blot Assay for 15 samples
considered to contain more than one HPV type by direct DNA sequence analysis of
the GP5+/6+ PCR product
ND = none detected
4 HPV 58 = HR-HPV genotype (Chan et al., 1999)
5 MM8 = LR-HPV genotype (Meyer et al., 1998b)
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5.4.5 Detection of HPV DNA in follow-up cervical scrape specimens
Of the 20 women with more than one specimen, six (30%) appeared to be
persistently infected with the same HPV type. Ten out of 14 women (70%), who had
at least three cervical specimens taken at approximately six-monthly intervals were
always HPV DNA positive but infected with different HPV types at different times.
Four HPV types whose oncogenicity still has to be determined or confirmed were
found in fifteen specimens from 10 women. These were MM7 (now designated
HPV83 (Brown et al., 1999)), JC9710, CP6108 and CP8304 (Table 5.6). All four
JC9710 isolates were HR-HCAII negative, GP5+/6+ PCR positive. CP6108 was also
HR-HCAII negative, GP5+/6+ PCR positive although one sample did produce a
weakly positive HR-HCAII result. On the other hand, CP8304 and MM7 genotypes
were all HR-HCAII positive, despite these genotypes not being present in the HCAII
high risk probe cocktail. Of these novel HPV genotypes, CP8304 was the only one to
be found in association with cervical dysplasia. This genotype was detected in
cervical scrapes from a 41-year old woman (Patient X). CP8304 was also associated















MM7 2 3 Neg x2 Pos x2 Pos x2
No smear xl Pos Pos
CP8304 4 6 Neg x3 Pos x3 Pos x3
Mild xl Pos Pos
Mod xl Pos Pos
Pos (1.43*) Pos
CP6108 1 2 Neg x2 Neg (0.63*) Pos
JC9710 3 4 Neg x4 Neg x4 Pos x4
TOTAL 10 15
Table 5.6 Four novel HPV genotypes identified by direct DNA sequencing of
GP5+/6+ PCR products with the associated cytology and HPV testing results.
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Figure 5.5 Summary of data collected from Patient X showing changes in cytology,
histology, HPV status, CD4 cell count and HIV RNA viral load over time
P = positive
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5.4.6 Influence of HlV-induced immunosuppression
At enrolment 23/114 women (20.2%) were receiving antiretroviral therapy (ART)
when their first sample was taken (between May 1995 and November 2000). Four
women were receiving one drug (AZT x3; ddl xl); ten women were receiving two
drugs (AZT+3TC x3; AZT+ddl xl, AZT+ddC x2; d4T+3TC x2; d4T+ddC xl;
d4T+ddI xl) and eight women were receiving HAART (unknown combination x5;
3TC+NVP+RTN xl; 3TC+NVP+AZT xl, 3TC+NVP+d4T xl). In addition, one
woman was receiving her drug regime as part of a drugs trial. Some of the women in
this group were receiving ART prior to July 1996 when HIV viral load testing
became available and therefore nine samples collected had no corresponding HIV
viral load result.
Of the 91 women who were not receiving ART when their first cervical specimen
was collected, 59 had at least one other sample taken. 21/59 (35.6%) were receiving
antiretroviral therapy when their last study specimen was collected: two women were
receiving one drug (AZT xl; 3TC xl); four women were receiving two drugs
(unknown combination xl; 3TC+d4T x2; ddI+d4T xl) and fifteen women were
receiving HAART (3 drugs xl2 ; 4 drugs xl; 5 drugs x2). 38/59 women were still
not being treated with any antiretroviral drugs when their last cervical specimen was
collected.
During the study period, 195 of an additional 269 specimens were obtained from
women who had a corresponding HIV RNA viral load result. 87 specimens were
collected from women who were not receiving antiretroviral drugs at the time of
specimen collection. The median HIV RNA viral load result associated with these
specimens was 18,873 copies/ml. A further 108 specimens were collected from
women who were receiving ART of some kind at the time of specimen collection.
Seven samples were obtained from women receiving one drug (median HIV RNA
viral load = 20,786 copies/ml), 26 samples were obtained from women receiving two
drugs (median HIV RNA viral load = 6,165 copies/ml) and 75 samples were
obtained from women receiving HAART (median HIV RNA viral load = 140
copies/ml).
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Of the 114 women who were receiving ART, 145 specimens were collected for
cytological analysis from 52 women who had a corresponding HIV RNA viral load
result and/or CD4 cell count. 18 women had one specimen collected, 13 women had
two specimens collected, 8 women had three specimens collected and 12 women had
between four and eight specimens collected. One woman had 12 specimens
collected. Analysis of the cytology results in relation to immune status, as indicated
by HIV RNA viral load and CD4 cell counts, can be seen in Tables 5.7 and 5.8
respectively. From Table 5.7, it can be seen that 45/124 specimens were obtained
from women with HIV RNA viral load results >5000 copies/ml and 79 specimens
were taken from women with HIV RNA viral loads <5000 copies/ml. 21 specimens
had to be omitted from this analysis as they were obtained prior to the introduction of
HIV viral load testing. Increased HIV RNA viral load appeared to be associated with
a highly significant increased risk of abnormal cytology. 20/45 (44.4%) samples
taken from women with HIV viral load results >5000 copies/ml were associated with
some degree of cervical cytological abnormality (B/L or worse) compared with
16.4% (13/79) of samples taken from women with HIV viral load results <5000
copies/ml (%2 = 11.4993 on 1 degree of freedom, P<0.001).
Cytology










Unknown 0 0 0 0 1 1
No smear 0 5(4) 0 4(4) 1(1) 10
Unsatisfactory (U/S) 0 2(1) 0 2 1 5
Negative (WNL) 1 44 (14) 14 (2, INT) 10(1) 6(1) 75
Borderline (B/L) 0 3(1) 2(2) 2(2) 3(3) 10
Mild dyskaryosis
(Mild)
0 5(5) 2(1) 2(1) 5(5) 14
Moderate/severe
dyskaryosis (Mod/Sev)
0 1(1) 0 5(5) 3(3) 9
TOTAL (HR-HPV+) 1 60 (26) 18 (5) 25 (13) 20 (13) 124
Table 5.7 Relationship between HIV viral load and cytology in HIV-seropositive
women
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From Table 5.8 it can be seen that 61 (42.1%) of the 145 samples obtained from the
same 52 women were associated with a CD4 count of less than 200 cells/fll. Of the
68 samples collected from women with a CD4 count above 200 cells/pl, only 20
samples (13.8%) were associated with CD4 counts of more than 500 cells/|ll. HIV-
infected women with abnormal smears showed lower CD4 lymphocyte counts (%2 =
5.4436 on 1 degree of freedom, P = 0.020). Twenty-four out of 61 samples (39.3%)
taken from women with CD4 counts <200 cells/pl were associated with cervical
cytological abnormalities (B/L or worse), whereas 14/68 (20.5%) samples taken from
women with CD4 counts of 200 cells/pl or more were found to have Pap smear
abnormalities. HPV DNA detection was also found to be more common in samples
taken from women with CD4 counts <200 cells/pl compared to women >200 cells/pl










Unknown 0 1 0 1
No smear KD 7(6) 4(4) 12
Unsatisfactory (U/S) 1 3 2(1) 6
Negative (WNL) 11 (1, INT) 26 (7) 48 (10) 85
Borderline (B/L) 3(1) 4(3) 7(6) 14
Mild dyskaryosis (Mild) 0 11(10) 5(4) 16
Moderate/severe dyskaryosis
(Mod/Sev)
0 9(9) 2(2) 11
TOTAL (HR-HPV+) 16(3) 61 (35) 68 (17) 145




5.5.1 Cytological abnormalities in HIV-seropositive women
Abnormal cervical cytology was common in HIV-infected women from Lothian but
the majority of abnormalities were low grade. Severe dyskaryosis was found in only
2.1% of satisfactory smears taken from the enrolled group. This supports a large US
study where high grade changes were found in only 2.5% of HIV-infected women
(Massad et al., 1999). It has already been reported that high grade CIN (CIN 2/3)
reached a peak in the Edinburgh HIV cohort in 1990-1992 and then dropped sharply.
Low grade CIN (CIN 1) increased between 1987-1997 but also now appears to be
decreasing (as shown in Figure 2; Cubie et al., 2000) (Appendix 2). This had
occurred well before the introduction of HAART and it is likely that regular
monitoring and treatment of HPV-related cervical lesions has been of great
significance in the clinical management of this group of HIV-seropositive women.
The importance of adequate screening and treatment programmes for HIV-infected
women to prevent progression to invasive disease has been highlighted by others
(Vernon eta/., 1995; Goodman eta/., 1999).
5.5.2 HPV testing methods
5.5.2.1 GP5+/6+ PCR and HCAII
On comparison of GP5+/6+ PCR and HCAII testing methods for the detection of
HPV DNA, the PCR-based method resulted in a higher HPV detection rate
compared to HR-HCAII. Unlike HCAII, the GP5+/6+ consensus primer PCR
method can detect high-risk, low-risk and novel HPV genotypes. However, PCR
amplification of certain HPV types may differ depending on the primer set chosen
(Karlsen et al., 1996; Qu et al., 1997; Baay et al., 1996). For example, GP5+/6+
primers have been shown to be less effective at detecting multiple infections
compared to other primer systems available (Qu et al., 1997). Improved HPV
detection in HIV-seropositive women using MY09/11 primers has been shown by
Uberti-Foppa et al., (1998), where HPV was detected by HCAII in 66% of cases but
MY09/11 PCR was positive in 91%.
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In this study, using HCAII alone would have missed 27 cases of HPV infection,
mostly due to LR-HPV genotypes. In contrast, nine specimens were HR-HCAII
positive but gave negative results upon GP5+/6+ PCR testing. These are most likely
false positive HCAII results since the RLU ratios of all except one sample were less
than 3. It is likely that upon repeat testing these samples would be HR-HCAII
negative. The HCAII results obtained were not used quantitatively although it has
been shown that HIV-seropositive women with normal cytology and HPV positivity
by HR-HCAII have more than seven times the amount of HPV DNA compared to
HPV-positive, HIV-seronegative women (Womack et al., 2000) and high viral load
but not viral risk category has been associated with disease persistence among HIV-
seropositive women (Ahdieh et al., 2001). Quantitative measurements of HPV DNA
by HR-HCAII have also been strongly associated with high-grade CIN in HIV-
seropositive women (Cohn et al., 2001) and some correlation has been shown
between HCAII RLU indices and the degree of squamous dyskaryosis in the
Edinburgh HIV-infected population (as shown in Table 2, Cubie et al., 2000
(Appendix 3). Sequencing data from the study reported here, showed that the high-
risk HCAII probe pool mix allowed detection by cross-hybridisation to additional
HPV genotypes. For example, all samples containing CP8304 and MM7 were HR-
HCAII positive, and GP5+/6+ PCR positive. The type specificity of HCAI has been
investigated by Konya et al., (2000) who concluded that several HPVs including
HPV53, 58, 62, 66, CP8304 and MM4 were detectable by the this test despite the
lack of specific probes for these types in the probe cocktail. Using HCAII, detection
of HPV53, 66, 67, 73, CP6108 and CP8061 has been reported (Peyton et al., 1998)
and cross-reactivity of some HR-HPV types with LR-HPV genotypes has also be
found (Meyer et al., 2001a).
5.5.2.2 Direct DNA sequencing of GP5+/6+ PCR products
Using a small aliquot of the GP5+/6+ PCR product as a template for direct DNA
sequencing proved to be a powerful method for HPV genotyping. It is particularly
suited to the identification of a wide range of genotypes, including rare, novel or
uncharacterised types, that may not be identified by other methods (Bernard et al.,
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1994). Indeed, direct sequencing of PCR products has been used in other studies for
identification of novel HPV genotypes JC9710 (Feoli-Fonseca et al., 1998a) and
JC9813 (Feoli-Fonseca et al., 1998b) from HIV-positive women. It is therefore
possible that additional new HPV genotypes may be discovered in this population
using PCR-direct sequencing or rare types may be further characterised in terms of
oncogenicity. However, the drawbacks of DNA sequencing included difficulty
resolving low quality sequence data from true multiple infection. In such cases,
manual interpretation of sequence data was sometimes necessary to assign an HPV
type. Since the LI region is highly conserved between different HPV types and the
PCR product sequenced was only 150bp in size, sometimes it was difficult to obtain
sufficient sequence homology to confidently assign a single HPV genotytype and
therefore these were considered true multiple infections. It is known that the
presence of excess primer can interfere with the sequencing reaction but attempts to
improve this were unsuccessful. Ambiguous sequence results could have been
resolved by reamplification and cloning but this was not possible during the current
study. A software database has now been created by Feoli-Fonseca and colleagues
(1999) to address the diagnostic problem of overlapping sequences (multiple peaks at
a given nucleotide position) that signify infection with more than one HPV type.
5.5.3 Novel HPVs and multiple HPV infection
HPVs 16 and 18 are documented to be the most prevalent genotypes in both HIV-
infected and non-infected women (Capiello et al., 1997; Chopra and Tyring, 1997).
Although HPV 16 and HPV 18 were most commonly detected in the current study
(29.2% prevalence for both), a total of 22 different HPV genotypes were found in
single infections. These findings are comparable to other studies where a variety of
HPV genotypes have been identified in HIV infected women, including novel HPV
types, which may or may not be oncogenic (Cappiello et al., 1997; Meyer et al.,
1998; Gon^alves et al., 1999, Slavinsky et al., 2000). Indeed, new HPV types have
been identified in oral warts with atypia from HIV-infected patients (Volter et al.,
1996). However, only the novel HPV type CP8304 was associated with cervical
dyskaryosis and histologically confirmed cervical disease. This genotype, which is
closely related to HPV62 (84.5%), a low-risk HPV genotype, was first identified in
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women from New Mexico who had normal cervical cytology (Peyton and Wheeler,
1994). More recently, Meyer et ah, (2001b) have concluded that CP8304 is probably
not associated with a high risk of malignant progression since this viral type has
never been detected in cervical cancer specimens. HPV sequences CP8304, CP6108
and MM8 and HPV types 61 and 62 are all members of the A3 group (internet
citation http://hpv-web.lanl.gov and Figure 1.1).
PCR-based assays have been used by others to show that HIV seropositive women
harbour a higher proportion of multiple HPV genotypes in the cervix compared to
HIV seronegative women (Eckert et al., 1999; Torrisi et al., 2000). In the study
reported here, direct DNA sequence analysis of GP5+/6+ PCR products indicated
that 15 samples contained more than one HPV genotype. The RLBA proved a useful
tool for determining the exact HPV types present in samples containing more than
one HPV genotype. Using this method, 4 of 15 samples were found to contain
between four and six different HPVs. The absence of HPV detection in four samples
does not mean that HPV is not present. Such results may have arisen due to either a
false positive PCR result or due to the presence of other HPV genotype(s) that cannot
be detected by this method due to the design of the probes used. Due to the lack of
type-specific probes for rare or novel HPVs, the prevalence of such HPVs in
particular may not have been fully realised (Ong et al., 1994; Peyton et al., 1994).
The challenge of future studies will be to show whether particular novel HPV
genotypes are clinically relevant. If so, then the range of specific probes included in
HPV assays will need to be expanded.
Findings from the study reported here also show that the HPV genotypes harboured
in the cervix of HIV-infected women do not always remain the same over time. In a
study by Miotti and colleagues (1996) only 62.5% women with HPV detected at two
visits had the same HPV type. Although changes in lifestyle and sexual practice
could influence the acquisition of HPV types, it has been suggested that
'epidemiological waves' of HPV types could be likely (Jin et al., 2000). If the HPV
genotypes do not remain the same then single time point HPV testing may
considerably underestimate both the prevalence of HPV infection and the genotypes
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associated with cervical neoplasia. Therefore care must also be taken about the use of
the term 'persistent infection'.
In the study reported here, 70% of women who had at least three cervical specimens
taken were shown to be HPV DNA positive in every sample, although this was not
necessarily associated with the progression of cervical disease. These findings
support the results of a longitudinal study of HPV carriage in HIV-infected and non-
infected women, (Minkoff et al., 1998) that concluded that HIV seropositve women
were more likely to have newly detectable oncogenic HPV at follow-up and were
more likely to have HR-HPV regularly detected. In a study by Ahdieh et al., (2000),
where study participants had a median of six visits, 59.3% of moderately
immunosuppressed women and 83.9% of severely immunosuppressed women were
HPV positive in all samples. The increased prevalence and persistence of HPV in
HIV-infected women is most likely due to the inability of the hosts depleted immune
system to clear the viral infection.
5.5.4 The effects of HIV-induced immunosuppression
In an African study, 70% of HIV-infected women with genital HPV infection
appeared to have a persistent infection which was still present 12 months later
(Miotti et al., 1996). Indeed in women with CD4 counts <200 cells/|il, HPV infection
is unlikely to be eliminated, as shown in the study by Ahdieh and colleagues (2000)
where only 16.1% of severely immunocompromised women cleared their HPV
infection. The influence of immunosuppression was also highlighted by Six et al.,
(1998) where CD4 counts of <500 cells/pl were associated with a higher incidence of
cervical abnormalities compared to women with CD4 counts above 500 cells/(ll. In
fact, no cervical disease progression was observed in HIV-seronegative women or
HIV-seropositive women whose CD4 count remained above 500 cells/pl. In
addition, a 2-year follow-up study by Sun et al., (1997) showed the prevalence of
HPV in HIV-infected women with CD4 counts less than 500 cells/fll was 95%
compared to 74% in women with CD4 counts of 500 cells/pl or above. In the study
reported here, women with CD4 counts less than 200 cells/pl were at greatest risk of
cervical disease and were found to harbour HPV DNA more frequently compared to
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women with CD4 counts greater than 200 cells/|ll. These findings thus support
suggestions that a woman with a history of abnormal cytology and a CD4 count less
than 200 cells/p.1 should be frequently screened (Goodman et al., 1999).
The effect of HAART on both cervical HIV and HPV viral load remains unclear. The
risk of developing squamous intraepithelial neoplastic lesions has been shown to be
higher in women not receiving antiretroviral therapy (Delmas et al., 2000) and
elevated HIV RNA levels of >10,000 copies/ml has been shown to be significantly
associated with abnormal cytology (Luque et al., 1999). In the study reported here,
women receiving antiretroviral therapy with HIV RNA viral load results of >5000
copies/ml appeared to be at greatest risk of cervical disease.
Heard and colleagues (1998) showed that HAART reduced the prevalence of cervical
lesions during follow-up despite the presence of persistent HPV infection (although
the numbers employed were too small to assess the incidence of cervical neoplasia in
relation to the type of antiretroviral therapy being administered). In an Italian study
by Lillo et al., (2001), HAART had no significant effect on the prevalence of
cervical lesions or HR-HPV. Indeed the incidence of invasive cervical cancer in Italy
does not appear to have declined, despite the introduction of HAART and an
associated decrease in prevalence of other AIDS-defining diseases since 1996
(Dorrucci et al., 2001). Many women in the Edinburgh HIV cohort have been
followed up after 1996 when HAART and HIV viral load testing became available
thus providing an ideal population for further study on the effect of antiretroviral
therapies on HIV RNA viral load, HPV DNA detection and the subsequent
occurrence of cervical neoplasia.
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5.6 Conclusion
It is apparent that the role of HPV in HIV-infected women is multi-faceted
involving persistent HPV infection, multiple HPV types, rare or novel genotypes and
possibly HPV variants. Although persistent HPV infection was common in the
Edinburgh cohort, this was not necessarily associated with progression of cervical
disease. However, the risk of squamous dyskaryosis was increased if CD4
lymphocyte counts were less than 200 cells/|il or the HIV RNA viral load was
greater than 5000 copies/ml. These findings support suggestions that HIV-infected
women should be screened more frequently. It remains to be seen if HAART will
improve local immune function and reduce the prevalence of cervical neoplasia and
HPV persistence.
Findings from this study, and others, suggest that the true prevalence of cervical
HPV infection in HIV-seropositive women has been underestimated. Some previous
studies have adopted screening methods that are not capable of detecting all HPVs
and do not differentiate between individual HPV genotypes. GP5+/6+ PCR resulted
in a higher HPV detection rate than HCAII (59% vs. 47%), as this method will also
detect low-risk and rare HPV genotypes. Direct DNA sequence analysis of GP5+/6+
PCR products provided very important information regarding the distribution of
HPV genotypes in this immunocompromised population. A total of 22 different HPV
types were identified in single infections including some rare or novel HPV types
which, to date, have not been fully characterised. Of these novel HPV genotypes,
only CP8304 was associated with cervical dysplasia. Some cross-reactivity with the
high-risk probe cocktail of HCAII was seen with other HPV types. Additionally, the
HPV genotypes harboured in the cervix do not always remain the same over time. In
this study, 12 out of 44 (27.3%) women who had samples tested by direct sequence
analysis and RLBA had infection with more than one HPV genotype. Up to six
different HPVs were detected by the RLBA from DNA extracted from a single
cervical specimen. Ultimately, understanding the distribution and oncogenicity of all
HPV types is important for clinical management of patients and vaccine
development.
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By the end of 2000, there were 759 known HIV-infected women in Scotland
(www.nhsis.co.uk/scieh/infectious/aidshiv/infaids) but there are no national
guidelines for cervical screening or clinical management of cervical neoplasia in this
population (Vonau et al., 1999). HPV testing may not be useful for directing clinical
management of HIV-seropositive women since the prevalence of HPV infection is
high in this population (as shown by the 25.3% of samples from women without any
cytological abnormality that were found to harbour HPV in the cervix) but this does
not appear to be associated with a higher incidence of CIN. However, HPV
genotyping may be a useful tool for identification of those women at most risk of
disease progression.
Although management of HIV-infected women within a cervical screening
programme remains controversial, it appears that cervical disease progression in the
Edinburgh HIV-infected cohort is contained by regular examination, early detection
of precancerous lesions, effective treatment and thorough follow-up. However, the
interactions between HIV, HPV and the development of cervical disease warrants
further investigation in longitudinal studies over at least 10 years. The Edinburgh
cohort will be followed as part of the 'Management of Cervical Screening in HIV-1'
(MACH-1) study that involves collecting data from various European centres to
determine the best cervical screening and treatment programme for the prevention of
cervical disease in HIV-infected women. Since an American study showed black and
young hispanic HIV-infected women to be at most risk of invasive cervical cancer
(Chin et al., 1998), it is important that such guidelines are introduced internationally
so that access to medical care facilities is made routinely available to all HIV-
infected women regardless of ethnic background or social status.
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CHAPTER 6
HPV IN WOMEN WITH BORDERLINE CYTOLOGICAL
ABNORMALITIES
6.1 Introduction
Despite a reduction in the cervical cancer incidence rate due to Pap smear screening,
the limitations of this method are now well recognised. In a study by the US Agency
for Health Care Policy and Research, the sensitivity of the Pap smear ranged from
29% to 56% (mean 49%) and the specificity was estimated at between 97-100%
(AHCPR Publication, 2000). Between 67% and 90% of all false negative Pap smears
occur due to sampling error (Gay et al., 1985; Yeoh and Chan, 1997). Depending on
the sampling device used, most of the cells removed from the cervix are not
transferred onto the glass slide and are discarded along with the sampler (6.5% at
best and 62.5% at worst in a study by Hutchinson et al., 1994). For a variety of
reasons as many as 15% of smears are reported as inadequate for laboratory
diagnosis (McGoogan and Reith, 1996). The main reasons for this are: insufficient
cells are present; inflammation and blood can often obscure cells; cells can be
overlapping; and air-drying artefacts are common. In addition, up to 20% of Pap
smears are reported as atypical (B/L nuclear changes or ASCUS) (McGoogan and
Reith, 1996). In the USA, ASCUS Pap diagnoses (approximates to B/L nuclear
changes) constitute approximately 2 million cytology reports (Manos et al., 1999)
and B/L smear reports account for approximately 5% of the annual 90,000 smears
workload in South-east Scotland (Dr McGoogan, personal communication).
Moreover, only 5-10% of women with ASCUS Pap smear reports harbour serious
cervical disease but more than one third of high-grade cervical lesions in screening
populations have been identified from further investigation following ASCUS Pap
results (Manos et al., 1999; Kinney et al., 1998). Although immediate colposcopic
examination of women with minimally abnormal smears is considered the safest
option (Soutter and Fletcher, 1994), this is not practical due to the resources
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available. Currently, management of women with borderline smear reports leads to
recall for a repeat Pap smear in six months and then referral for colposcopic
examination to identify underlying CIN and treatment if necessary. Unless two
subsequent negative smear reports at six monthly intervals are obtained the patient
will not be safely returned to routine recall. Since only a small percentage of these
women will have clinically significant disease unnecessary pressure is imposed on
colposcopy clinics and many women are subject to an inessential, psychologically
stressful procedure. With the introduction of LBC, where the entire cervical
specimen is collected into a vial of preservative solution, a more accurate assessment
of cervical dyskaryosis is now possible. Automated technology is used to make
monolayer preparations, free from blood and mucus, which can be screened more
effectively and efficiently than conventional Pap smears (Figure 6.1).
Since the association between HR-HPV types and the development and progression
of CIN and cervical cancer has been clearly demonstrated, HR-HPV testing has been
suggested as a strategy to improve the management of women with low-grade
cytological abnormalities (Cox et al., 1999). HR-HPV prevalence precedes abnormal
cytology in women who develop cervical cancer (Zielinski et al., 2000b) and HPV
positivity has been associated with an 8-fold increased risk of histological
confirmation of cervical neoplasia (Cox et al., 1995) whereas HPV negative women
are more likely to have no visible lesion at colposcopy or to have a lesion that will be
diagnosed as negative after biopsy. By introducing HPV testing, women with B/L
smears may be more effectively managed into one of two groups: continued
cytological follow-up or immediate referral to colposcopy depending on their HR-
HPV status.
The aim of the work presented in this chapter was to compare the cytologic
diagnoses of ThinPrep® slides and conventional Pap smears and to assess whether
HR-HPV testing using HCAII would be a valuable triage method for women with
borderline cytological abnormalities in order to allow better identification and
management of women whose cervical lesions are likely to persist.
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(b)
Figure 6.1 Comparison between conventional Pap smears and ThinPrep® slide
preparations
(a) A manually prepared, conventional Pap smear designated unsatisfactory for
assessment since the smear is obscured by inflammation, preventing interpretation of
50-75% of the epithelial cells.
(b) A ThinPrep® slide prepared using the TP2000 automated slide processor. The




Between March 1998 and February 2000, 903 women, aged 18-69 years, providing
routine or follow-up cervical smears in a primary care setting were recruited. 246
women (mean age = 34.2 years) who were attending for an early repeat smear
following a borderline (B/L) or mildly dyskaryotic smear were targeted (Appendix
2). This smear is indicated as the index smear. 206 women recruited had a previous
B/L abnormality and 40 women had a previous mild abnormality (including 1 with
an interim negative smear). These 246 cases were considered the study set.
Additionally, samples were collected from other women, who had provided consent
and were undergoing routine screening at the same clinics on the same day. Once the
cytology result was known, women who were the same age and had no history of
cervical abnormality were then matched to individual study cases, thus forming an
age-matched control set. Wherever possible, the criterion used to match each control
was women attending the same practice who had no more than five years age
difference with the study case. If this was not possible, a woman with an age
difference of one year from any practice was used. Finally, women with an age
difference of five years from any practice were assigned as controls if necessary. 220
controls are included in this analysis. The remaining 437 samples were collected
from other women who attended these clinics on the same day and who were not
assigned to either the study or control set.
Study Set
Women recruited with a previous B/L smear report 206
Women with a previous mildly dyskaryotic smear report 40
Control Set Women (age-matched) with no previous cytological
abnormalities
220
'Others' Women not assigned to either the study or control set 437
TOTAL 903
Table 6.1 Specimens collected from women attending primary care facilities for
routine or follow up cervical smears
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6.2.2 Specimen collection and processing
This was a 'split sample' study: cells were collected from the cervix using a plastic
'broom-like' sampling device (Cervex-brush®, Rovers Medical Devices B.V., The
Netherlands). A routine Pap smear was prepared first in the standard way before the
residual material on the sampler was rinsed vigorously in 20mls of PreservCyt®
solution. The sampling device was then discarded. ThinPrep® slides were made as
described in Section 2.1.
6.2.3 HPV DNA testing
After TP monolayer preparation, specimens were sent by van to the HPV testing
laboratory at the RCVL. Specimens were stored at ambient temperature until
specimen processing was performed. Specimen processing was carried out within 21
days after sample collection, as recommended by the manufacturer. In a small
number of cases this was not possible and the samples were kept at 4°C until
processed. 4ml of PreservCyt® fluid was used for the Digene Sample Conversion
protocol to make the specimen suitable for HCAII testing (Section 2.7). The residual
fluid present was processed for DNA extraction and stored at -20°C until required.
DNA extraction was performed using QIAGEN spin columns (Section 2.5.2). To
increase sample throughput, DNA from some specimens was extracted using the
QIAGEN QIAVac® 24 procedure (Section 2.5.3) rather than the totally manual
protocol. PCR testing was performed using conventional GP5+/6+ PCR (Section
2.8.1).
If less than 4ml of PreservCyt® fluid was present in the specimen vial, the exact
volume was noted and the cells pelleted directly. After removal of the supernatant,
the dry pellet was stored at -20°C.
6.2.4 Cytology reporting
The conventional Pap smears and TP monolayers were examined and reported
independently. Pap smears were screened by trained cytotechnologists, confirmed by
consultant pathologists and reported as the diagnostic smear using the NHS CSP
national guidelines. Two consultant pathologists (Dr E McGoogan and Dr A
Williams) classified the TP smears. The TP cytologic diagnoses were translated to
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the Bethesda system for cervical/vaginal diagnostic reporting to allow results from
the different cervical cytology methods to be easily distinguished. There are however
important differences between these nomenclature schemes. Firstly, B/L nuclear
change includes visible HPV cytopathic effect (i.e. koilocyte development) whereas
ASCUS does not include HPV changes. Secondly, in the UK, an unsatisfactory
diagnosis is applied when less than 33% of the slide (40 x 22mm coverslip) is
covered with squamous epithelial cells (British Society for Clinical Cytology, 1990)
whereas in the USA, smears are classified as inadequate if less than 10% of the slide
(60 x 24mm coverslip) is covered with cells.
The TP monolayer results were used for research purposes only and were not given
to the clinicians. Thus clinical management was determined on the basis of the
conventional smear result only. Likewise, HPV test results were not used to
influence the management of patients. Ethical permission for this study was received
from Lothian Health (LREC Number 1702/97/4/16).
6.2.5 Patient follow up
Follow-up information for women recruited to the study was found using the
pathology department computer system. Management of cervical abnormalities was
performed in accordance with NHS CSP national guidelines. No LBC specimens
were collected during the follow-up period. Women with U/S smears were recalled
within one month for a repeat smear. Women with B/L reports were re-examined in
3-6 months by repeat Pap smear. Women with normal results were followed up 12-
36 months later with repeat Pap smears, depending on their previous cervical
screening history. If high-grade cervical lesions were detected, patients were referred




6.3.1 Comparison of ThinPrep® and conventional Pap Smear cytology data for
all study participants
103 TP results were not available to allow comapartive analysis. Analysis of the
cytology results obtained for the remaining 800 TP and conventional smears can be
seen in Table 6.2. Sixteen slides diagnosed as inadequate by TP and 58 diagnosed as
U/S by Pap smear were omitted from further analysis. Of the 726 satisfactory slides,
641 (88.3%) showed complete diagnostic agreement between TP and Pap smear
results. 51 of the 90 discrepant cases (56.7%) occurred due to the detection of a more
severe abnormality by TP analysis. These included 11 cases that were reported as
normal by conventional Pap smear but mild dyskaryosis (equivalent of LSIL) was
detected by the TP smear and 3 cases that appeared normal by Pap smear screening
but showed moderate or severe dyskaryosis (equivalent of HSIL) on the TP slide.
Conventional Pap smears showed a more severe abnormality in 39 cases (43.3%).
These included 38 cases where a borderline (equivalent of ASCUS) or mildly
dyskaryotic (equivalent of LSIL) smear diagnosis had been reported by conventional
Pap smear but designated WNL by TP analysis. One case was diagnosed as moderate/
severe dyskaryosis by conventional Pap smear but was reported as LSIL by TP
analysis.
Despite the use of 'left-over' material for this split sample study, TP analysis reduced
the number of inadequate smear results compared to the conventional Pap smear
(from 58 (7.3%) to 16 (2%)). The inadequate TP smear reports largely resulted from
insufficient epithelial cells present on the slide (data not shown). Likewise TP
reduced the number of borderline (equivalent of ASCUS) diagnoses from 63 (7.9%)
to 34 (4.2%). In addition, TP analysis identified eight more cases of low-grade
cervical abnormality and 13 additional cases of high-grade neoplasia. Fifteen patients
of 673 with inadequate or negative reports by the Pap smear had a significant
abnormality (LSIL or worse) detected by TP analysis: four out of 12 women with
low-grade smear abnormalities detected by TP and one of three women with high-
grade dyskaryosis detected by TP had subsequent conventional Pap smears during
follow-up. All were considered to be WNL at this stage.
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U/S NEG B/L Mild Mod or Sev
INAD 5 9 2 0 0 16
WNL 51 576 32f 6f 0 665
ASCUS J 16* 17 0 0 34
LSIL 1 11* 10* 25 lf 48
HSIL 0 3* 2* 9* 23 37
TOTAL 58 615 63 40 24 800
Table 6.2 Cytology results for 800 ThinPrep® slides and conventional Pap smears
Conventional Pap smears were classified using the Richardt classification system:
U/S = unsatisfactory for assessment; Neg = negative; B/L = borderline nuclear
changes; mild = mild dyskaryosis; mod = moderate dyskaryosis; sev = severe
dyskaryosis.
ThinPrep® slides were classified using the Bethesda classification system: INAD =
inadequate for diagnosis; WNL = within normal limits; ASCUS = atypical squamous
epithelial cells of undetermined significance; LSIL = low-grade squamous
intraepithelial lesion; HSIL = high-grade squamous intraepithelial lesion.
1 Detection of a more severe cytological abnormailtyusing the Pap smear
Detetction of a more severe cytological abnormality using TP analysis
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6.3.2 Detection of HPV DNA in cervical samples from all study participants
using HCAII
Sixty-three (7%) of 903 specimens were not included for HPV testing. This included
55 specimens that had insufficient PreservCyt® volume (<4mls) and therefore did
not meet the manufacturer's guidelines for Cytyc specimen conversion. 745 of 840
satisfactory specimens had results available for both cytology methods and HR-HPV
testing by HCAII (Table 6.3). The overall HR-HPV prevalence was 29.1%
(217/745).
6.3.3 Comparison between HCAII and PCR for the detection of HPV DNA in
cervical samples from all study participants
387 out of 840 satisfactory specimens were also tested using conventional GP5+/6+
PCR. There was overall agreement between GP5+/6+ PCR and HCAII for the
detection of HPV DNA in 87.6% of the samples tested (Table 6.4).
It was only possible to test a few of these samples by LightCycler GP5+/6+ PCR (LC
PCR). This included 37 of the 116 specimens that had tested HPV positive using
HCAII and conventional GP5+/6+ PCR. 34 results were confirmed by LC GP5+/6+
PCR (Figure 6.2). The remaining three LC PCR negative cases were found to be
false negative LC PCR results since HPV 31, HPV 54 and HPV 59 were detected by
direct DNA sequencing of the conventional GP5+/6+ PCR product. Fifteen of 27
samples that gave HCAII positive results and conventional PCR negative results
were also tested. 13/15 samples that had tested HPV positive using HR-HCAII were
found to be HPV negative by both conventional and real-time GP5+/6+ PCR
methods. These most likely indicate false positive HR-HCAII results since 5 out of
13 specimens gave HCAII ratios near to the manufacturers' cut-off highlighting that
caution must be applied when interpreting low-level HCAII positive results. Lack of






























U/S or INAD 57 12(21%) 15 3 (20%)
Neg 567 120 (21.2%) 614 121 (19.7%)
B/L or ASCUS 58 28 (48.3%) 33 18(54.5%)
Mild or LSIL 39 34 (87.2%) 46 39 (84.7%)
Mod/Sev or
HSIL
24 23 (95.8%) 37 36 (97.3%)
TOTAL 745 217 (29.1%) 745 217 (29.1%)
Table 6.3 HR-HPV results by HCAII in relation to the conventional Pap smear and





< POS 116 27 143
s
X
® NEG 21 223 244
TOTAL 137 250 387
Table 6.4 Comparison of HPV results by HCAII and GP5+/6+ PCR for the 387
samples that were tested using both methods
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6.3.4 Detection of HPV DNA in cervical samples from women with previous
borderline smears
Two samples from women assigned to the study set were not tested by HR-HCAII. As
shown in Table 6.5, HR-HPV DNA was detected by HCAII in 44.7% of smears
obtained from the remaining 244 women in the study set (i.e. those with a previous
borderline or low-grade cervical abnormality). 100% of samples associated with smears
showing high-grade dyskaryosis (the equivalent of HSEL) by either TP or conventional
Pap smear were HR-HPV positive. Approximately 80% of samples associated with
low-grade cytological abnormalities (equivalent of LSIL) were HR-HPV positive by
HCAII. 50% and 61% of women whose repeat smear showed B/L abnormalities by
conventional Pap and TP cytology respectively were found to be HR-HPV positive.
STUDY SET (n=246; 2NT)
Conventional Pap smear ThinPrep® smear
n HPV Pos % n HPV Pos %
U/S or INAD 14 3 21.4 5 1 20.0
Neg 159 55 35.0 173 53 31.0
(2NT) (2NT)
B/L or ASCUS 35 17 50.0 18 11 61.1
Mild or LSIL 26 22 84.6 30 24 80.0
Mod/Sev or HSIL 12 12 100.0 20 20 100.0
TOTAL 109/244 (44.7%)
Table 6.5 Comparison between the HR-HPV results using HCAII and the
ThinPrep® and conventional Pap smear results for the 246 women in the study set.
NT = not tested; n= number tested
Women under 30 years were more likely than older women to test positive for HR-HPV
using HCAII. The HR-HPV positivity rate in women <30 years was 62.3% (68/109) and
this gradually declined with age to 20% (13/65) in women over the age of 40 (Table 6.6).
Women under 30 were also more likely to have high-grade cytological abnormalities.
























<25 37 28 75.7 CP 2 21 6 6 1 1
TP 0 22 2 10 3
25-29 72 40 55.5 CP 3 45 9 11 2 2
TP 2 44 7 13 6
30-39 71 28
(INT)
40 CP 6 46 9 6 1 3
TP 1 55 4 2 9
40-49 42 10 23.8 CP 2 30 6 3 0 1
TP 1 32 4 4 1
50-59 21 3
(INT)
15 CP 1 15 4 0 0 1
TP 1 18 0 1 1
>60 3 0 0 CP 0 2 1 0 0 0
TP 0 2 1 0 0
TOTAL 246 109 44.7
Table 6.6 Age breakdown of the 246 women in the study set with corresponding
cytology results and HPV positivity by HCAII
CP = conventional Pap
TP = ThinPrep®
NT = not tested
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6.3.5 Detection of HPV DNA in cervical samples from women with no previous
cytological abnormalities
HR-HPV DNA was detected by HCAII in 17.3% of smears obtained from the 220
age-matched women in the control set (i.e those with no previous cytological
abnormality). Approximately 16% of women with normal cytology (by either Pap
smear or TP) were found to harbour HR-HPV types in the cervix (Table 6.7). The
results also suggested that HPV prevalence was higher in women with negative
cytology that had a previous abnormality (30-34% as shown in Table 6.5) compared
to those that had never had any cytological abnormality when either Pap smears (%2 =
15.3546 on 1 degree of freedom, P<0.05) or TP (%2 = 12.4175 on 1 degree of
freedom, P<0.05) were assessed.
CONTROL SET (n=220)
Conventional Pap smear ThinPrep® smear
HPV Pos % HPV Pos %
U/S or INAD 0/1 0/3
Neg 38/219 17.4 33/209 15.8
B/L or ASCUS 0 0/3
Mild or LSIL 0 4/4
Mod/Sev or HSIL 0 1/1
TOTAL 38/220 (17.3%)
Table 6.7 Comparison between the HR-HPV test results using HCAII and the
ThinPrep® and conventional Pap smear results for the 220 age-matched women in
the control set.
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6.3.6 Follow-up results for the Study Set
The recommended recall interval for 5 women of the study set lies outwith the study
period and no follow-up results are available. These women will however continue
to be followed up. In addition, 10 women have defaulted to date from follow-up
despite at least one reminder, but will still be subject to failsafe follow-up.
Of the 231 remaining women, the first repeat Pap smear results showed 158 women
with normal cytology, 35 with borderline nuclear changes, 26 women with mild
dyskaryosis, 4 with moderate dyskaryosis and 8 with severe dyskaryosis.
6.3.6.1 Women with a negative cytology result on the first repeat smear
Of the 158 women who had a normal smear (WNL) following their index smear, 55
were HR-HPV positive (35%) and 101 were HR-HPV negative (Table 6.8). Two
thirds (66/101) of the HPV negative women had a further negative smear. Although
no further follow-up was available for 25 of the 36 remaining HPV negative women,
only three women with satisfactory smears had subsequent borderline cytology.
Twenty-two of the 55 (40%) HR-HPV positive cases had another negative smear.
Further follow-up in six of these HPV positive women has shown three women to
have subsequent borderline smear reports and three women to have histologically
confirmed CIN 2 or CIN 3.
Three women were referred immediately to colposcopy on clinical grounds after the
result of their index smear, including one HR-HPV positive women less than 30
years old. Histological assessment of tissue removed from the cervices of these
women did not reveal any neoplastic changes.
Fifteen out of 158 women had an inadequate result in the second repeat smear. Eight
out of nine women with subsequent investigations had negative Pap cytology. Two
of these women have had further follow-up: one HR-HPV negative woman, >30
years, had a subsequent negative smear and one HR-HPV positive woman over 30
years old had an inflammatory biopsy. The other woman was HR-HPV positive,
more than 30 years of age and had subsequent B/L cytology followed by an
inadequate smear report.
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Index 1st repeat 2nd repeat
smear
Age HR-HPV by HCAII
smear smear
Pos Neg
B/L or Neg Colposcopy <=30 1 0
mild (n=158) (n=3) >30 1 1
(n=246) 2NT TOTAL 2 1
None <=30 15 8









Neg (n=89) <=30 11 20
















TOTAL 158 (2NT) 55 101
Table 6.8 Follow-up cytology in relation to HPV status in 158 women with a
negative result on their first repeat smear
NT= not tested
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89 women had two consecutive negative smears after the index smear and 66
(74.2%) of these were HR-HPV negative. Six out of 89 women have had further
negative follow-up.
Seven women had a borderline result in the second repeat smear. Four were HR-
HPV positive and three were HR-HPV negative. One HPV-positive women was
found to have CIN3 on biopsy at follow-up. Follow-up of the others, over 1-10
months failed to detect cervical neoplasia.
Two women, under 30 years of age, had a mildly dyskaryotic smear result on the
second repeat smear. Both were HR-HPV positive, have had subsequent negative
smears and are due further follow-up.
No moderately or severely dyskaryotic smears were found on the second repeat
smear in this group.
6.3.6.2 Women with a borderline cytology result on the first repeat smear
Of the 35 women who had a borderline smear following their index smear, 17
(48.6%) were HR-HPV positive. Thirteen out of 17 (76.5%) were less than 30 years
old (Table 6.9). Two women were referred immediately to colposcopy on clinical
grounds after the B/L result of their index smear: a 26 year old, HR-HPV positive
woman was found to have histologically confirmed CIN 2.
Five out of 35 women with further cytological follow up had a second repeat smear
reported as inadequate. All four HR-HPV negative women had subsequent negative
smears. The HR-HPV positive woman is awaiting further follow up.
Sixteen out of 35 women had a negative second repeat smear. Three out of six HR-
HPV positive women under 30 years old had subsequent smears, including three with
negative smears and one women with a mildly dyskaryotic smear, confirmed as CIN
1-2 on biopsy. Eight out of 9 HR-HPV negative cases were women 30 years of age
or more. Three have had subsequent negative follow up smears.
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Three out of seven women with borderline changes on the second repeat smear were
HR-HPV positive. Two of these women were less than 30 years old and had
histologically confirmed CEN 1 or CIN 3. Two out of four HR-HPV negative women
over 30 years of age had biopsies within normal limits. The other two HR-HPV
negative women were found to have CIN 1 lesions. The presence of low-grade HPV
types was investigated in LBC specimens collected from both women with HR-HPV
negative CIN 1 using conventional GP5+/6+ PCR. DNA from low-risk genotypes
was not detected by this method in extracted DNA from either of the specimens.
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Index 1st repeat 2nd repeat Age HR--HPV Histology
smear smear smear by H1CAII
Pos Neg
B/L or Mild B/L (n=35) U/S (n=5) <=30 1 2
(n=246) >30 0 2
TOTAL 1 4
Neg (n=16) <=30 6 1
>30 1 8
TOTAL 7 9
B/L (n=7) <=30 2 0 CEN1 xl CIN 3 xl
>30 1 4 Inflamxl CIN 1 x2 WNL x2
TOTAL 3 4
Mild (n=3) <=30 1 0 Neg xl
>30 2 0 CIN1 x2
TOTAL 3 0
Mod (n=l) <30 1 0 CIN1 xl
>30 0 0
TOTAL 1 0
Sev (n=l) <=30 1 0 CIN3 xl
>30 0 0
TOTAL 1 0
Colposcopy <=30 1 0 CIN2 xl
(n=2) >30 0 1 Inflam xl
TOTAL 1 1
TOTAL 35 17 18
Table 6.9 Follow-up cytology in relation to HPV status for 35 women with a
borderline cytology result on their first repeat smear
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Three women had mild results on the second repeat smear. All were HPV positive.
Both women over 30 years had CIN 1 on biopsy and the younger women had a
subsequent negative smear.
One HR-HPV positive women under 30 years of age had a moderately dyskaryotic
second repeat smear. This was confirmed as CIN 1 by biopsy. Another HR-HPV
positive women under 30 years of age had a severely dyskaryotic smear on the
second repeat. This was histologically confirmed as CIN 3.
6.3.6.3 Women with mild dyskaryosis on the first repeat smear
Of the 26 women who had a mildly dyskaryotic smear after their index smear, 22
(84.6%) were HR-HPV positive. 65.4% (17/26) were less than 30 years old (Table
6.10). On clinical grounds, twelve were immediately referred to colposcopy. 10 of
these 12 women were HR-HPV positive and were found to harbour neoplastic
lesions (CIN 3 three times, CIN 2 twice and CIN 1 five times). Histological
examination of biopsy material from both HR-HPV negative cases showed
inflammatory changes only (one biopsy has been independently reviewed).
Five out of 26 women had second repeat smears that were reported as negative. Two
of three HR-HPV positive women were less than 30 years old: one woman had a
subsequent B/L smear which was confirmed as CIN 1 by histological assessment and
the other HR-HPV positive woman had a subsequent negative smear. One woman
over 30 years of age was HR-HPV negative and had a subsequent negative smear
followed by a B/L smear report.
Seven women had subsequent borderline or mildly dyskaryotic smears on the second
repeat. All were HCA positive. Six of these women were referred for colposcopic
examination and the biopsy results showed WNL twice, CIN 1 twice, CIN 2 once
and CIN 3 once. The other HR-HPV positive woman was over 30 years of age and
had two subsequent negative smears.
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Two HR-HPV positive women had moderately dyskaryotic smears. One had CIN 1
on biopsy and the other woman had two subsequent negative smear reports. There
were no inadequate or severe reports in the second repeat smears.
Index 1st repeat 2nd repeat HR--HPV Histology
smear smear smear by F1CAII
Age Pos Neg
B/L or Mild Mild (n=26) Neg (n=5) <=30 2 1 CIN 1 xl
(n=246) >30 1 1
TOTAL 3 2
B/L (n=3) <=30 3 0 WNL x2 CIN1/BL xl
>30 0 0
TOTAL 3 0
Mild (n=4) <=30 2 0 CIN2 xl CIN3 xl
>30 2 0 CIN 1 xl
TOTAL 4 0
Mod (n=2) <=30 1 0 CIN1 xl
>30 1 0
TOTAL 2 0
Colposcopy <=30 9 1 CIN1 x4 CIN2 x2 CIN3 x3
(n=12) >30 1 1 Inflam xl
TOTAL 10 2
TOTAL 26 22 4
Table 6.10 Follow-up cytology in relation to HPV status in 26 women with mild
dyskaryosis on their first repeat smear
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6.3.6.4 Women with moderate or severe dyskaryosis on the first repeat smear
Twelve HR-HPV positive women had moderate or severe dyskaryosis on their first
repeat smear (Table 6.11). All were HR-HPV positive. Six were less than 30 years
old. Three out of 4 HR-HPV positive women with moderate dyskaryosis on the first
repeat smear were less than 30 years old and had CIN 2 once and CIN 3 twice on
biopsy. The other HR-HPV positive woman was older than 30 and had CIN 2 on
biopsy.
Three out of eight HR-HPV positive women with severe dyskaryosis on the first
repeat smear were less than 30 years of age. All had CIN 3 confirmed by histological
examination. The other five HR-HPV positive women were over 30 years old. One
woman had CIN 1; one had CIN 2 ; three women had CIN 3 and one had squamous
cell carcinoma (SCC). In summary, the colposcopic biopsies from all 12 women










smear smear Pos Neg
B/Lor Mod <=30 3 0 CIN 2x1 CIN 3x2
Mild (n=4) >30 1 0 CIN2 xl
(n=246) TOTAL 4 0
Sev <=30 3 0 CIN3 x3
(n=8) >30 5 0 CIN1 xl CIN2 xl CIN 3 x2 SCC xl
TOTAL 8 0
TOTAL 12 12 0
Table 6.11 Follow-up results in relation to HPV status in 12 women with moderate
or severe dyskaryosis on their first repeat smear
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In summary, 64.6% of women who had a previous B/L smear had a negative smear
on their return visit and two-thirds of these were HR-HPV negative. A further
64.7% of these HR-HPV negative women remained cytologically normal on their
second return visit. In the remaining third, three of 11 women with satisfactory
smears had a further B/L smear report. 14.2% of women who had a previous B/L
smear continued to show B/L nuclear changes on the first early repeat smear. Of the
HR-HPV negative women in this group, two had a biopsy showing CIN1. 10.6% of
women had a mildly dyskaryotic smear on first early repeat, and 84.6% of women in
this group harboured HR-HPV DNA in their cervices. All HR-HPV negative cases
were found to have no cytological abnormality on biopsy or subsequent smear. 4.9%
of women had a moderately or severely dyskaryotic smear on first early repeat which





For accurate diagnosis of cervical disease, a truly representative cervical sample is
needed. Since TP was approved by the United States Food and Drug Administration
(FDA) in 1996, as a replacement for conventional Pap smears, several studies have
evaluated the effectiveness of this method to detect significant cervical disease. Early
comparative studies between TP and Pap smears found TP to yield fewer diagnostic
cells (Bur et al., 1995) and no increase in the detection of cervical abnormalities was
reported (Aponte-Cipriani et al., 1995). Indeed, in the first population-based
comparison study by Hutchinson et al., (1999) considerably more TP slides were
diagnosed as ASCUS (equivalent to B/L changes) compared to Pap smears.
However, that particular study involved use of the (3-model of the ThinPrep®
processor that allows for less specimen variability and does not place as many cells
on each slide. In contrast, more recent studies using improved TP technology, such
as the FDA-approved TP2000 slide processor, have shown good correlation between
TP and Pap smear results. In the study reported here,using TP2000, 87.5% agreement
was found between satisfactory TP and Pap smear results. This is similar to other
studies where the level of agreement has ranged from 85.4% to 94.6% (Ferenczy et
al., 1996, Roberts et al., 1997; Wilbur et al., 1994; Bur et al., 1995). The use of the
TP test in both split-sample and direct-to-vial studies has resulted in significantly
increased detection of low-grade and high-grade squamous intraepithelial lesions
(Roberts et al., 1997; Wilbur et al., 1994; Guidos and Selvaggi, 1999; Yeoh et al.,
1999) and an increase in biopsy-proven high-grade disease (Papillo et al., 1998). In
the split-sample study reported here, analysis of 800 TP and Pap smear preparations
showed that TP allowed for a more accurate assessment of cervical cytology with the
detection of eight more cases of low-grade abnormalities and 13 additional cases of
high-grade dyskaryosis. In 56.7% (51/90) of cases where diagnostic agreement was
not found between both smear preparations, this was attributed to the TP method
detecting a more severe abnormality than the Pap smear. This included 3 cases that
appeared normal by Pap smear assessment but high-grade abnormalities were
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detectable by TP. Indeed, the conventional Pap smear has been shown to have a false
negative rate of 15% for the detection of cervical abnormalities whereas cytological
assessment by TP has a false negative rate of only 3.9% (Wilbur et al., 1994).
Weintraub and Morabia (2000) concluded that there is a 2.2 times greater chance of
having a positive diagnosis with TP compared to conventional Pap smears and a 1.86
times greater chance of detecting HSIL using this screening method.
During TP slide preparation, the LBC sample is concentrated with obscuring
artefacts being removed from the specimen, whilst preserving cell morphology,
before the cells are displayed as a monolayer, evenly distributed within a 20mm
diameter circle on the slide. Thus, many of the problems associated with
unsatisfactory conventional Pap smear reports are eliminated thus producing better
cell preparations for morphological analysis. In the study reported here, TP resulted
in improved diagnostic quality as shown by the reduction in unsatisfactory smear
reports compared to the Pap smear (7.3% to 2%). This result concurs with the
findings of other larger split-sample studies where TP reduced the number of
inadequate smear reports by as much as 94% (Roberts et al., 1997; Aponte-Cipriani
et al., 1995). Such reduction in the number of inadequate smear reports clearly has
benefits for both patients and clinicians at the primary care level by reducing the
number of repeat patient visits required during follow-up. In the study reported here,
TP also caused a reduction in the number of B/L smear diagnoses compared to the
conventional Pap smear (7.9% to 4.2%). As a result of improved TP sample
preparation, the majority of samples that were diagnosed as B/L by Pap screening
had been classified as either negative (n=32) or LSIL (n=10) by TP. In addition, two
cases that had been diagnosed as B/L by Pap smear showed high-grade
abnormalities on TP analysis. Although the number of B/L smears was reduced by
approximately half by TP analysis, more were HPV positive (48.3% to 54.5%).
Although this increase in HPV positivity is not statistically significance (%~ = 0.3307
on 1 degree of freedom, P = 0.5652) it may suggest that B/L abnormalities detected
by TP that are also HPV positive are more likely to be clinically significant.
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Unfortunately TP slide preparations are more expensive than Pap smears. Both the
reagents and hardware are expensive and the consumables are non-recyclable.
Additionally, other manipulations might be required in the laboratory to get a
satisfactory smear, which further increases the cost. In a six-month study by Yeoh
and colleagues in 1999, 82% of practices that were given an informed choice
between ThinPrep® and Pap, chose to convert to ThinPrep® smear preparations. The
main reason stated by the other clinics for not converting was cost. Other problems
might include the shelf life and storage of supplies in clinics and both the
practicalities and cost of transporting alcohol-containing specimens from the clinic
to the laboratory. Additionally, considerable retraining of laboratory staff is required
before they can be competent at screening TP monolayer smears and education of
smear-takers is necessary to inform them of the method required for TP cervical
specimen collection. Nevertheless, due to the reduction in both false negative and
false positive results, long-term savings are possible through more effective use of
medical resources. A decrease in the number of inadequate smears and more efficient
management of women with low-grade abnormalities would have additional cost
savings. If the study reported here had been performed in clinical practice, where
cervical specimens had been direct-to-vial instead of being split samples collected
after conventional Pap smear preparation, it is likely that the inadequate TP smear
rate in this study would have been even lower.
In June 2000, the National Institute for Clinical Excellence (NICE) report
(www.nice.org) concluded that there was insufficient evidence to justify the national
implementation of LBC for cervical screening. However, a six-month multi-centre
LBC demonstration project has recently been completed in Scotland and a 12-month
multi-centre trial is currently underway in England, to assess the effects of
introducing such technology into the cervical screening programme.
6.4.2 HPY testing
Several small clinical studies showed that HR-HPV DNA positivity using the first
generation HCAI, improved the detection of high-grade cervical neoplasia in women
with abnormal cytology compared to Pap cytology alone (Hatch et al, 1995; Cox et
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al., 1995; Farthing et al., 1994). PreservCyt® samples were also shown to be suitable
for HPV testing using HCAI, with increased HPV DNA detection in LBC samples
compared cervical specimens collected into Digene STM at the same time (45% and
36.5% respectively). In more recent studies, the more sensitive second generation
test (HCAII) has been shown to have 70% sensitivity for the detection of all grades
of CIN and more than 90% sensitivity for detecting CIN 2 or above (Mould et al.,
2000). In the study reported here, HCAII detected DNA from HR-HPV genotypes in
25.8% of all the LBC samples tested. All samples associated with moderate or severe
dyskaryosis on TP analysis were HR-HPV positive and >80% of samples associated
with mildly abnormal smears were found to harbour HR-HPV DNA. Using HCAII,
HR-HPV prevalence in the study set (i.e. women with a previous B/L smear
abnormality) was 44.3% and 17.3% in the age-matched control set (i.e. women with
no previous history of cervical smear abnormality).
Two large studies in the United States have provided evidence that HPV testing is
suitable for triaging women with minimal smear abnormalities who have underlying
CIN lesions. Firstly, results from 3488 women (mean age = 29 years) with ASCUS
cytology enrolled in the ALTS trial, showed that HPV testing had 96.3% sensitivity
for the detection of CIN 3 or above but 56.1% of the women would be referred to
colposcopy (Solomon et al., 2001). However, the predictive value of a negative test
for detection of CIN 2 was shown to be 98.9%. Secondly, a study involving 46,009
women (mean age = 38 years) attending routine Pap screening at the American
health care organisation, Kaiser Permanente, found that 38.8% of women with
ASCUS showed high-grade cervical neoplasia on histological examination and
68.6% of women with either ASCUS or LSIL harboured high-grade cervical
neoplasia (Kinney et al., 1998). HPV testing by HCAII was performed on LBC
specimens collected from 995 women with ASCUS and was concluded to be 89.2%
sensitive for identifying histologically-confirmed high-grade CIN (Manos et al.,
1999). It was concluded that triage based on HPV testing would reduce the number
of colposcopy referrals and follow-up appointments required compared to the
current practices. Similar results have been found by Fait et al., (2000), where
colposcopy examination of 503 women with ASCUS or LSIL diagnosed on two
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consecutive Pap smears would have been reduced to 24.6% of cases if women
harbouring HR-HPV DNA only had been referred while still maintaining sensitivity
of 87% for the detection of CIN 2 and CIN 3.
While there is evidence to suggest that HPV testing is useful in triaging women with
B/L smear results, several workers have concluded that there was limited potential
for HCAII to direct decisions about the clinical management of women with low-
grade squamous intraepithelial lesions (LSIL, approximates to mild dyskaryosis).
The ALTS Group (2000) found 82.9% of women with LSIL diagnosis from Pap
smears harboured HPV DNA by HCAII testing and Rebello et al., (2001) found the
overall test sensitivity and specificity of HCAII to be 94% and 39% respectively for
detecting underlying high-grade CIN in women with mildly abnormal smears. A
repeat smear at six months has shown better sensitivity and specificity for the
detection of underlying high-grade CIN than HPV testing by PCR in women with
mild dyskaryosis (Cruickshank et al., 1999). In the study reported here, most of the
woman enrolled had previous B/L smears, not mild dyskaryosis, and the results
suggest that HCAII testing from LBC samples collected from such women could be
used to predict the absence of progressive disease.
Few studies investigating HPV testing in triage of women with B/L or mild
cytological abnormalities have provided information on long-term follow-up and the
incidence of high-grade CIN. Follow-up data from women enrolled in the study set
suggests that the predictive value of a negative HPV result (i.e. the likelihood that a
woman without HPV infection does not have high-grade CIN) is very high. 65.7% of
women with a previous B/L abnormality had subsequent negative cytological follow
up and 66.3% of these were HR-HPV negative. Two thirds of these HR-HPV
negative women remained cytologically normal on their second repeat visit. If all
HR-HPV negative women had been returned to routine recall only two cases of
CIN1 would have been missed but 160 repeat visits would have been saved. In a
similar sized study by Ziehlinski et al., (2001a), the overall sensitivity of a HR-HPV
positive test for a CIN 2/3 lesion at the first colposcopy visit was 96.3%; the
specificity was 60.2% and the PPV was 20.6%. However, the high NPV (99.3%) of a
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HPV test reinforced its potential use as a management strategy for women with B/L
or mild dyskaryosis. Although the PPV was shown to be higher in women younger
than 40, the NPV was found not to be affected by age variation. In another recent
study of Dutch women with mild to moderate or severe dyskaryosis, Nobbenhuis and
colleagues (1999) showed that those who did not harbour HR-HPV never developed
CEN 3 and only women with persistent HR-HPV infection showed clinically
progressive cervical disease. A repeat Pap smear after 6 months has been shown to
be less significant than a repeat HPV positive test for identifying women at risk of
developing CIN 3 and suggestions have been made that that only women with a
second HPV positive result should be sent for colposcopy whereas the screening
interval could be considerably increased for HR-HPV negative women (Nobbenhuis
etal., 1999).
A practical triage strategy is required for women who have minimally abnormal
smears. Possible approaches include repeat cytology and/or HPV testing or referral
for colposcopy and biopsy. Based on the results from this investigation a possible
triage algorithm is shown in Figure 6.3. This proposal is based on reflex HPV testing
using HCAII from residual LBC fluid for all women who have a B/L smear. Since
the median duration of HR-HPV clearance in women with B/L or mild dyskaryosis
has been shown to be longer than 6 months (Ho et al., 1998; Nobbenhuis et al., 1999;
Ziehlinski et al., 2001a) and persistent infection is necessary for the development of
cervical neoplasia, a repeat HPV test after six months would be considered
redundant. A repeat smear and HPV test after 12 months would provide more
accurate information regarding the risk of disease progression. At that point, women
with a second HR-HPV positive result in association with the repeat LBC smear
would be recommended for colposcopic examination. HR-HPV negative women
with abnormal cytology would also be recommended for immediate colposcopy
referral to minimise the risk of a false negative HPV test result. However, HR-HPV
negative women with no evidence of any cytological abnormality would be safely
returned to routine screening. This approach would reduce the number of colposcopy
referrals and the number of repeat smears. By inclusion of a HPV test, over treatment
of women with B/L smears would be limited. If, in addition, the screening interval
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was increased for women who have been HR-HPV negative on both occasions, a
marked decrease in the current expenditure associated with follow-up would result.
It has also been suggested that fewer women would be lost to follow-up if HPV
DNA testing was used rather than repeat smear testing (Lytwyn et al., 2000).
Review of the literature has shown that there have been some disparate results
reported in studies on this topic. Possible reasons for this is that it is difficult to
compare studies in the USA to the UK because cervical screening populations and
procedures are different and there are important differences between the
classification of cytological abnormalities. Additionally, differences in the HPV
testing methodology and the age distribution of the women studied may also vary
between different studies. In the study reported here, the HPV prevalence was
highest in women under 30 years old (62.3%) and declined with increasing age to
just over 11% in women over 40 years of age. In view of similar findings by others,
it has been suggested that HPV testing would be cost-effective in women with low-
grade cervical abnormalities only if women over 30 years of age who are less likely
to have transient HPV infection were tested (Cuzick, 1998). However, in this
reported investigation, nine of 20 cases showing high-grade abnormalities were
detected in TP monolayers from women under 30. Seven of these 9 women were
referred to colposcopy on the basis of mild, moderate or severe dyskaryosis detected
by the conventional Pap smear. However, TP analysis was more effective than the
Pap smear for identification of significant cervical disease in the other two women:
one woman with mild dyskaryosis by Pap smear analysis had two subsequent smears
(reported as WNL and B/L) before CIN 1 was identified by histological examination.
The other woman aged 25 years was found to be WNL by Pap cytology and has not
had further follow up to date. The number of women over 60 years enrolled into this
study was small and therefore it is not possible to confirm or dispute previous
observations of increased detection of cytological abnormalities in post-menopausal
women (Herrero et al., 2000).
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INCREASE SCREENING INTERVAL? Figure6.3Proposedtriagalg rithmf wom nitbo derlinsmeareports
Finally, the HTA systematic review (Cuzick et al., 1999a), recommended that HPV
testing be introduced on a pilot basis for women with B/L and mildly dyskaryotic
smears and a large trial of HPV testing should be undertaken in conjunction with
other new technologies (such as LBC and computer-assisted cytology reading) to
determine the best way to integrate them into ongoing screening programmes
(Cuzick et al., 2000). Many of these issues will be addressed by the pilot studies of
HPV testing, in conjunction with LBC, for women with B/L or mildly dyskaryotic




When this study began, the Scottish Office had not given approval for LBC samples
to be used as diagnostic specimens, so the TP specimens collected could not be used
for cytology diagnosis. Despite the potential bias introduced by preparing the Pap
smear first, improved specimen adequacy provided in part by the sampling device;
removal of artefacts; specimen mixing and the random selection of cells during TP
monolayer preparation allowed better detection of clinically important cervical
disease and a reduction in the number of unsatisfactory and B/L smear diagnoses.
From a laboratory perspective, improved specimen adequacy and quality provided by
the ThinPrep® test significantly reduced the time required for screening and the
problems associated with interpretation (Dr. E. McGoogan, personal
communication). With release of the fully automated TP3000 system which can
process four batches of 80 slides per 8-hour shift the problem of single specimen
handling has been addressed. In clinical practice, where the entire cell sample would
be transferred into the PreservCyt® fluid, the performance of TP would be expected
to be even more impressive. Although the initial expenditure to implement LBC may
be high, in the long term, there are cost savings to be made through reduced cytology
recalls and colposcopy referrals. More importantly, if improved detection of cervical
disease has a reducing effect on the national cervical cancer incidence rate, then
more costly tests become affordable due to the savings made from cancer
management. Data generated from the Scottish LBC demonstration projects will
provide further important information about the implications of introducing liquid-
based cytology technology into the NHS cervical screening programme.
The introduction of LBC allows the cervical material collected to be used for
additional tests from a single specimen without the requirement for a second patient
visit. The results reported here suggest that HPV testing using HCAII may be useful
for triage of women with borderline abnormalities by streamlining patient
management according to high-risk HPV status. Lor this purpose, 'reflex HPV
testing' may be employed where the LBC specimen is only selected for HPV testing
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if a B/L smear result is obtained. Since the predictive value of a HCAII-negative test
has been shown to be very high, women with borderline smear diagnoses who do not
harbour HR-HPV could be safely returned to routine recall whereas HR-HPV
positive women would be referred for further follow-up. A proposed triage
algorithm, based on the results from this study, recommends colposcopy referral only
when persistent HPV infection is present, as shown by two successive HR-HPV
positive results. Single time point HPV test results should be interpreted with caution
since many women will be transiently infected, particularly those under 30 years of
age. In this context, it is predicted that LBC combined with HR- HPV testing by
HCA II would be a cost-effective measure although the results generated from this
study's control set suggest that HPV testing by HCAII is unlikely to be cost-
effective in the routine screening of normal women.
From recent reports (Ferenczy and Franco, 2001; Meijer and Walboomers, 2000) the
future of cervical screening is likely to include automated cytology and molecular
virology methods for the detection of cervical cancer and its precursors and accurate
prediction of disease outcome. The technologies described in this chapter hold great




DEVELOPMENT OF AN AUTOMATED PROCEDURE FOR DNA
EXTRACTION FROM LIQUID-BASED CYTOLOGY SPECIMENS AND A
REAL-TIME PCR SYSTEM FOR HPV DETECTION
7.1 Introduction
The Pap smear has remained relatively unchanged since it was introduced 50 years
ago. It is expensive, labour intensive, time consuming, requires highly skilled staff
and has many inherent opportunities for failure. The advent of LBC to replace
conventional Pap smears, will address many of the sensitivity issues due to sampling
and preparation errors associated with conventional smears. Testing for HR-HPV in
conjunction with LBC may further improve the cervical screening programme by
identification of women at increased risk of cervical disease progression or for triage
of B/L or low-grade smear abnormalities. This, however, depends on a rapid,
sensitive test for the detection of HR-HPV genotypes. So far, the best methodology
for this purpose has not been determined. Neither current consensus PCR methods
nor the second generation HCAII test can distinguish between individual HPV
genotypes or detect infection with more than one type without performing additional
procedures. The ability to distinguish between different HR-HPV types in a single
assay and quantify the amount of DNA present would be advantageous for laboratory
testing. Thus, to distinguish HR-HPV types present in clinical samples, other
molecular technologies including automated DNA extraction protocols and rapid
HPV detection methods are required. As the clinical use of LBC becomes more
widespread for the collection and cytological assessment of cervical specimens, the
ability to test the residual cells from large numbers of LBC specimens for HR-HPV
types becomes possible.
For molecular tests to be applicable in a routine diagnostic laboratory, sample
preparation and DNA extraction should be as simple as possible. The use of robotics
enhances rapidity and automated nucleic acid extraction systems are now
commercially available, such as the BioRobot® 9604 (QIAGEN Ltd, Crawley, East
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Sussex), MagNA Pure LightCycler (Roche Diagnostics Ltd., Lewes, East Sussex)
and the RoboAmp® (MWG Biotech, Milton Keynes). The advantages of such
commercial systems include the potential for high throughput of clinical samples for
DNA extraction with reliable results and consistent yields while reducing the 'hands-
on' time involved.
The BioRobot® 9604 is a workstation for the extraction of nucleic acid from clinical
specimens prior to PCR using QIAamp® silica-based membrane technology in a 96-
well plate format. Currently, licensed BioRobot® 9604 protocols are available for
automated DNA extraction from blood, body fluids, cultured cells and buccal swabs.
The MagNA Pure system uses magnetic glass bead technology for extraction of
nucleic acids from blood or cultured cells. However, the most important feature of
the MagNA Pure LightCycler (LC) system is that it will automatically set up real¬
time PCR reaction mixes following the automated DNA purification step. In
addition, this system will load the PCR reaction mixes into the LightCycler
capillaries in the LC carousel. In a recent comparative assessment of these automated
extraction systems, both methods were found to be equivalent for the extraction of
herpes simplex virus (HSV) DNA from swab specimens prior to LC PCR, since the
number of amplification cycles required for HSV detection differed by no more than
1.5 between both methods (Espy et al., 2001).
Conventional PCR sample preparation and final detection using agarose gel
electrophoresis does not lend itself to automation, and therefore is not suitable for
large specimen numbers. Since kinetic PCR analysis by real-time monitoring of PCR
amplicon formation was first described by Higuchi et al., (1992), the potential of
PCR testing has been revolutionised due to increased PCR rapidity, reduced
contamination risks due to the use of closed PCR reaction vessels and, if required,
the ability to perform quantitative PCR. Although several manufacturers are now
producing real-time PCR equipment, the ABI PRISM® 7700 Sequence Detection
System (Perkin Elmer Applied BioSystems, Warrington, Cheshire) and the
LightCycler (now supplied by Roche Diagnostics Ltd.) are the most used.
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The LightCycler instrument allows rapid automation of PCR (approximately 30
cycles in 30 minutes) by precise air-controlled temperature cycling and real-time
monitoring of amplicon production after each PCR cycle using either SybrGreen I™
or fluorogenic probe technology (Section 3.2). SybrGreen I™ is a fluorescent dye
which, during each round of PCR amplification, binds to the minor groove of
accumulating dsDNA. To detect the increase in fluorescence that occurs as specific
PCR product accumulates, a microlens at the end of each capillary detects the
increase in fluorescence as product accumulates and bounces the light from a blue
light-emitting diode (LED) into the sample. A photodiode detects the fluorescence
signal generated at the end of each primer extension stage. Data from the high
precision optics that monitor the amplification reaction can be followed on a
computer screen in real-time. Fluorescence melting-curve analysis can be used to
identify PCR products with different GC:AT ratios without the need for post-
amplification sample manipulations. As the temperature increases, dsDNA becomes
denatured and SybrGreen I™ molecules become unbound resulting in a rapid
decrease in fluorescence. Alternatively, product detection formats using fluorophore-
labelled hybridisation probes can be used for sequence-specific detection of PCR
products. In such cases, one primer is designed with an internal label (e.g. Cy5
acceptor). Since real-time PCR uses a much smaller sample volume and combines
amplification and detection in closed PCR reaction capillaries, the risk of
contamination generated by carry-over of amplified products during post-PCR
manipulation is much reduced. Therefore, this methodology has potential compared
with other methods for both faster throughput of patient samples and a reduced risk
of false positive results.
In contrast, the ABI PRISM® 7700 Sequence Detection System uses TaqMan
chemistry for DNA and RNA quantitation (Grove, 1999). In summary, the method
uses probes that are end-labelled with two fluorecent dyes (a reporter and quencher).
The inherent 5'-3' exonuclease activity of Taq polymerase cleaves the 5'-reporter
fluorochrome from the bound probe during the PCR primer extension stage. This
event also removes the reporter dye from the proximity of the 3'-quencher dye,
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generating a fluorescent signal that is proportional to the amount of product
generated in each PCR cycle. A quantitative HPV and (3-globin multiplex PCR assay
based on this technology was developed by Swan et al., (1997) using a combination
of type-specific LI primers and probes for the detection of HPV 16, 18, 31, 33 and
35. The same group later developed a real-time HPV PCR assay, (using a ABI Prism
7700 Sequence Detection System) for the quantitative detection of HPV 16, 18, 6 and
11 (Tucker et al., 2001). A multiplex format was also employed in that study to
allow simultaneous amplification of a cellular target to act as an internal PCR
control. The multiplex PCR assay performance was tested using extracted DNA from
54 LBC specimens and twelve (22%) were found to be HPV 16 positive.
Since the advent of real-time PCR, the number of publications arising from its
application in virology is increasing rapidly. So far, most diagnostic virology
investigations have focused on the detection and quantitation of nucleic acid from
herpes viruses (Nicoll et al., 2001), including cytomegalovirus (Schaade et al., 2000;
Schalasta et al., 2000a; Nitsche et al., 1999), varicella zoster virus (Espy et al.,
2000a) and herpes simplex virus (Kessler et al., 2000; Espy et al., 2000b). Due to the
sequence relatedness of HSV genotypes, differentiation based on the melting
temperature (Tm) of PCR products alone can be difficult (Dr. S. McDonagh,
personal communication). However, differentiation between HSV genotypes 1 and 2
(HSV-1 and HSV-2) has been possible using a hybridisation probe designed to
target a region of the HSV-2 glycoprotein B gene where there is a G:T mismatch.
This yields a lowered probe/product Tm for HSV-1 (69°C) compared to HSV-2
(64°C) allowing clear separation of both genotypes in the same run (Schalasta et al.,
2000b).
More specifically, a real-time nested PCR assay has been recently developed for
HPV DNA detection using both MY09/11 and GP5+/6+ primers (Strauss et al.,
2000). The real-time PCR sensitivity was found to be comparable to that achieved
by performing nested PCR on a conventional metal block thermocycler, with 86.1%
agreement between both methods. Sequence analysis of PCR positive amplicons
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from both real-time and conventional PCR assays showed 70% to contain the same
HPV type(s).
7.2 Aims of this study
The aim of this study, was to develop an automated DNA extraction protocol to
replace the manual nucleic acid extraction procedure for DNA isolation from routine
cervical LBC specimens, so that high specimen throughput could be achieved. A
further aim was to apply the LightCycler PCR protocol for HPV detection to DNA
extracted from the LBC samples and to test the validity of Tm analysis as a means of
differentiating between HPV genotypes. An alternative HPV genotyping assay




To avoid the need for a conventional smear in addition to the LBC specimen, patient
enrolment to this study was delayed until after the Chief Medical Officer's letter
relating to LBC in May 1999. Thus, in the first 'direct-to-viaT study in the UK,
more than 4700 LBC samples were collected between December 1999 and July 2000
from women attending routine cervical screening clinics in 16 Lothian General
Practices. The collection devices were each rinsed in 20mls of Preserveyt® solution
and then discarded. Informed consent was obtained for use of the residual samples
for detection of microrganisms (Appendix 2) and ethical permission was granted
from Lothian Health (LREC No. 1702/98/2/22).
7.3.2 Preparation of ThinPrep® slides
In the UEPD, monolayer smear preparations were made using ThinPrep® 2000
technology, stained conventionally using Pap stain and examined by cytoscreeners
trained in the use of LBC and reviewed by trained cytopathologists. Cytological
assessment of the monolayers was carried out within the normal turn-around time
and the results returned to the GP practices in the usual way.
7.3.3 Processing of LBC specimens for HPV testing
Samples were then sent to the HPV testing laboratory at RCVL and stored at 4°C. To
adhere to manufacturers' guidelines, LBC specimens were processed within 21 days
receipt at the laboratory. The first 309 samples obtained were processed for both
HCAII and LightCycler GP5+/6+ PCR testing following DNA extraction using the
manual protocol. For these samples, a 4ml volume was processed for HCAII testing
(as outlined in Section 2.7) then the entire residual cell suspension was processed for
manual DNA extraction. This was particularly labour intensive and unsuitable for
large numbers, so subsequent specimens were processed for DNA extraction only.
For all other specimens, the robotic DNA extraction procedure was used. For 873
specimens, the entire residual specimen was processed but a reduced volume of 10ml
was processed for 668 samples. Additionally, 50 specimens were processed using
150
10ml, 5ml and 1ml volumes from the same residual LBC specimen (Table 7.1). Cell
pellets were resuspended in 180jul ATL Lysis Buffer (provided by QIAGEN Ltd.)
and stored at -70°C until DNA extraction was performed.
No. of
samples
DNA extraction method HPV detection
method
309
heat denaturation + NaOH HCAII
Manual spin columns Real-time PCR
873 Robotic extraction of whole sample Real-time PCR
668 Robotic extraction of lOmls Real-time PCR
50 Robotic extraction of 10, 5, 1ml aliquots Real-time PCR
1900
Table 7.1 Summary of the methods used for DNA extraction from 1900 LBC
samples and for subsequent HPV DNA detection
7.3.4 Data handling
A study database was constructed containing full cytological, histopathological and
clinical histories for all women enrolled and the HPV results obtained. The patients
were anonymised and given unique identifiers. The HPV status of the patients did
not influence clinical management and the HPV results were not released to the GP
practices. To reduce bias, the cytology results were not made available until after the
HPV testing had been completed.
7.3.5 DNA Extraction from LBC specimens using the BioRobot® 9604
Automated DNA extraction from LBC specimens involved considerable optimisation of
QIAGEN approved protocols in conjunction with the manufacturer and BioRobot
Applications Specialists (Section 3.2). Software used for the QIAamp® 96 DNA blood
extraction protocol was modified using the conditions used for manual DNA extraction
(Section 2.5.2). The main adaptations were the introduction of an initial lysis step at 56°C
for one hour (performed by a heat block); robotic addition of proteinase K to samples (that
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were contained in a plastic square-well block on the heat block in preparation for lysis) and
the introduction of additional mixing steps to ensure sample homogeneity. Samples were
eluted twice with Buffer AE to give a final volume of 400|il.
Initial work involved checking for cross-contamination of samples during the
extraction procedure by alternating rows or columns of HPV-containing SiHa cells
or ATL Buffer across the QIAamp® plate. (3—globin PCR was performed on the
extracted material to check the efficacy of each extraction ran (Section 2.8.2). A
maximum of 24 samples was extracted during this validation stage. Due to the small
numbers involved, an internal buffer system was applied for delivery of ethanol and
wash buffers AW1 and AW2 from internal 'slots' on the BioRobot platform. For
clinical specimen extraction, 96 samples were extracted per run and an external
buffer system was used with buffers delivered from buffer bottles connected to the
system via the main probe.
7.3.6 Real-time GP5+/6+ PCR using the LightCycler
GP5+/6+ PCR was performed on a LightCycler instrument (Idaho Technology Inc,
supplied by Biogene Ltd, Kimbolton, Cambridgeshire, UK) using the method
outlined in Section 3.3. A HotStart PCR method was used. TaqStart antibody
(Sigma-Aldrich Co. Ltd., Dorset, UK) was added directly to the PCR master mix and
the mixture was incubated at room temperature for 10 minutes. 1.25(ll of DNA
template and 3.75|il of PCR master mix was added to each capillary. Sealed
capillaries were centrifuged and placed in the LightCycler carousel. Nucleic acid
extracted from SiHa cell dilutions (made from stocks containing lxlO6 cells/ml with
1-2 copies of HPV16 DNA per cell) were included as positive controls and sterile
water was included as a negative control. Detailed Tm analysis was performed on
PCR positive samples by continuous measurement of the fluorescence as the samples
were individually heated at 0.2°C/sec from 50°C to 85°C after a single round of PCR
was complete. Samples with a PCR product within the Tm range of the HPV16 or
HPV18 controls (mean Tm of 79.1° and 80.9°C (± 2SD) respectively) were
considered to be positive for these HPV genotypes. For confirmation of the LC PCR
results obtained, some samples were tested using the RLBA (Section 2.10).
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7.4 Results
7.4.1 Effects of using LBC on cervical cytology results
In this direct-to-vial study, monolayer preparations from LBC samples reduced the
inadequate smear rate from around 10% to less than 1% (Table 7.2). In addition,
LBC reduced the number of borderline smear diagnoses from 4.1% to 2.3% and
increased the detection rate of moderate or severe cytological abnormalities from
1.4% to 2.1%. These results suggest an increase in sensitivity due to the use of LBC
smear preparations, although histological assessment would be required to confirm
this. Table 7.2 summarises the cytology results for all 4702 LBC specimens
collected. The conventional Pap smear results of the 16 GP practices involved in this
study during 1998-1999 are also tabulated to allow a comparison of the results
obtained. The substantial improvements made by the use of LBC sampling by the
reduction of unsatisfactory and unsatisfactory reports and the improved detection of
severe cytological abnormalities is shown, particularly for one GP Practice (PO)
where the percentage of and U/S and B/L reports was substantially reduced.
Cytology





U/S 0.6% 10.2% 0.4% 7.3%
WNL 92.4% 82.1% 96.2% 85.4%
B/L 2.3% 4.1% 1.7% 4.5%
Mild dyskaryosis 2.6% 2.3% 0.4% 1.9%
Moderate dyskaryosis 0.8% 0.9% 0.0% 0.4%
Severe dyskaryosis 1.3% 0.5% 1.3% 0.5%
Other 0.1% 0.1% 0.0% 0.0%
TOTAL 4702 8660 239 576
Table 7.2 Comparison of LBC and conventional Pap cytology results for all 16 GP
Practices and Practice PO involved in this study
U/S = unsatisfactory; WNL = Within Normal Limits; B/L = borderline
153
7.4.2 Validation of BioRobot® 9604 protocol for DNA extraction from LBC
specimens
During BioRobot® 9604 protocol validation, when only cell culture material was
used during extraction runs, there did appear to be some weak cross-over
contamination across the QIAamp® plate, as shown by (3-globin PCR (Figure 7.1).
Despite the use of fresh reagents, tips and extensive swabbing of the BioRobot
apparatus with 70% ethanol, decontamination of the centrifuge with weak HC1 and
washing of the removable hardware with laboratory disinfectant (1% Virkon), this
could not be eliminated. During this development stage, liquid transfer failures had
often resulted in temporary stoppage of the procedure so reagents could be manually
added to the QIAamp® extraction plate wells. To eliminate the possibility that this
intervention was the cause of the cross-contamination, the automated extraction
protocol was repeated using only Buffer ATL in the wells without manual
intervention. Nevertheless, two of 24 ATL samples were still p-globin PCR positive.
Weak p-globin PCR results remained in subsequent extractions using Buffer ATL
only despite UV irraditation of the main BioRobot platform, all movable hardware,
the centrifuge (and the buckets within) and pipettes.
GP5+/6+ PCR was also performed on the DNA extracts to determine if the
contamination was occurring due to the presence of HPV DNA or other viral DNA
that was present in the laboratory where the BioRobot was situated. Some weak HPV
PCR positive results were obtained suggesting the source of PCR contamination was
indeed occurring from the laboratory (data not shown). Thorough washing of the
benches and floor around the BioRobot with soapy water eliminated the problem and
subsequent P-globin and GP5+/6+ PCRs on negative control material showed no
amplification. Subsequently, the BioRobot platform and surrounding bench area
were washed with 70% ethanol before and after use and access to the area housing
the platform was restricted.
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Gel Position on QIAamp® Extracted p-globin PCR
Lane plate during extraction sample result
1 A1 SiHa cells +
2 B1 ATL buffer -
3 CI SiHa cells +
4 D1 ATL buffer —
5 El SiHa cells +
6 F1 ATL buffer (+)
7 G1 SiHa cells +
8 HI ATL buffer —
9 A2 SiHa cells +
10 B2 ATL buffer —
11 C2 SiHa cells +
12 D2 ATL buffer —
13 E2 SiHa cells +
14 F2 ATL buffer —
15 G2 Caski cells +
16 HI ATL buffer -
17 A3 SiHa cells Evaporated
18 B3 ATL buffer (+)
19 C3 SiHa cells +
20 D3 ATL buffer (+)
21 E3 SiHa cells +
22 F3 ATL buffer (+)
23 G3 Caski cells +
24 H3 ATL buffer -
Figure 7.1 (3-globin PCR results showing contamination of samples during
automated DNA extraction using the BioRohot® 9604. Weak (5—globin PCR positive
results' due to contamination seen in Lanes 6, 18, 20 and 22. Lanes 25 and 26 contain
the PCR positive (SiHa DNA) and negative controls (sterile water) respectively.
M = kb ladder; - = PCR negative result; + = PCR positive result; (+) = weak PCR
positive result
As shown by presence of specific PCR product (209bp)
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7.4.3 DNA Extraction from LBC specimens using BioRobot® 9604
7.4.3.1 Sample volume effect
Testing of clinical specimens collected using a fluid optimised for cell preservation
resulted in problems during the automated DNA extraction procedure. Blockage of
the QIAamp® extraction plate was initially attributed to insufficient sample lysis and
considerable time was spent experimenting with the QIAsoft™ 3.0 software and
heat-block temperatures. The heat-block temperature was difficult to record since
daily fluctuations in the room temperature of the laboratory affected the ability of the
heat-block to reach the correct temperature within the prescribed time. Despite
attempts to improve specimen lysis by increasing the temperature or extending lysis
time, a substantial number of samples were found to still cause clogging of the
QIAamp® plate (Table 7.3). After extraction of 873 specimens, clogging of the
QIAamp® plate was still a considerable problem with 328/873 (37.5%) of samples
failing to pass through the silica membrane during the extraction process (Table 7.4).
The degree of blockage observed was related to the total volume of residual sample
used for processing, with 41.8% (322/770) of samples more than 12mls in volume
causing column clogging, 6.9% of samples with 9-12mls processed caused column
clogging and 6.6% of samples with between 5 and 8mls of residual LBC sample
processed caused blockage. No blockages were seen when l^fmls of fluid was
processed but no HPV positive results had been obtained in this group either, due to
the small numbers involved. It appeared therefore that overloading the column with
cells was causing the silica matrix to become blocked thus preventing efficient
extraction. Insufficient specimen lysis may also be partly due to the use of a
methanol-based fixative for specimen collection, which toughens any protein present
thus reducing the efficiency of specimen digestion by proteinase K. Manual
intervention to centrifuge the QIAamp® extraction plate often resolved the














































































































Table7.3hinfluenceofdifferentexperim ntalconditionsf rs cimenlys sgBi Rob ®9604DNAxtractionth QIAamp®plateblock grate.
BioRobot Extraction
Blocked Slightly No
Specimen Volume Column (% Blocked blockage TOTAL
HPV Pos) Column (% (% HPV
HPV Pos) Pos)
>12mls 305 (10.2) 17 (6.2) 448 (11.4) 770
9-12mls 4 1 (100) 67 (22.2) 72
5-8mls 1 0 14 (25.0) 15
l-4mls 0 0 14 14
Unknown (T371 & 0 0 2 (50.0) 2
T1057)
TOTAL 310 (10.1) 18 (11.8) 545 (13.1) 873
Table 7.4 The influence of specimen volume on the QIAamp® plate blockage rate
for 873 samples where the total residual LBC volume was used for specimen
processing
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7.4.3.2 Sample quality effect
PreservCyt® fluid was designed for optimal cell preservation for cytological
assessment and cervical specimens are particularly mucous in nature. In an attempt to
overcome these obstacles to DNA extraction, 177 mucus-rich specimens were
treated with CytoLyt (CL) solution, which is designed to dissolve mucous in
respiratory and gastrointestinal samples prior to processing. In addition, due to
problems encountered with blocking of the QIAamp® membranes during the
automated extraction process, the volume of sample removed from each
PreservCyt® sample vial for processing was reduced to lOmls. This volume was
chosen because at that point no samples with lOmls of PreservCyt® fluid processed
for DNA extraction had shown blockage of the QIAamp® membranes and the issue
surrounding possible loss of HPV sensitivity had not been adequately addressed.
Sample processing was modified so that after centrifugation of lOmls of
PreservCyt® fluid, lOmls CL solution was added to each specimen pellet before re-
centrifugation as recommended by the manufacturer for processing of non-
gynaecological specimens. However, the blockage rate was still found to be 23.7%
(42/177; Table 7.5).
QIAamp® plate Cytology n HPV Pos (%) HPV Neg
U/S 1 NT NT
Blocked columns Neg 38 6 (15.8) 32
(n=42) mild 2 2 0
sev 1 1 0
TOTAL 42 9 (21.4) 32
Slightly blocked Neg 12 2(16.7) 10
columns (n=13) B/L 1 0 1
TOTAL 13 2 (15.4) 11
U/S 1 1 0
Neg 108 14(13.0) 94
No blocked columns B/L 4 3 (75.0) 1
(n=122) mild 4 4 0
mod 3 3 0
sev 2 2 0
TOTAL 122 27 (22.1) 95
Table 7.5 DNA extraction of 177 CytoLyt-treated specimens using the BioRobot®
9604
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7.4.3.3 Effect of blockage on HPV detection
A further 668 samples were processed using only lOmls of the available sample. Of
these, 25.8% (173/668) were found to cause blockage of the QIAamp® plate during
extraction (Table 7.6). At this point, 50 samples were selected from 14 women who
had a current smear showing some degree of dyskaryosis and 36 women who had a
current negative smear but were on early recall for a previous cytological
abnormality, and therefore were more likely to harbour HPV in the cervix than





HPV Neg HPV NT TOTAL
Blocked extraction
column
32(18.5) 139 2 173
Slightly blocked
extraction column
9 (23.6) 29 0 38
No blockage 98 (21.4) 358 1 457
TOTAL 139 526 3 668
Table 7.6 QIAamp® plate blockage rates for 668 samples where lOmls LBC volume
was used for specimen processing
NT = not tested
Reduction of the volume of processed PreservCyt® specimen from lOmls to 5mls
caused less overloading of the QIAamp® membranes and thus reduced the clogging
of the QIAamp® extraction plate from 5% to 1%. 8% of lOml-processed samples
caused QIAamp® plate blockage and 2% of 5ml-processed samples caused
QIAamp® plate blockage. None of the 1 ml-processed samples caused blockage of
the QIAamp® plate during the extraction process. Twenty-one of these 50 samples
(42%) produced HPV positive results by LC GP5+/6+ PCR when 10ml or 5ml
volumes were used for automated DNA extraction (Table 7.7). However, only 19/50
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samples produced HPV positive LC GP5+/6+ PCR results when 1ml of processed
specimen was used for extraction.
This preliminary experiment using 10ml, 5ml and 1ml of sample suggested that
processing 5ml of the residual original LBC specimen was optimal for reducing the
QIAamp® plate blockage rate to less than 5% without any loss of sensitivity for
HPV detection by real-time PCR. Additional testing of 150 specimens using the
above three processing volumes confirmed these findings but the blockage rates were
increased to 17.5% and 3% for 10ml- and 5ml-processed sample volumes
respectively (Cuschieri et al., manuscript in preparation).
lOmls or 5mls of LBC
specimen processed for
DNA extraction












WNL 8 28 36 6 30 36
B/L 6 0 6 6 0 6
Mild dyskaryosis 4 0 4 4 0 4
Moderate
dyskaryosis
2 1 3 2 1 3
Severe dyskaryosis 1 0 1 1 0 1
TOTAL 21 29 50 19 31 50
Table 7,7 HPV testing results using LC GP5+/6+ PCR for pre-selected samples
processed using both lOmls, 5mls and lmls of the residual LBC specimen
WNL = within normal limits; B/L = borderline
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7.4.4. HPV DNA detection using LightCycler PCR
Table 7.8 shows the cytology results and LC GP5+/6+ PCR testing results for 1082
specimens. This group comprises 300 of the first 309 specimens that had the total
residual volume extracted using the manual QIAamp® tissue protocol and 782 of the
subsequent 873 samples had the total residual volume extracted using the BioRobot®
9604 automated DNA extraction protocol. DNA extracted from 100 LBC samples
was not tested by real-time PCR. From these results it can be seen that increasing
HPV positivity was associated with increased cytological abnormality. 7.9% of
women with no cytological abnormality were HPV positive, 43.5% of women with
borderline cytology harboured HPV genotypes and 77.4% of women with mild
dyskaryosis tested HPV positive using the real-time PCR assay. It was also possible
to obtain HPV positive results in the absence of satisfactory cytology.
TP Cytology LC GP5+/6+
TOTALHPV Pos (%) HPV Neg
U/S 1 4 5
WNL 80 (7.9) 927 1007
B/L 10 (43.5) 13 23
Mild dyskaryosis 24 (77.4) 7 31
Moderate dyskaryosis 2 (66.6) 1 3
Severe dyskaryosis 8 (66.6) 4 12
Glandular abnormality 0 1 1
TOTAL 125 957 1082
Table 7.8 Correlation between LBC result and HPV results using LightCycler
GP5+/6+ PCR for 1082 specimens that were processed for DNA extraction using the
total residual LBC volume
U/S = unsatisfactory; WNL = within normal limits; B/L = borderline
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Five out of 15 samples showing moderate or severe dyskaryosis were HPV negative.
To eliminate the possibility of a false negative LC GP5+/6+ PCR result, these
specimens were tested using conventional GP5+/6+ PCR. Four out of 5 generated
F1PV positive results, although two were only weakly positive. The HPV negative
result was associated with a LBC specimen that had shown severe dyskayosis upon
cytological assessment. No problems had been encountered during automated DNA
extraction from pelleted cells from this sample, which had 16mls of the PreservCyt®
fluid processed for HPV testing.
Table 7.9 shows the cytology results and LC GP5+/6+ PCR testing results for the
668 specimens (3 were not LC tested) that had 10ml of the residual volume
processed for DNA extraction. Once again, increased HPV positivity was associated
with increased cytological abnormality but the degree of HPV positivity was higher
in this group. 14.8% of women with no cytological abnormality were HPV positive,
68.7% of women with borderline cytology harboured HPV genotypes and all women
with mild or moderate dyskaryosis tested HPV positive using LightCycler GP5+/6+
PCR. One LBC specimen that showed severe dyskaryosis was HPV negative and one
LBC sample reported as adenocarcinoma was also HPV negative. No further testing
was performed on either of these samples.
7.4.5. Detailed melting temperature analysis of LightCycler PCR-positive
products
Detailed melting temperature analysis for HPV products showed that the majority of
PCR positives were classified as HPV 16 (44.3%). Several HPV 18 (15.5%) and
double infections (12.5%) were also found. Approximately 19% of the samples
tested appeared to contain other HPV genotypes as suggested by different melting
temperatures (range 76.1°C to 82.3°C), and these were designated HPV 'X'.
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Cytology LC GP5+/6+ PCR TOTAL
HPV Pos (%) HPV Neg
Unknown 1 5 6
U/S 1 3 4
WNL 89(14.8) 511 600
B/L 11 (68.7) 5 16
Mild dyskaryosis 17 (100) 0 17
Moderate dyskaryosis 7(100) 0 7
Severe dyskaryosis 13 (92.8) 1 14
Adenocarcinoma 0 1 1
TOTAL 139 526 665
Table 7.9 Correlation between LBC result and HPV results using LightCycler
GP5+/6+ PCR for 668 specimens that were processed for DNA extraction using
lOmls of the residual LBC volume
U/S = unsatisfactory; WNL = within normal limits; B/L = borderline
7.4.6 HPV genotyping using the RLBA
The RLBA was performed to identify the HPV types present in LC GP5+/6+ PCR
samples and to assess whether detailed melt analysis of LC GP5+/6+ PCR products
was accurate for the identification of HPV 16 and HPV 18 in clinical samples.
Detailed melt analysis of 117 samples gave Tms within the range 78.3°C to 79.9°C
and thus were considered to be HPV 16. Of these samples that were tested by the
RLBA assay, 23/39 were found to contain HPV 16 DNA but 16 of these also had
additional HPV genotypes present (Table 7.10). The remaining 15 samples were
found to contain HPV types other than HPV 16, with up to four different HPV
genotypes being detected in the same sample. Specimens found to contain HPV11,
45, 56, 35 and MM9 by the RLBA assay gave similar detailed melting temperatures
to the HPV 16 controls used in LC GP5+/6+ PCR. Similarly, 41 samples were
considered to be HPV 18 on detailed melt analysis following LC GP5+/6+ PCR. Six
out of 18 samples tested by the RLBA assay were found to contain HPV 18 DNA, but
four of these contained additional HPV genotypes also (Table 7.11). Samples
containing HPV11 and HPV52 by the RLBA assay gave similar detailed melting































HPV16+51(78.97) HPV16+51+52x2(79.19;79.64) HPV16+MM9x2(79.2;79.05) HPV16+58x2(78.53;79. 1) HPV16+4552(78.73) HPV16+56x2(78.66;79 3) HPV16+33(78.7) HPV16+59(79.08) HPV16+31(78.74) HPV16+52+43(78.33)
HPV1(79.73) HPV451(79.77) HPV56(78.43) HPV35(79.14)
HPVMM9(78.37)
HPV53,66(78.81) HPV35,66(78.46) HPVMM7,54(79.84) HPV45,58(79.64) HPV39,55(78.6) HPV5LMM42(79.22)
HPV31,586(79.41)
HPV35,52684(79.16)
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HPV18+6(80.7) HPV18+631(80.62) HPV18+33551+4 (81.17) HPV18+16+52+MM963 (81.62)
HPV11(80.7) HPV52(81.36)
HPV56,59(81.34) HPV42,57(80.69) HPV6,MM8(80.15) HPV52,53(80.36)
HPV56,MM9,6 (80.08)
HPV58,34.MM8 (80.27)
Table7.11RLBAresultsforsamp edenot dsHPV18byr al-timePCRwi hGP5+/6+prim rsnt inaly is,including breakdownofd tailedTmresultsf rs mp econsideredtHPV18uf rmntaith rgeno yp sRLBA analysis n=umber;Tmeltingte p rature;NTosted
Detailed melt analysis of 51 samples gave Tm values outwith the ranges obtained
using HPV 16 and HPV 18 control material. These samples were considered to
contain DNA of other HPV genotypes, thus designated HPV 'X'. RLBA testing of
18 of these samples showed that eight contained more than one HPV type (Table
7.12). Four of the single infections found by the RLBA assay were HPV 16. These
four samples had given detailed Tm values of 78.10, 78.19, 77.85 and 78.11. The
remaining single infections were found to contain genotypes other than HPV 16:
HPV 31, 58,45 and MM9.
Fourteen of 33 samples considered to contain more than one HPV genotype by
detailed melting analysis (as shown by the presence of more than one peak) were
tested using the RLBA to determine the exact HPV types present (Table 7.12). Only
four samples were found to contain multiple HPVs. The remaining seven samples
contained either HPV 16, 18, 35, 45 or MM9.
To assess any association between the number of infecting HPV genotypes and the
development of cervical abnormalities, the RLBA assay results were compared to the
LBC results (Table 7.13). Infection with multiple HPV types appeared to be more
common in women with normal cytology, with up to seven different HPV genotypes
being detected in a single specimen. Prior infection with specific HPV types is not
believed to affect the risk of acquiring another infection with a phylogenetically

































































Table7.12RLBAresultsforsamp edenotedsHPV'X' rp ssibleublinfec ionbyreal-timePCRw hGP5+/6+prim rs anddet iledmeltingte peraturenalysis Tm=meltingte perature
Cytology Number of
samples
No. of HPV genotypes detected by RLBA





17 14 2 1 0 1 1
Borderline
(ASCUS)
3 0 1 0 2 0 0 0 0
Mild
dyskaryosis
18 0 6 7 1 3 1 0 0
Moderate
dyskaryosis
7 0 2 4 1 0 0 0 0
Severe
dyskaryosis
14 0 6 5 1 2 0 0 0
TOTAL 89 10
(+1NT)
32 30 7 6 1 1 1
Table 7.13 Correlation between LBC result and number of HPV genotypes detected
by RLBA
NT = not tested
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7.5 Discussion
7.5.1 General problems associated with automated DNA extraction from LBC
Specimens
To perform HPV testing on residual LBC fluids, a suitable DNA extraction
procedure is necessary that can successfully extract nucleic acid from a large number
of specimens. This proved to be a difficult task since PreservCyt® fluid is an
methanol-based medium designed to preserve cell morphology. Since the number of
HPV-infected cells in any LBC specimen may be small, a main concern of this study
was that reducing the volume of sample processed would compromise the sensitivity
of the downstream GP5+/6+ LC PCR assay for the detection of HPV DNA.
Standardisation of LBC specimens would be very difficult since the nature of
individual specimens (for example, mucous or blood content) and the amount of
residual fluid remaining after the LBC smear had been prepared differed from
specimen to specimen. Ideally, quantification of the number of cells in each LBC
sample would have allowed standardisation of the extracted material. This could
have been done by quantitatively estimating cellular (3-globin. For instance,
quantifying the number of cells per specimen would have allowed an exact volume
of PreservCyt® fluid to be processed containing a known number of cells e.g. 106
cells/ml. After resuspension of the cell pellet in 180pl Buffer ATL, every specimen
that was extracted would have contained the same number of cells. However, this
practice does not control for the proportion of HPV-infected cells per sample. Since
cell quantification would be very labour intensive, it was not considered suitable for
high specimen throughput, and thus was not investigated as part of this study.
Instead, LBC specimens were processed using varying volumes of the residual LBC
specimen and DNA extraction experiments were performed using the automated
BioRobot® 9604 protocol. When the entire residual LBC specimen volume was
processed for extraction, approximately 38% of the QIAamp® extraction plate
columns were blocked. Pre-treatment of the residual LBC fluid with CytoLyt
solution (designed to break down mucous in respiratory samples) and attempts to
improve the specimen lysis stage did not improve the QIAamp® plate blockage rate.
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Blockage of the QIAamp® extraction plate required manual intervention: additional
QIAamp® plate centrifuge steps at 10,000rpm were performed to remove blockages
since centrifugal force was more effective than a vacuum at drawing the samples
across the QIAamp® silica membrane. After QIAamp® extraction plate blockage,
subsequent washing steps were often also problematic and manual intervention to
centrifuge the plate was again required to resolve the blockage problems. These
additional centrifuge steps were time-consuming and compromised the automated
advantage of using the BioRobot® 9604. Reduction of the processed LBC specimen
volume to 10ml did reduce the blockage rate to 23.7% but this was still considerably
higher than the 5% blockage rate considered acceptable by the BioRobot® 9604
manufacturer (QIAGEN Ltd., personal communication). If <5% blockages occur, the
BioRobot® 9604 can be programmed to locate the blocked sample(s) on the
QIAamp® extraction plate and remove the sample from the plate well. Meanwhile,
the software notes the blocked sample and the extraction procedure continues
without interruption.
Additional investigations performed on 50 selected LBC specimens using 10ml, 5ml
and 1 ml volumes of the original sample for processing showed that reduction of the
processed LBC specimen volume to 5ml resulted in a QIAamp® extraction plate
blockage rate of <5%, without a subsequent loss in sensitivity for the detection of
HPV by GP5+/6+ LC PCR. Using 1ml of residual LBC specimen for processing did
not cause any blockage of the QIAamp® extraction plate columns during the
automated protocol but reduced sensitivity was found for the detection of HPV DNA
by GP5+/6+ LC PCR since two samples that tested HPV positive when 5mls of fluid
was used for extraction, tested HPV negative when only 1ml was used. Thus, 5mls of
PreservCyt® fluid was recommended as the volume to be processed for automated
nucleic acid extraction and any QIAamp® plate blockages that occurred were noted
and dealt with by the BioRobot® 9604 automatic well-clearance facility.
Due to the large number of LBC specimens received in a six-month period
(approximately 250-300 specimens per week) and the problems encountered during
development of the automated DNA extraction protocol, many specimens were
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processed some time before either DNA extraction or GP5+/6+ LC PCR testing was
performed. Thus, in most cases, retrospective DNA extraction and LC PCR testing
were performed after cells from the residual specimen volume had been pelleted.
Thus many of the specimens had already been processed using a 10ml sample
volume before the influence of this sample volume on QIAamp® plate blockage
rates was detected.
7.5.2. Technical problems associated with DNA extraction from LBC specimens
using the BioRobot® 9604
Initial work to optimise the BioRobot® 9604 extraction protocol was complicated by
cross-contamination occurring across the QIAamp® extraction plate. Considerable
time and effort was spent investigating this. Following helpful discussion with Drs
Jon Turner and Shona Kerr at the Molecular Medicine Centre, Western General
Hospital, Edinburgh, who have expertise in high-throughput DNA extraction from
clinical specimens, the location of the BioRobot was deemed the most likely
explanation for the PCR contamination problem. Due to the small area dedicated for
DNA extraction at RCVL, the BioRobot had been assembled in the main molecular
laboratory, which has designated areas for LBC specimen processing, PCR
amplification and agarose gel electrophoresis. It was thought that P-globin PCR
positivity was due to PCR product contamination of the BioRobot bench area. Use of
another primer set for the detection of another cellular gene (kindly provided by Dr.
J. Warner) failed to generate any positive results (data not shown), thus confirming
that PCR product was the explanation for negative control contamination.
Other problems encountered with the BioRobot protocol development included
software problems such as liquid detection errors, dripping from the tips, total
sample transfer from the heat block to QIAamp® plate and software failures. Due to
the initial problems with PCR product contamination of the BioRobot® 9604
platform and bench area, the instrument and bench tops were swabbed down with
70% ethanol before and after use. After each extraction run the centrifuge was wiped
using weak acid then water, the vacuum manifold was washed thoroughly in 1%
Virkon disinfectant then rinsed with water and the plastic square-well blocks were
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autoclaved. These measures were performed to minimise the risk of PCR product
contamination.
Although the BioRobot® 9604 extraction method could process 96 samples in one
run, it took approximately 3.5 hours to complete the protocol. The limiting step was
the plate centrifugation stage (to dry the QIAamp® plate prior to elution) that
prevented the extraction procedure being completely automated and a true 'walk¬
away' system.
7.5.3. LightCycler PCR
Real-time PCR offers many advantages over conventional PCR systems. Since real¬
time GP5+/6+ PCR amplification and product detection occur simultaneously in the
same glass capillary, post-PCR manipulations are unnecessary. Hence, this method
is much quicker and less labour intensive than conventional GP5+/6+ PCR methods.
In the study presented here, the entire DNA extraction and amplification procedure
for 96 samples could be performed within approximately 4.5 hours. In contrast, the
time required for manual DNA extraction of 24 samples is at least one hour, followed
by a 4-hour conventional PCR amplification step then 30 minutes for detection of
the PCR product by agarose gel electrophoresis; a minimum of 5.5 hours. The true
strength of real-time PCR is the ability to quantitate the amount of target DNA
present. This is important because some studies have indicated that the quantity of
HPV DNA detected is predictive of cervical disease (Ylitalo et al., 2000; Josefsson et
al., 2000). Although quantitative analysis of clinical samples was not included in the
present study, extraction of HPV DNA from a known copy number of SiHa cells
shows that the LightCycler could be used for this purpose. We found that 10-fold
dilutions of SiHa and HeLa cells of known copy number for HPV 16 and HPV 18
could be detected as parallel amplification curves, approximately three cycles apart
(data not shown). Quantitative fluorescence-based real-time PCR assays have been
developed by others, particularly for cytomegalovirus - a major cause of morbidity
and mortality in immunosuppressed individuals such as HIV patients and solid organ
transplant recipients (Schaade et al., 2000; Kearns et al., 2001; Gault et al., 2001).
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Practical problems encountered in the study reported here included handling the
fragile capillaries and interpreting the LC PCR Tm analysis results. Some samples
produced a very low melting peak, which is associated with a smaller number of
target copies (Schalasta et al., 2000b), making visual interpretation of results more
difficult. Improvements to the current system could be made by introduction of an
internal amplification control to allow quantification of the input sample DNA and to
detect PCR inhibitors. The LC is equipped with other channels for the detection of
other reporter dyes, which could be used to introduce an internal control. For
example, human (3-globin is present in one copy/cell and primers for (3-globin
detection have been successfully incorporated into multiplex real-time PCR formats
(Tucker et al., 2001). Using standard curve analysis, the number of HPV copies per
microgram of input DNA can then be calculated.
7.5.4. Comparison of HPV DNA detection by LightCycler PCR with Tm
analysis and RLBA
Attempts were made to differentiate between HPV 16, 18 and others (designated
HPV 'X') using Tm analysis. Further HPV genotyping using the RLBA (that can
detect up to 13 different HPV types) showed that clinical samples containing
multiple HPVs are common and these could not be distinguished by detailed melt
analysis of LC GP5+/6+ PCR products alone. Cervical samples from 19 out of 46
(41.3%) women with normal cytology were found to contain more than one HPV
genotype (with up to seven different HPV types being detected). Such findings could
lead to a requirement for HPV genotyping to increase the specificity and delineate
further those HPV types most frequently associated with persistence and cervical
disease progression. Different line blot assays have been reported for this purpose
(Gravitt et al., 1998; Kleter et al., 1999; van den Brule et al., 2002).
Nonetheless, the results obtained by real-time PCR detailed melt analysis and the
RLBA should be interpreted with caution. These molecular assays employ different
primer sets (GP5+/6+ and MY09/11 respectively) for the amplification of a wide
range of anogenital HPV genotypes. It is being increasingly recognised that the
technical parameters of available detection systems may have led to preferential
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detection of some types and underestimation of the prevalence and thus significance
of certain other HPV genotypes (J. Kornegay, personal communication). For
example, GP5+/6+ primers were designed to have the least number of mismatches
with HPV 16 and HPV 18 LI DNA sequences. Thus, the analytical sensitivity of the
GP5+/6+ PCR system will be greater for these HPV genotypes. For other HPV types,
a greater number of primer mismatches result during PCR amplification and
therefore DNA from such types will be amplified with less efficiency. It is
noteworthy that in comparisons of the GP5+/6+ and MY09/11 primer sets for the
detection of HPV DNA in cervical specimens, the MY09/11 primers were far more
effective at detecting samples with multiple HPV types than GP5+/6+ (90% and 47%
respectively; Qu et ai, 1997). Tucker and colleagues (1993) investigated whether
PCR amplification of HPV DNA in cervical specimens accurately reflected the
relative amounts of each HPV genotype present. They concluded that the selective
amplification of one HPV over another could occur when multiple genotypes are
present. It could therefore be possible that the GP5+/6+ primers are amplifying the
predominant HPV genotype only during real-time PCR. The GP5+/6+ PCR system
using the LightCycler was standardised using HPV 16 and HPV 18 cell culture
material and plasmid DNA, including mixtures of these DNA types.
More work is required to optimise the LightCycler GP5+/6+ PCR system for the
detection of other HPV genotypes. Since it appears impossible to distinguish
between all the known HPVs by detailed melting temperature analysis alone,
increased specificity may be achieved using LC hybridisation probes. This would
involve fluorescence resonance energy transfer (FRET) technology through the use
of two independent single-labelled oligonucleotides that are designed to hybridise
adjacently on the PCR amplicon internal to the flanking PCR primers. The upstream
probe would be labelled at its 3'- end with a donor dye (e.g. fluorescein) and the
downstream probe would be labelled at its 5'- end with an acceptor dye (e.g. the
cyanine dye Cy5™ or LightCycler Red 640). After light excitation by the LED,
FRET would occur from the donor to the acceptor dye resulting in an increase in
fluorescence, which would be directly proportional to the amount of PCR product
generated. Real-time quantitative PCR using FRET technology has been applied for
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CMV (Nitsche et al., 1999; Schaade et al., 2000) and HSV (Espy et al., 2000b).
Although the use of LC hybridisation probes might be considered more complex for
HPV detection due to the larger number of viral genotypes found in clinical
specimens, molecular beacons containing a hairpin loop structure in which
fluorescent donor and quencher molecules are held in close proximity have been




This was the first UK study to report on the use of LBC to replace conventional
smears within the NHS Cervical Screening Programme. Monolayer preparations
from PreservCyt® specimens reduced the inadequate smear rate from around 10% to
less than 1%. This reduced the level of anxiety in women and provided savings in
repeat visits for patients, repeat laboratory tests and administrative time. LBC also
reduced the number of B/L smear diagnoses and increased the detection of severe
cytological abnormalities confirmed by histology. The GPs involved in this study
were very impressed by the LBC screening system and the improved results made
them reluctant to return to conventional Pap screening.
New technologies to improve the cervical screening programme include detection of
high-risk human papillomavirus types to identify those women at increased risk of
cervical disease progression. A protocol suitable for such testing has not yet been
determined, but the limitations of current hybridisation methods and consensus PCR
methods for screening purposes are known. For HPV testing within cervical
screening programmes, the development of an efficient, sensitive and automated
extraction procedure is a prerequisite for high sample throughput. Our priority was to
develop a robust system for this purpose without compromising the sensitivity of
subsequent HPV testing using LC GP5+/6+ PCR. A robot extraction procedure using
a QIAGEN BioRobot® 9604 was successfully developed. This method was based on
cellular lysis, followed by binding of nucleic acid to a silica matrix and subsequent
elution of the DNA. The manual QIAGEN extraction protocol, based on the same
principle, had been successfully used for DNA extraction from LBC samples in a
previous study (described in Chapter 6). However, the manual procedure used a
water bath set at 55°C to perform lysis of samples contained in 1.5ml eppendorf
tubes, followed by the use of centrifugal force to draw the samples across the silica
membrane. The automated BioRobot® 9604 extraction protocol, used a heat block to
lyse the samples that were contained in a plastic square-well block and vacuum
pressure was used at most stages to draw the samples across the silica membrane.
This was found to be less effective than centrifugation, resulting in a large number of
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QIAamp® plate blockages. In addition, problems were encountered with mucous-
rich specimens as PreservCyt® fluid is designed for optimal cell preservation, rather
than DNA extraction. Pre-treatment with CytoLyt solution and improvements to the
sample lysis stage of the extraction protocol failed to reduce the number of
blockages, which were finally attributed to cellular overloading of the QIAamp®
columns. Reducing the volume of specimen processed for DNA extraction to 5mls
resulted in <5% blockages which could be dealt with by the BioRobot® 9604 and
did not compromise the sensitivity of HPV detection by real-time PCR.
Although PCR allows faster result turn around times within a diagnostic laboratory,
detection of conventional PCR positive samples has to be performed by agarose gel
electrophoresis. LightCycler PCR eliminates the need for this extra manipulation
since PCR positive samples are identified as a peak during Tm analysis.
Additionally, detection of individual HPVs in conventional PCR positive samples
requires testing with an enzyme immunoassay using many type-specific probes. LC
GP5+/6+ PCR was found to be a rapid and efficient method for the detection of HPV
in LBC extractions. It was possible to test up to 150 samples per day using one
LightCycler following robotic extraction of the DNA. Since the melting temperature
of DNA is dependent on the sequence, length and GC content, preliminary work
using DNA extracted from cell culture material and plasmid DNA had suggested it
was possible to differentiate between HPV 16 and HPV 18 by DNA melting
temperature analysis following GP5+/6+ LC PCR. It was hoped that Tm analysis
would also allow further differentiation between other HPV types. However, only
17.9% and 11.1% of single HPV 16 and HPV 18 infections indicated by detailed melt
analysis of DNA extracted from clinical specimens were confirmed by the RLBA.
RLBA testing showed that multiple HPV infections were common, both in women
with and without cytological abnormalities. Apart from the suggested association of
HPV 18 with rapid progression of cervical neoplasia, there is yet little evidence to
suggest that the risk of developing cervical cancer is different for the other high-risk
HPV genotypes. It has therefore been suggested that tests that detect all the known
HR-HPV types together are sufficient for clinical management. HPV genotyping is
necessary to distinguish persistent HPV infection and re-infection with different
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HPV types. RNA analysis may be necessary to distinguish which HPV genotypes are
actively replicating and those which are latent infections. If current clinical research
suggests that HPV genotyping is necessary for making clinical management
decisions, then genotyping assays will be required to differentiate specific HPV types
and even variants of the same type (Mayrand et al., 2000).
The development and optimisation of the automated extraction system and real-time
PCR system was more time consuming than expected. Of the 4702 LBC samples
collected and processed over a six-month period, 1900 had DNA extracted and
stored. 1750 of the 1900 samples were tested for HPV DNA during this time.
GP5+/6+ PCR using the LightCycler following automated BioRobot® 9604
extraction detected HPV DNA in 90-100% of LBC samples that had shown
moderate or severe dyskaryosis on cytological assessment, leading to the conclusion
that the combination of automated DNA extraction using a BioRobot® 9604 and
real-time LightCycler PCR is suitable for HPV detection in a diagnostic laboratory
setting. Further work is required to confirm the real-time PCR findings using the
RLBA assay and to optimise the real-time PCR assay for the detection of other HPV
genotypes. This approach is likely to involve the use of hybridisation probes since it
is impossible to distinguish between individual HPV types from the array of known
genotypes on the basis of melting temperature analysis alone. This study has
generated a unique resource of more than 5000 fully characterised LBC samples
from consenting women attending routine cervical screening clinics within the
Scottish Cervical Screening Programme. This collection will be a valuable resource
for continued development of molecular tests for HPV and for other microbes




The work covered in this thesis focuses primarily on the role of HPV testing in
cervical screening to improve the identification of women who are at risk of
developing cervical neoplasia. To assess this, several different patient populations
were investigated using various methods for HPV DNA detection. In addition, the
assessment of LBC for the improved detection of cytological abnormalities was
performed and the suitability of preservative fluids for HPV tests was critically
evaluated. However, the potential uses of HPV testing in the cervical screening
programme remains a complex issue and this chapter sets out a summary of the
findings of the work that has been presented with discussions of the advantages and
disadvantages on screening protocols along with description of some topics for future
research that would supplement the findings.
8.1. Limitations of the current NHS cervical screening programme
using the conventional Papanicolaou smear
For effective screening of cervical neoplasia, a truly representative sample taken
from the cervical transformation zone is essential for assessment. Since the
introduction of the Pap smear by George Papanicolaou in the 1940's, organised
screening programmes have successfully reduced the mortality associated with
cervical cancer. Now, the level of success achievable using the Pap smear has been
reached and the drawbacks of the technique are well recognised (Gay et ai, 1985;
van der Graaf and Vooijs, 1987). Poor preparation and fixation is a major limitation
that results in a large number of inadequate and borderline Pap smear results. A
significant proportion of the collected cervical cells are not transferred to the glass
slide and are instead discarded along with the sampling device. Moreover, the cells
that are successfully transferred are often overlapping and obscured by inflammation
or blood (McGoogan and Reith, 1996). Unsatisfactory smears result in a need for
repeated cytological assessment and the majority of B/L smear reports are of no
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clinical significance (Cuzick et al., 1999b). So, new methodologies are required to
improve the sensitivity and specificity of the National Cervical Screening
Programme.
8.2 The Way Ahead
8.2.1 LBC
The results presented in this thesis suggest that LBC has the potential to improve
cervical cytopathology through the collection of a more representative specimen. TP
slide preparations made using automated technology operated by skilled staff show
optimal cell preservation as well as reduced debris from inflammatory cells, blood or
mucus. Additionally, only a proportion of the cervical cells collected into the
preservative fluid are used to make a TP slide, so the residual material can be
processed for additional laboratory tests without another patient visit. Comparative
assessment of 800 TP smears and conventional Pap smears prepared during the
'split-sample' study (Section 6.3.1), where a Pap smear was prepared in the standard
way before the cells were collected into PreservCyt® fluid, showed that LBC
provided a more accurate assessment of cervical cytological abnormality. While
87.5% of the smears showed complete diagnostic agreement, the TP smear detected a
more severe abnormality in over half of the remaining cases. The remaining
discrepant results were due to overdiagnosis of the cytological abnormality using the
conventional Pap smear. Furthermore, TP significantly reduced the number of
inadequate and B/L smear diagnoses (from 7.3% to 2% and from 7.9% to 4.2%
respectively). The few inadequate TP reports primarily resulted from insufficient
epithelial cells on the slide rather than inflammation, blood or drying artefacts. This
improved effectiveness of screening was further accentuated in the 'direct-to-vial'
study (Chapter 7), which was the first UK study where the TP slide replaced the
conventional Pap smear for screening purposes. As a result of the entire cervical
sample being collected into preservative fluid, the number of inadequate TP smears
was reduced from 10% to less than 1% and the number of B/L smears was reduced
from 4.1% to 2.3%. The use of TP slide preparations was again associated with
greater detection of high-grade cervical abnormalities from 1.4% to 2.1%. Although
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a report by the NICE in June 2000 concluded that there was insufficient evidence to
support the immediate introduction of LBC, the Lothian GPs involved in the direct-
to-vial study were so impressed by the clinical value of LBC that they were reluctant
to return to conventional Pap screening. The analysis of data collected from the LBC
demonstration projects performed at four different Scottish sites over a six month
period during 2001 was reported in January 2002. Lollowing the success of these
pilot studies, the Scottish Executive have announced that £2.75 million will be
invested to introduce LBC throughout Scotland for all women by 2004 (internet
citation: http://www.scotland.gov.uk/pages/news/2002/03/p_SE5603.aspx).
From a laboratory perspective, the cost of non-recyclable consumables, reagents and
hardware is more expensive for LBC compared to conventional Pap smears and
cytotechnologists need to be retrained to interpret LBC smears. However, trained
personnel can screen LBC slides in half the time taken to screen conventional Pap
smears. As the time taken for administration is the same, the daily workload can be
increased by 25-40% (Dr. E. McGoogan, personal communication) which is likely
to have cost benefits for the National Health Service. Practical problems associated
with producing LBC preparations may include the shelf-life and storage of supplies
in GP clinics, education of smear-takers in the correct method for LBC sampling and
the cost and practicalities of transport of alcohol-containing specimens. However,
these minor drawbacks are heavily outweighed by the benefits to both the patient and
clinician and the potential to generate long term savings through a reduction in the
number of unsatisfactory and borderline smear reports generated. As a result, patient
anxiety would also be reduced which may result in a decline in the number of women
who are lost to follow-up.
8.2.2 HPV Testing
8.2.2.1 Within the CSP
The epidemiological evidence from the literature clearly shows that HPV infection is
an essential element in the development of cervical neoplasia and infection with HR-
HPV types is the major risk factor for the subsequent development of cervical
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carcinoma, although the exact mechanism of HPV-associated cervical
carcinogenesis is still incompletely understood. In the work reported here, increased
HPV positivity was shown to be associated with increased cytological abnormality,
with 90-100% of samples showing high-grade dyskaryosis by LBC or conventional
Pap smear being found to contain HPV DNA and more than 80% of low-grade
abnormalities were also HPV positive.
Although there is substantial evidence in the literature to suggest that HPV testing
would be useful as an adjunct to cervical cytology, there is still debate as to whether
this should be implemented for detection of cervical abnormalities as part of the
primary screening process or only for management of women with B/L smear results.
The results presented here suggest that testing for high-risk HPV genotypes may
confer a positive role at the secondary screening stage when used in combination
with LBC. Specifically, its application could allow more effective triage of women
with B/L smears by delineating them into one of three groups:
(i) return to routine screening
(ii) continued cytological follow-up or
(iii) immediate referral to colposcopy.
If all HPV negative women in the 'split-sample' study reported here (Section 6.3.7)
had been managed by routine recall, then two cases of CIN 1 would have been
missed but no cases of CIN 2/3 would have been left untreated. Yet 110 women
would have been saved a total of 160 unnecessary repeat visits and smears. Thus
HPV testing in this situation would most likely prove to be cost-effective through the
reduction in colposcopy referrals. The high negative predictive value (NPV) of a
negative HCAII result and normal cytology was also shown by retrospective analysis
of archival Pap smears from women with a previous cervical biopsy (Section 4.4.4).
Although the positive predictive value (PPV) of combined cytology and HPV testing
before biopsy was higher at 78% than the PPV of cytology alone or HPV testing
alone, the NPV of a negative HCAII result and normal cytology was 100%. This
would support the introduction of HPV DNA testing to aid exclusion of severe
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cervical disease rather than predicting its presence. In March 2001, large-scale trials
of HPV testing in combination with LBC began at three separate locations in
England as part of a 12-month pilot study.
Results from the work described here (Section 6.3.5) suggest that HPV testing by
HCAII is unlikely to be cost effective for primary cervical screening since on
average 15% of women with no previous history of cytological abnormality were
found to harbour HR-HPV types in their cervices. Since only a small proportion of
these women would develop cervical neoplasia, cytological and histological follow-
up of such HPV-positive cases, as part of the primary screening process, would not
be cost effective. Another important consideration for the implementation of HPV
testing as part of primary screening would be the age range for screening since age
appears to be an important factor in the complex relationship between the sensitivity
and specificity of HPV testing. In all women enrolled the split-sample study
(Chapter 6), HPV positivity was found to decrease with age with the majority of
HPV positive results (43.8%) obtained from women aged 24-29 years (data not
shown). Evidence from the literature suggests that HPV testing is unlikely to be cost
effective in women under 35 years of age since the majority of these women would
only have transient viral infection. Indeed, in the split-sample study, nearly 39% of
women under 35 years of age were HPV positive compared to 15% of women aged
35 or more. Only one woman over 60 years of age showed significant cytological
abnormality (severe dyskaryosis) and was HPV positive. Currently, standard practice
is to screen women until they are 65 years old but the results presented here suggest
that older women who lack HPV do not require such prolonged surveillance. This
would also have beneficial cost implications for the service.
8.2.2.2 In HIV-seropositve women
In the longitudinal study of HIV-associated HPV infection, HR-HPV positivity
increased to 44.2% although this was not necessarily associated with the progression
of cervical disease since the majority of abnormalities found were low-grade.
Indeed, HR-HPV genotypes were found in 62.5% of HIV-seropositive women
without any associated cytological abnormality. Although there are currently no
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defined UK guidelines on cervical screening in this population, it would appear that
cervical neoplasia progression has been contained in the Edinburgh HIV cohort by
regular monitoring of patients and prompt, effective treatment of cervical lesions
with good follow-up. Evidence to support this view is the observation that HPV
status was not used to influence the clinical management of these patients and cases
of CIN began decreasing several years ago, well before the introduction of
antiretroviral drug therapy. Therefore HPV testing may be of limited use in the
gynaecological management of cervical neoplasia in HIV-infected women, whereas
improved patient monitoring may play a more important role in the prevention of
cervical neoplasia in this high-risk group. Understandably, in some areas, achieving
this may be difficult if clinic attendance rates are low. Although it is too early to
assess fully if HAART will have a positive effect on cervical neoplasia progression
the results reported here suggest that women with CD4 counts <200 cells/p.1 or HIV
RNA viral loads of >5000 copies/ml are certainly at greatest risk of cervical
neoplasia. Indeed the European MACH-1 study, which includes the Edinburgh
cohort, may provide important information on the effect of antiretroviral therapies on
cervical neoplasia in a larger group of HIV-infected women. Its findings will not be
available for a further 2-3 years.
Caution should be applied in the clinical use of HPV testing, particularly when
interpreting single time point results, even in relation to cytology. HPV tests should
be performed at regular intervals, for example six-monthly, for identification of
persistent HPV infection that is known to be associated with a higher risk of
developing cervical neoplasia. This would increase the cost of introducing HPV
testing as a primary screening tool. However, care must be taken about the use of the
term 'persistent HPV infection'. 70% of the Edinburgh HIV cohort who had at least
three cervical specimens collected at approximately six-monthly intervals were
shown to have HR-HPV DNA regularly detected in all samples, but the HPV types
detected in the cervix changed over time in a number of cases. Thus continued
detection of HPV DNA in two consecutive samples could occur as a result of lasting
infection with the same HPV type, elimination of one HPV genotype and reactivation
of another latent HPV infection or re-infection with a new type or variant. Direct
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DNA sequence analysis of GP5+/6+ PCR products identified 22 different HPV
genotypes in the Edinburgh cohort of HIV-seropositive women, including some
novel types which, to date, have not been fully characterised. For example, CP8304
was shown to be associated with histologically confirmed CIN, and this has led to
collaborative work with Dr E.M. deVilliers at Deutsches Krebsforschungszentrum,
Heidelberg, Germany to characterise this isolate further (Dr C. Cuschieri, personal
communication). It is therefore logical to hypothesise that the prevalence and
oncogenic potential of some rare HPVs has probably not been fully recognised.
8.2.2.3 Usefulness of different HPV tests
The introduction of HPV testing for triage alone will result in a large number of HPV
tests (approximately 250,000 in the UK). Although the format of current HPV tests
would be acceptable for this volume, the introduction of HPV testing in primary
screening would generate many more tests (approximately 3.5 million in the UK)
(Davies et al., 2001). Thus, automated DNA extraction protocols and a rapid
molecular test for the detection of HPV DNA would be required to cope with the
large numbers involved. However, the ability to be able to distinguish between
individual HPV genotypes in a single assay and quantify the amount of DNA present
would be an advantage.
Most of the studies described here have involved comparison between two of the
most well-established methods for HPV DNA detection: HCAII and consensus
GP5+/6+ PCR. HCAII is a simple, reproducible and user-friendly test available from
Digene that can distinguish between 5 low-risk and 13 high-risk genotypes by the
use of group-specific oligonucleotide probe pools for DNA detection. Use of a
simple procedure (using a Digene Specimen Conversion Kit) renders PreservCyt®
LBC specimens suitable for HCAII testing. However, HCAII alone cannot quantitate
the amount of viral DNA present nor can it identify the specific genotype(s) present.
From DNA sequence data generated as part of this work, it appears that the high-risk
HCAII probe cocktail allows cross detection of some additional HPV types,
particularly rare genotypes, despite the lack of specific probes for these types in the
probe pool. This has been noted by others (Peyton et al., 1998; Vernon et al., 2000;
Schopp et al., 2001). Several studies have attempted to measure HPV viral load
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using the relative light unit (RLU) indices produced by Hybrid Capture technology
since it has been suggested that productive viral infection, as measured by high HPV
viral load, is indicative of an increased risk of the development of cervical disease.
However, the HCAII test involves signal amplification and was not designed for
accurate DNA quantification. So, at best, comparison of RLU index values against a
single standard is semi-quantitative. A standard curve with several standards of
different HPV copy number would need to be included in every run for a more
quantitative approach.
Conventional GP5+/6+ PCR sample preparation and final detection using agarose gel
electrophoresis does not lend itself readily to automation, and therefore is very
laborious for large specimen numbers. It is also impossible to differentiate between
different HPV genotypes by agarose gel electrophoresis of GP5+/6+ PCR products
since the amplified products are very similar in size. Genotyping must be performed
by some additional method such as an enzyme immunoassay using a range of type-
specific probes, restriction enzyme analysis or DNA sequencing. Results described
here show that HPV positivity was higher using GP5+/6+ PCR compared to hybrid
capture technology, but this technique will detect both high-risk and low-risk HPV
genotypes in the same reaction. However, detection of HPV DNA by PCR is
dependent on prior isolation of the DNA from infected cells. Depending on the
specimen type, several approaches have been used for DNA extraction, ranging from
simple boiling to phenol-chloroform extraction. DNA extraction from LBC
specimens was complicated by the fact that PreservCyt® fluid is designed for
optimal cell preservation rather than nucleic acid extraction and cervical scrape
specimens can be particularly mucous in nature. In the work described here, manual
DNA extraction using individual QIAGEN spin columns under centrifugal force was
successfully used to isolate DNA from residual LBC fluid but this procedure was
considered too laborious for high specimen through-put. Thus, a BioRobot® 9604
(QIAGEN Ltd.) protocol was developed for automated DNA extraction from routine
LBC specimens. However, vacuum pressure was less effective than centrifugation at
drawing clinical samples across the silica membrane and 37.5% of samples blocked
the QIAamp® extraction plate when cells from the total residual volume were used.
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Blockage of the QIAamp® extraction plate was attributed to cellular over-loading of
the columns so to improve extraction efficiency, the residual volume used for
processing was reduced to 5ml. This reduced the blockage rate to less than 5%
without compromising downstream HPV testing. These technical improvements took
considerable time for optimisation but it is hoped that QLAGEN will incorporate the
final protocol in future product inserts. For large-scale HPV DNA detection, a real¬
time GP5+/6+PCR system was developed using the LightCycler instrument. Of the
1750 LBC specimens extracted using the automated BioRobot® 9604 extraction
protocol, 15% were found to contain HPV DNA by real-time PCR including >80%
of samples associated with moderate or severe cytological abnormalities.
Real-time PCR technology is beginning to revolutionise the potential of PCR by
using rapid temperature control to reduce testing time (typically 40 cycles in 25
minutes) and minimising the risk of contamination by performing both PCR
amplification and product detection simultaneously in closed glass capillaries.
Although the glass PCR capillaries are more expensive than eppendorf tubes, the
overall costs are less due to the smaller volumes of reagents used. Initial studies
using the LightCycler and GP5+/6+ PCR were published recently (Cubie et al.,
2001). Detailed Tm analysis was used to differentiate between HPV 16 (mean
Tm=79.1 ± 0.8°C) and HPV18 (mean Tm=80.9°C ± 1.0°C) sequences. In the work
presented here, Tm analysis suggested that many of LightCycler PCR positives were
HPV16 (44.3%). A further 15.5% were identified as HPV18, 12.5% contained more
than one HPV genotype and 19.3% had other HPV types present (HPV 'X'). To
confirm these results, a RLBA (currently available for research purposes only) was
used. However, only 17.9% of single HPV 16 and 11.1% of single HPV 18 infections
were confirmed. On-going studies using the RLBA performed at the Regional
Clinical Virology Laboratory suggest that multiple HPV infections are common in
women irrespective of cytology (Dr. C. Cuschieri, personal communication). It
appears that Tm analysis is not sufficient to distinguish reliably between HPV 16 and
HPV 18 genotypes or identify multiple infection. However, these results should be
interpreted with caution since both these molecular assays employ different primer
sets and evidence from the literature suggests that preferential detection of some
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types may result depending on the primer set chosen. For example, the analytical
sensitivity of GP5+/6+ is considered to be greatest for HPV16 and HPV18 since the
primers were designed to be optimal for these common genotypes whereas MY09/11
primers are more efficient at amplifying multiple HPVs (Qu et al., 1997). This may
explain why detailed melt analysis of 158 samples suggested that either HPV16 or 18
was present but 20/56 (35.7%) tested using the RLBA contained these and additional
genotypes. It is possible that selective amplification of one genotype (i.e. the
predominating HPV 16 or 18) over another was occurring during LC GP5+/6+ PCR
of multiple infection samples, and only the predominant type was detected.
Nonetheless, results from RLBA testing support other recent findings that the range
of HPV genotypes and their association with cervical disease may be just as variable
in immunocompetent women as in immunosuppressed women. At present,
gynaecological management of women based on their HPV status would be
independent of the associated HPV genotype(s) involved, although in future HPV
detection methods may be used to identify individual HPV genotypes. The RLBA is
a useful tool for PCR product analysis, since it can detect up to 27 different HPVs,
including some novel HPV genotypes. A more recent typing procedure for GP5+/6+
PCR products can detect up to 37 different mucosotropic HPVs (van den Brule et al.,
2002). The ease of use and absence of expensive detection equipment required for
such tests may make them the method of choice for HPV genotyping in the future,
although the results obtained from different genotyping systems may also differ
slightly due to the primers sets used (van Doom et al., 2002).
8.3 Final Conclusions and Future Work
The improved detection of cervical cytological abnormalities by the use of LBC have
been very encouraging and it is anticipated that the level of improvement in
inadequate smear rates will be maintained in the larger Scottish and English LBC
demonstration projects. Although rigorous cost-benefit analyses are not yet
complete, the future of the National Cervical Screening Programme is likely to
include LBC which would result in improved detection of women who are at risk of
developing significant cervical neoplasia. Rationalisation of the screening
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programme by the introduction of LBC would minimise the financial implications of
establishing a system of HPV testing, particularly if performed by a centralised
facility designed for efficient large-scale HPV testing.
The value of HPV testing in population screening or for management of women with
borderline smears is being assessed in various multi-centre studies. The results
presented here suggest that HPV testing in primary screening is unlikely to be cost
effective since the population prevalence of HPV infection is over 15%. As a result,
to ensure that women with significant CIN are not missed, many HPV positive
women with no cervical neoplastic abnormality detectable by cervical cytology
would be followed up unnecessarily. Even if HPV testing was restricted to women
aged 35 or over to improve the specificity obtained and the screening interval was
increased for women considered to be at low-risk (negative for both cytological
neoplastic abnormality and for HPV), HPV testing in primary screening may still not
be financially viable. However, this issue would be addressed by larger randomised
trials such as the UK-based five centre screening trial of HPV testing with routine
Pap cytology in 12,000 women aged 30 or older (the HART Study) (Cuzick, 2001).
Evidence from the work described here suggests that combined LBC and HPV
testing using HCAII on a single specimen would be cost-effective for the
management of women with borderline smears because this approach would result in
a reduction in the number of repeat cervical scrapes and colposcopy referrals.
When assessing the potential circumstances in which HPV testing may be of value, it
is important to consider screening separately from diagnosis, since the types of HPV
tests employed are likely to differ. For example, for routine screening of large
numbers of clinical specimens, automated DNA extraction followed by real-time
PCR using GP5+/6+ primers would be suitable for detection of a broad range of
HPV types in LBC samples. However, for diagnosis and effective clinical
management of immunosuppressed women or those with persistent CIN, assessment
of HPV genotype or viral load would be a more useful tool. The work presented here
suggests that there is a lack of reliability using detailed melting temperature analysis
of real-time PCR products for HPV genotyping and therefore other methods are
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more appropriate for clinically reliable HPV genotyping, such as hybridisation-based
techniques. It is likely that hybridisation probe technology may be appropriate to
distinguish accurately between the 30 or so known anogenital HPVs. In addition
real-time PCR could be used to develop a quantitative system for assessment of HPV
viral load by controlling for variation in the cellular content of the cervical sample by
quantification of a host cell gene, such as (3-globin, or using probe based techniques.
Since PreservCyt®-fixed cells are also suitable for RNA extraction (Tarkowski et
al., 2001), RNA analysis of specific genes such as E6 and E7 (Molden et al., 2001;
Bahrani-Mostafavi et al., 2001) may allow differentiation between latent and
productive infection, and identify those women who would be more likely to develop
progressive cervical disease due to active gene expression. To elucidate the clinical
significance of multiple HPV infection, delineation of those HPV genotypes most
frequently associated with cervical neoplasia progression is required. The RLBA
may also prove useful for this purpose since it is less labour intensive than direct
DNA sequencing which was of limited use for the identification of multiple HPV
infections. Additionally some of the novel HPV genotypes require further
characterisation so that molecular assays can be adapted to include them if they are
considered to have oncogenic potential.
Additional approaches that may be implemented to improve prospective cervical
screening programmes include the following. Use of automated cytology that would
require high quality cytological preparations without overlapping cells or mucus such
as those provided by LBC. The development of novel assays that detect other
markers of cervical carcinogenesis such as markers of cellular proliferation (e.g.
Ki67 or Mcm-2). The use of self-sampling devices to improve population coverage
and increased screening intervals for HPV negative women with no cytological
abnormality who are considered to be of limited risk.
This study contributes significant evidence on the usefulness of LBC within the
Scottish cervical screening programme. The use of a variety of tests for HPV
detection provides some direction for future studies where HCAII could be
considered for screening purposes and HPV genotyping may be useful in specific
clinical situations. Implementation of LBC and HPV testing may help provide
191
significant cost savings to the screening programme while improving female health
by earlier detection of cervical neoplasia. Thus, such improvements may help reduce
the morbidity and mortality rates associated with cervical cancer to an all-time low.
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Solutions and Laboratory Media
Earles Balance Salt Solution
90ml sterile water
10ml Earles balanced salt solution (lOx)




3ml 4.4% sodium bicarbonate
0.3ml penicillin/streptomycin (added prior to use)
GTC-containing Lysis Buffer
Dissolve 120g guanidinium thiocyanate in 100ml of 1M Tris-HCl, pH6.4. Add 22ml
of 0.2M EDTA adjusted with NaOH to pH8 and 2.6g of Triton-X-100. Homogenise.
GTC-containing Wash Buffer
Dissolve 120g guanidinium thiocyanate in 100ml of 1M Tris-HCl, pH6.4.
50x TAE
242g Tris Base
57.1ml glacial acetic acid
100ml 0.5MEDTA
Make up to one litre.
lx TE Buffer, pH 7.4
lOmM Tris-HCl (pH 7.4)






lml 2M Mg2+ stock (1M MgCl2.6H20, ImM MgS04.7H20), filter sterilised
lml 2M glucose, filter sterilised
Add Bacto®-tryptone, Bacto®-yeast extract, NaCl and KC1 to 97ml deionised water.
Stir to dissolve. Autoclave and cool to room temperature. Add 2M Mg~+ stock and
2M glucose stock, each to a final concentration of 20mM. Filter the complete
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Aims—To assess the validity and practi¬
cality of real time polymerase chain reac¬
tion (PCR) for human papillomavirus
(HPV) testing in combination with liquid
based cytology samples for cervical
screening.
Methods—Real time PCR using consensus
(GP5+/6+) and type specific primers was
developed to detect genital HPV types.
This provides rapid, efficient amplifica¬
tion followed by denaturation of the prod¬
uct and computer analysis of the kinetics
data that are generated. Liquid based
cytology samples were obtained from
patients attending routine cervical
screening clinics. DNA was extracted
from the residual cellular suspension after
cytology using spin columns.
Results—Real time PCR successfully dis¬
tinguished between HPV-16 and HPV-18
on the basis of amplification with consen¬
sus primers followed by DNA melting
temperature (Tln) analysis. Sensitivities of
one to 10 copies of HPV-16 (mean
Tm = 79.4°C; 2 SD, 0.8) and four to 40 cop¬
ies of HPV-18 (mean Tm = 80.4°C; 2 SD,
0.4) were obtained. In a mixed population
of SiHa and HeLa cells containing known
copy numbers of HPV-16 and HPV-18
genomes, HPV-16 and HPV-18 products
were clearly separated by Tln analysis in
mixtures varying from equivalence to
1/1000. Together with detailed melt analy¬
sis, type specific primers from the same
region of the LI gene confirmed the
differential ability of this system. The
method was applied to 100 liquid based
cytology samples where HPV status using
conventional GP5+/6+ PCR was already
known. There was 95% agreement be¬
tween the methods, with 55 positives
detected by conventional PCR and 59 with
real time PCR. The method was then
tested on 200 routine liquid based cytology
samples. Approximately 10% were posi¬
tive by real time PCR, most ofwhich were
classified as HPV-16 by detailed melt
analysis. Thirteen (6.8%) HPV positives
were identified in 189 samples showing no
evidence of cervical cytological abnor¬
mality.
Conclusions—Real time PCR is a rapid,
efficient method for the detection ofHPV
with the separation of HPV-16 and
HPV-18 on the basis of differential Tm.
Preliminary results suggest it could prove
useful if HPV testing is added to cervical
screening programmes.
(J Clin Pathol: Mol Pathol 2001 ;54:24-29)
Keywords: real time polymerase chain reaction; cervical
screening; human papillomavirus types 16 and 18
More than 40 types of human papillomavirus
(HPV) infect the genital epithelium and several
high risk types including HPV types 16,18,31,
33, and 45 are found in almost all cases of high
grade cervical intraepithelial neoplasia and
cervical cancer.12 In Europe, the most preva¬
lent type is HPV-16,1 but there are several
reports that HPV-18 infection can lead to the
development of more clinically aggressive
disease.3-5
Laboratory diagnosis of HPV infection is
dependent upon molecular techniques such as
DNA hybridisation or nucleic acid amplifica¬
tion. Several polymerase chain reaction (PCR)
methods have been developed to detect a broad
spectrum of mucosotropic HPV types using
either degenerate or consensus primers.6-9 A
second generation commercial hybridisation
assay, Hybrid Capture™ (HCA II), is also
available for the detection of HPV DNA in
cervical swab samples,10 and has been used
widely in epidemiological studies.11-13 However,
both consensus PCR and HCA II have impor¬
tant limitations. They are costly and labour
intensive and, without additional procedures,
neither technique can differentiate between
individual types or detect infection with more
than one type. Furthermore, HPV infections
are often transient, frequendy cleared by
immunocompetent people, and require inter¬
action with cofactors for the progression of
disease. Thus, the development of highly sensi¬
tive detection tests for high risk HPV raises
problems of clinical interpretation.
The potential use ofHPV testing in cervical
screening programmes is dependent on a rapid
sensitive test that can distinguish high risk
HPV types present in clinical samples. In most
conventional PCR assays, amplification is per¬
formed by automated temperature cycling, but
product analysis requires a subsequent manual
operation.
Rapid real time PCR can distinguish closely
related sequences on the basis of amplification
followed by DNA melting temperature analy¬
sis. The commercial LightCycler (Idaho Tech¬
nology Inc, supplied by BioGene Ltd, Kimbol-
ton, Cambridgeshire, UK) combines
simultaneous PCR amplification with sophisti¬
cated computer analysis of the kinetics data
generated. The use of air as a circulating
medium during PCR cycling allows rapid tem¬
perature control and thus a significant reduc¬
tion in testing time (typically 40 cycles in 25
minutes). The use of fine capillaries of
borosilicate glass provides efficient heat trans¬
fer and by acting as wave guides facilitates sen-
znww.molpath. com
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sitive fluorimetry and enhances the efficiency
of the amplification. The amplification mix
contains a fluorescent dye, SYBR Green I™,
which binds to the minor groove of double
stranded DNA and emits light on excitation.14
Thus, as the PCR product accumulates,
fluorescence increases. On denaturation of the
product, SYBR Green I is released and
fluorescence rapidly decreases. Because the
melting curve of DNA is dependent on
sequence, length, and GC content, PCR prod¬
ucts can be distinguished by their melting
curves. The determination of melting curves
can be carried out on each sample after ampli¬
fication without opening the reaction vessels.
We report the differentiation of HPV-16 and
HPV-18 in mixed cell populations using
GP5+/6+ consensus primers," with confirma¬
tion using type specific modifications of these




HPV containing cell lines
The cell lines, SiHa and HeLa, which contain
one to two copies of HPV-16 DNA and 30^0
copies of HPV-18 DNA/cell, respectively,15
were grown as monolayers and passaged at
regular intervals using standard cell culture
techniques. Cells were removed from the plas¬
tic with gende trypsinisation, counted, and the
DNA extracted from a known number of cells
in 200 pi of phosphate buffered saline (PBS)
using spin columns (Qiagen DNA mini kit;
Qiagen Ltd, Lewes, West Sussex, UK) in
accordance with the manufacturer's tissue pro¬
tocol.
Cloned material
Cloned DNAs of HPV types 16, 18, and 45
originally isolated from clinical material were
provided by Professor E-M de Villiers (Ref-
erenzzentrum fur humanpathogene Papillom-
viren, Heidelberg, Germany) and HPV-33 was
obtained from Dr G Orth (Institut Pasteur,
Paris, France). HPV types 16, 18, and 33 were
provided in pBR322 and HPV-45 in pGEM4.
HPV-31 was cloned in pT713 and was
obtained from Dr A Lorincz (Digene Diagnos¬
tics, Silver Spring, Maryland, USA).
Transformation was performed using Li¬
brary Efficiency DH5a™ competent cells (Life
Technologies, Paisley, Scotland, UK). Plasmid
containing colonies were selected using L-Amp
plates and were then cultured in L-broth
containing ampicillin. Plasmid DNA was
isolated from this bacterial cell culture using
the Hybaid recovery quick mini spin kit
Table 1 Sequences ofprimers used and optimal cycling conditions found
(Hybaid Ltd, Middlesex, UK) according to the
manufacturer's instructions. The extracted
DNA was digested with selected restriction
enzymes (BamHI, EcoRI, Hindlll, Hindll, and
Bglll) and electrophoresed in 1% agarose to
check the identity of the DNA. Finally,
GeneQuant II spectrophotometric analysis
(Amersham Pharmacia Biotech, St Albans,
Hertfordshire, UK) was performed to measure
the concentration of DNA.
CLINICAL SAMPLES
A total of 300 liquid based cytology samples
were collected from women attending general
practitioner clinics for routine cervical screen¬
ing or follow up. Cells were collected from the
cervix using a Cervex Brush® rinsed in 20 ml
ofPreservCyt® (PC) solution (Cytyc Corpora¬
tion; Boxborough, Massachusetts, USA). The
sampler was then discarded. One hundred
specimens were "split samples", where a
conventional smear had been made before the
residual cervical material was rinsed into the
liquid based cytology medium. The other 200
samples were collected routinely and only a
ThinPrep® (TP) monolayer smear was made
for diagnostic purposes.
DNA EXTRACTION
Cells from the residual volume were pelleted at
2900 xg for 15 minutes before resuspending in
200 pi Tris EDTA (TE) buffer (pH 7.2). DNA
extraction was then performed directly using
the Qiagen DNA mini kit, according to the
manufacturer's tissue protocol, resulting in
400 pi of extracted sample.
PRIMERS AND PCR PROTOCOL
Three primer pairs were used in our study: the
GP5+/6+ consensus primer pair, together with
HPV-16 and HPV-18 specific primer pairs,
which were modified from GP5+/6+ (table 1).
These were designed after a thorough search of
the HPV sequence database (Los Alamos
National Laboratory) in the GP5+/6+ primer
target region of the LI gene. The DNA
sequence of all known HPV types was critically
reviewed for optimal product length, annealing
temperature, base variations between types,
and the possibility of non-specific amplifica¬
tion.
Reaction mixes contained 0.5 pi of 5 pM
forward and reverse primers, 1.25 pi of tem¬
plate nucleic acid, 0.25 pi of 1/1000 SYBR
Green I, and 2.5 pi of master mix containing
4 mM MgCh (Biogene Ltd) and TaqStart
antibody (Sigma-Aldrich Co Ltd, Poole, Dor¬
set, UK). The cycling profiles were optimised
for each set of primers and are detailed in table
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95°C for < 1 second 62°C for 3 seconds, 72°C for 3 seconds
85°C for < 1 second 62°C for 3 seconds, 72°C for 3 seconds
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Table 2 Detailed melt analysis of DNA extractedfrom SiHa and HeLa cells
Number of Tm with GP5+/6+ Number of Tm with TS primers
replicates (mean Tm (2 SD)) replicates (mean Tm (2 SD))
SiHa 20 79.1 (0.8°C) 30 78.2 (0.4°C)
HeLa 20 80.9 (1.0°C) 30 80.4 (0.3°C)
1. Detailed melt analysis was used for the
accurate determination of the melting point of
the amplified product. This consisted of a sin¬
gle cycle of 65°C for three seconds to 90°C for
one second at a transition rate of 0.2°C/second,
followed by measurement of the fluorescent
signal at greater frequency.16 The entire assay
including DNA extraction, PCR amplification,
and melting temperature analysis can be
performed in approximately three hours.
HYBRID CAPTURE ASSAY
A 4 ml volume of PC fluid was processed for
the Digene HPV hybrid capture assay (HCA)
according to the manufacturer's recommenda¬
tions and using the second generation (HCA
II) test. This is a sandwich capture hybridisa¬
tion system using chemiluminescent signal
amplification for the qualitative detection of 13
different high risk HPV types (HPV types 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and
68). The emission of light is measured as rela¬
tive light units (RLUs) and is proportional to
the amount of target DNA present. Samples
with an RLU > 1 were considered positive for
any of the high risk HPV types contained in the
probe pool. HPV results were correlated with
the cytology results obtained.
CYTOLOGICAL ASSESSMENT
TP slides were made using the semi-automated
ThinPrep 2000 slide processor (Cytyc Corpo¬
ration, Boxborough, Massachusetts, USA).
The methodology has been well documented
elsewhere.1718 Both conventional and TP
smears were reported independently. The
Richart system for cervical diagnostic reporting
was used (unsatisfactory (U/S), negative
(WNL), borderline changes (B/L), mild dys-




Cultured cells containing HPV-16 or HPV-18
With GP5+/6+ primers, replicate 10-fold dilu¬
tions of SiHa cells containing 1000-2000
genome copies down to 0.1 copy of the
HPV-16 genome were tested and the product
gave a single peak and a sensitivity of 1-2
copies/pl. Similarly, 10-fold dilutions of HeLa
cells containing 5000 down to 0.5 copies of the
HPV-18 genome showed a sensitivity of 3-50
copies/pl. Detailed melt analysis of 20 samples
each of SiHa and HeLa cells gave the mean Tm
of the HPV-16 product as 79.1°C (2 SD, 0.8)
and the mean Tm of the HPV-18 product as
80.9°C (2 SD, 1.0) (table 2). In a mixed popu¬
lation of SiHa and HeLa cells, a composite
melting curve was observed on standard analy¬
sis, with a Tm of 79.4°C (fig 1A). On further
analysis using a detailed melt cycle, this
resolved into two clearly differentiated peaks
with temperatures of 78.4°C and 80.1°C (fig
IB). Using this system, HPV-16 could be
detected in a 1/1000 mixture of SiHa to HeLa
cells.
Type specific primers, TS165+/166+ and
TS185+/186+ (table 1), from a similar region
of the LI gene gave individual peaks at 79.2°C
and 81.3°C for HPV-16 in SiHa and HPV-18
in HeLa cells, respectively, and detailed melt
analysis of 30 samples confirmed these mean
melting points as 78.2°C (2 SD, 0.4) and
80.4°C (2 SD, 0.3), respectively. The specifi¬
city of these primers led to a smaller standard
deviation in Tm (table 2). Different cycling
conditions were required for each set of specific
primers, reflecting the optimal conditions for
stringency of each pair. The differential ability
of the specific primer pairs was assessed by
amplifying mixtures of SiHa and HeLa cells in
the presence of one or other primer pair. In
mixtures with equivalent copy numbers, both
types were readily detected. Again, HPV-16
from a single SiHa cell could be detected in a
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Figure 1 Melting curve analysis ofPCR products after amplification of a 150 bp fragment of the human papillomavirus
(HPV) LI gene. Y axis: negative differential offluorescence over temperature (-dF/dT). (A) Standard melt analysis of
SiHa/HeLa mixed DNA product, using GP5+6+ primers showing single peak (Tm = 79.4°C). (B) Detailed melt analysis
ofSiHa and HeLa mixed DNA product, showing two peaks with Tm — 78.4°C (HPV-16) and 80.1°C (HPV-18).
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Standard melt Tm Detailed melt Tm Comments Standard melt Tm Detailed melt Tm Comments
100/1000 80.9°C 79.9/81.4°C Double peak 79.1°C 78.2°C Single peak
10/1000 81.0°C 79.9/81.5°C Double peak 79.1°C 78.2°C Single peak
1/1000 81.5°C 80.1/81.8°C Double peak 79.1°C 78.1°C Single peak
0.1/1000 81.4°C 80.3°C Single peak ofHPV-18 No amplification No amplification No peak
Table 4 Melting temperature (TJ of high risk human
papillomavirus (HPV) cloned material using real time












Table 5 Comparison of conventional and real time PCR
on 100 selected clinical samples
Conventional
PCR HPV results
Light Cycler PCR HPV results


















Detailed melt analysis allowed the differentia¬
tion of five different types of high risk HPV
from cloned material and showed a range from
76.7°C for HPV-33 to 80.4°C for HPV-18
(table 4). We are currendy investigating the
differentiation by Tm of additional HPV types.
PATIENT SAMPLES
One hundred preselected samples previously
analysed using HCA and conventional PCR
were assessed using real time PCR. Table 5
shows the comparison between conventional
and real time PCR. Five samples were positive
by real time PCR but negative by conventional
PCR. Of these five discrepant samples, one
contained HPV-16 as shown by use of type
specific primers from both the LI and E6
regions,15 one contained an HPV-16 related
type as shown by detection with HPV-16 E6
primers but not HPV-16 LI primers, and three
contained HPV "X", being positive by HCA
but negative with HPV-16 LI and E6 primers
and also HPV-18 type specific primers.
The first 200 routine cervical screening
samples from our study looking at the com¬
bined effectiveness of liquid based cytology
sampling and real time PCR were processed
within 21 days of receipt and analysed without
Table 6 Human papillomavirus (HPV) findings related to cytology in 200 unselected,
routine liquid based cytology samples
Cytology
Total number
ofsamples HPVpositive HPV negative
Unsatisfactory 2 0 2
Negative 189 13 (6.8%) 176
Borderline 1 0 1
Mild dyskaryosis 7 5 2
Moderate dyskaryosis 0 0 0
Severe dyskaryosis 1 1 0
Total 200 19 (9.5%) 181
previous knowledge of the cytology results.
Nineteen (9.5%) of the 200 samples contained
HPV (table 6), of which 13 (6.8%) were found
in women with no evidence of cytological
abnormalities. Most of the positive samples (12
of 19) appeared to contain HPV-16 by detailed
melt analysis (fig 2A) and an occasional double
infection was noted (fig 2B).
Discussion
We have shown that HPV-16 and HPV-18 can
be detected by rapid real time PCR using con¬
sensus primers and can be differentiated by
melting curve analysis. In mixed samples, two
separate peaks of distinct Tm are seen, even
when there is a considerable difference in the
copy number of each type. This approach has
been confirmed with type specific primers.
Because HPV-16 and HPV-18 product
lengths are very similar, it is impossible to dif¬
ferentiate between individual HPV types by
agarose gel electrophoresis after GP5+/6+
PCR amplification. In contrast, melting curve
analysis using LightCycler technology can dis¬
tinguish between products of the same length
but different GC : AT ratios.18 Woo and
colleagues" reported the use of genus specific
amplification primers and specific fluorogenic
hybridisation probes to differentiate patho¬
genic and non-pathogenic strains of leptospira.
In their study, the lower limit of detection was
200 genome copies. The same group also used
melting curve analysis to differentiate different
strains of leptonema20 and to distinguish refer¬
ence strains and field isolates of leptospira
without the use ofhybridisation probes.21 More
recendy, reports of the use of the LightCycler
in detecting viruses have begun to appear.
These include the quantitative detection of
human cytomegalovirus (CMV) in plasma22
and the sensitive diagnosis of herpes simplex
virus in clinical samples using Tm analysis to
distinguish between herpes simplex virus 1
(HSV-1) and HSV-2.23 We have used a similar
approach to separate HPV types, specifically
for the differentiation of HPV-16 and HPV-18
products that differ in Tm by less than 2°C.
Real time PCR technology has great poten¬
tial for clinical and non-clinical development.
Nevertheless, it is still a new technique and
some technical problems have been reported,
including the presence of primer dimer forma¬
tion." In our hands this could be minimised by
careful attention to optimisation conditions,
with very small changes in concentration, tem¬
perature, and the use of TaqStart antibody
having a considerable effect on the shape of the
analytical trace. In addition, the presence of a
high molecular weight non-specific PCR prod¬
uct has been noted in some applications."Wit-
www.molpath. com
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Figure 2 Melting curve analysis ofPCR products from clinical liquid based cytology samples. (A) Detection ofa single
peak of human papillomavirus 16 (HPV-16) using detailed melt analysis. (B) Detection of a mixed infection with HPV
types 16 and 18 using detailed melt analysis.
twer and colleagues'4 suggested that "shoul¬
ders" of non-specific PCR product might be
caused by substantial product to product
annealing in later amplification cycles. A small
shoulder was sometimes seen in our study on
the high temperature side of the melting curve.
The problem was minimised by reducing the
amplification mix from 10 pi to 5 pi and indeed
the manufacturers recommend a volume of
5-7 pi as optimal in each capillary. Larger vol¬
umes can result in uneven temperature distri¬
bution and therefore inefficient amplification
towards the top portion of the capillary. With
optimal conditions and volume, we only
observed this phenomenon occasionally with
type specific primers and it did not interfere
with the determination of the Tm value. The
effect was never seen with the consensus prim¬
ers. Quality control of the reagents used is
undoubtedly important to limit variations in
Tm, and positive control material was included
and fully analysed in every run.
Additional practical problems have included
the fragility of the capillaries. However, break¬
ages were minimal with experienced operators
and the second generation LightCycler pro¬
duced by Roche Molecular Systems uses more
robust capillaries. The extended use of the
LightCycler for detailed melt analysis can
result in overheating of the carousel and, in our
hands, only 10 detailed melt analyses could be
carried out before a 30 minute cooling period
was required. Nevertheless, the rapid cycling
time with standard melts allowed up to seven
PCR runs to be carried out in a single working
day.
We used melting point analysis after amplifi¬
cation in a single reaction for the detection of
single and mixed samples of HPV-16 and
HPV-18 in both cell lines in vitro and in cervi¬
cal secretions from patients, including 100
samples validated by both conventional PCR
and HCA II. Subsequently, the protocol was
applied successfully to 200 liquid based
cytology clinical samples, with HPV DNA
being detected in 9.8% of samples (table 6),
including 13 of 189 (6.8%) showing no
cytological abnormality. Although this is con¬
sistent with other studies," 24 analysis of the
HPV results in relation to cervical dyskaryosis
requires a much larger study group and this
work is currendy under way. The combined
approach of rapid amplification and product
identification in a single PCR reaction is an
exciting one, with great potential for both clini¬
cal and non-clinical development, particularly
in terms of introducing HPV testing into cervi¬
cal screening programmes. Opportunities for
high throughput are possible by combining one
of several available robotic handling instru¬
ments for DNA extraction with the LightCy¬
cler system and we are testing the maximum
daily capacity of such combinations.
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